Structural and functional studies of AT-Rich DNA ligands and their effect on trypanosoma brucei by Millán Elías, Cinthia Raquel
 
UNIVERSITAT POLITÈCNICA DE CATALUNYA 
DOCTORAL THESIS 
 
Structural and Functional Studies of 
AT-Rich DNA Ligands and Their 





Dr. J. Lourdes CAMPOS 
Dr. Núria SAPERAS 
 
A thesis submitted for the degree of Doctor of Philosophy 
at the Universitat Politècnica de Catalunya 
 
Doctoral Program: Polymers and Biopolymers 






















Dedicated to my sisters,  















"Almost all aspects of life are engineered at the molecular level, and 
without understanding molecules we can only have a very sketchy 




 i  
ACKNOWLEDGEMENTS  
First of all, I would like to thank my supervisors, Dr. Lourdes Campos for all the 
guidance, unlimited support and patience, encouragement and advice she has always 
been able to provide throughout my time as her student; and to Dr. Núria Saperas, for 
her invaluable guidance and immense support every day, she always encouraged me to 
do it better. I can affirm that I have been very lucky to have two supervisors who 
always cared and showed their interest in my research and work, and who have been 
available to provide their guidance in every stage of the development of this thesis, 
making it possible for me to achieve my goals.  
I would also like to thank Dr. Juan Antonio Subirana and all the members of the 
MACROM group: David, Sonia and Fabiola. A special recognition to Raquel and Paco, 
for sharing with me their knowledge and experience in protein purification and 
crystallography. I want to thank them both for the support they provided every time I 
needed it, their helpful advises, but also their friendship. It was a pleasure to work with 
you both. I admire you so much.  
I want to express my gratitude to Dr. Harry de Koning for giving me the opportunity to 
be a part of his group at the University of Glasgow and for introducing me to the 
world of parasites. I want to thank him for the valuable suggestions and his 
thoughtful guidance that made my stay in Glasgow so remarkable and successful. This 
thesis would not have been possible without his help. I would like to acknowledge the 
members of Dr. de Koning’s research lab: Anne, Jane, Manal, Amani, Lauren, Gordon, 
and Daniel, and a very special thanks to my dear friends Gustavo and Khalid, 
for sharing their knowledge with me, for being patient and for their support during 
my experiments. I am so grateful to all them who have contributed to make my 
experience in Glasgow unforgettable and fulfilling. 
I would like to thank our thoughtful collaborators. To Dr. Christophe Dardonville, as his 
continuous interest helped me enormously during the development of Chapter 4. I 
would like to thank him for his valuable help during my short stay in Madrid and 
 
 i i  
during the last two years, having always a prompt response to my numerous questions. 
To Laura Lagartera, for the time she dedicated me, and her invaluable support with the 
SPR experiments. To Dr. Leandro Lemgruber for performing amazing TEM images and 
providing all those useful insights. 
Thanks to all the generous and kind people I have met in the Chemical Engineering 
Department of the ETSEIB and EEBE: Dr. Juan Jesús Pérez, Dr. Ma. Teresa Casas, Dr. 
Lourdes Franco, Dr. Alfonso Rodríguez, Dr. Luis J. del Valle, Dr. Jordi Puiggali, Manolo, 
Neudys, Ana, Silvana, Angélica and Georgina. To the great international group of 
students we have formed during the last year: Jordi, Guillem, Hamidreza, Reza, Amir, 
Anna, Maricruz, Brenda, with a special mention to Ina, for me, the best leader this 
group could have, and Max, for his special and kind way to see this life.  
Thanks to the best friends I could have: Grey and Dany, you are the best partners for 
the most unforgettable adventures I can have; to my favourite Catalans Mary and 
Pablo; to my old-school friends Melissa, Anilú, Paulina and Polette; to Fátima and 
Claudia; to my dear Daniel; to my mother from Barcelona, Lilia; to Luz, for being 
always there for me, for showing me your support and for having the right words; and 
to my best friend José Angel, for everything he has done for me, for his trust and 
support, for making me laugh no matter what, and for being next to me through this 
years. I love you all very much. I would also like to thank Chris, for changing my life. 
And finally, I want to show my infinite gratitude to my amazing family, the most 
important part of my life. To my parents Rosy and Edgardo, for the unconditional love 
and the enormous support they have always given me throughout my life, for giving 
me the freedom and courage to pursue my ambitions, for making me who I am. I will 
always carry a part of you everywhere I go. To Rosiel and Riza, for being the best 
sisters I could have had, for always pushing me to be a better person, for being my 
mentors, my role models, and my inspiration to be better every day, thank you very 
much. To my wonderful, amazing and funny nephews, Ruben and Leonardo, for giving 
me the chance to feel love in ways I didn’t know existed. Life is continuous research. 
 i i i  
ABSTRACT 
Adenine (A) and thymine (T) rich sequences confer unique properties to DNA, such as 
high polymorphism and flexibility. The abundance of AT-rich DNA in several pathogens’ 
genomes and the ability of specific molecules to selectively target AT base pairs have 
prompted studies on ligands that interact with the minor groove of high AT content 
DNA. Of special interest are kinetoplastid parasites, such as Trypanosoma brucei, the 
causative agent of sleeping sickness, which are distinguished by the presence of a very 
AT-rich mitochondrial DNA structure called kinetoplast.  
Minor groove binding ligands have offered critical information on DNA molecular 
recognition, providing clinically useful strategies against diseases. Thus, the binding 
affinity and structural characteristics of AT-rich oligonucleotides in complex with 
different ligands, specifically with HMG proteins and bisimidazolinium compounds, has 
been chosen as the object of study. 
The ‘High Mobility Group’ (HMG) is a family of architectural proteins that bind to DNA 
and influence a myriad of essential cellular processes. This research work has focused 
in two HMG subfamilies: HMGA and HMGB. They bind to the minor groove of the DNA 
by means of different binding motifs: AT-hook (HMGA) and HMG-box (HMGB). An 
HMGA1a fragment containing AT-hook II and III, HMGB1 box B and HMGB1 box AB 
have been expressed and purified. High and similar binding affinity to an AT-rich DNA 
sequence containing [AATAAT_ATTATT] has been found by surface plasmon resonance 
(SPR)–biosensor experiments for both proteins. A complex of the HMGB1 box B with 
d[CCAATAATCGCGATTATTGG]2 was crystallized. The diffraction patterns of the crystal 
at 2.68 Å resolution presented well-defined spots revealing two diffraction orientations. 
On the other hand, a series of diphenyl-based bis(2-iminoimidazolidine) derivatives of 
FR60 [4-((4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-2-yl) 
amino)phenyl)benzamide] have been proved to be high affinity DNA binders with a 
preference for AT over GC-rich DNA, showing slight selectivity towards sequences 
containing [AATT] versus [(AT)4] or [AATAAT_ATTATT]. Furthermore, competition assays 
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have demonstrated that JNI18 competes with HMGA1a and HMGB1 for binding to 
DNA and it is able to displace the proteins from their DNA binding sites. This last 
interaction is of prime importance, as related proteins have been found to be essential 
in kinetoplastid parasites. 
The structure of the bis(2-aminoimidazoline) compound CDIV32 [4,4'-bis(1-hydroxy 
imidazolinylamino)diphenylamine] with the oligonucleotide d[AAATTT]2 partially solved 
at 3.10 Å resolution, displays DNA columns of stacked oligonucleotides forming a 
pseudo-continuous helix packed in a crossed column configuration of DNA helices that 
are at ∼90° to each other. The presence of the drug CDIV32 modulates the 
organization of duplexes. 
The crystal structure of the complex of the oligonucleotide d[AAATTT]2 with the lead 
compound FR60, solved at atomic resolution of 1.25 Å (PDB-ID: 5LIT) by X-ray 
crystallography, is constituted of stacked oligonucleotides organized as infinite 
continuous parallel columns, packed in a pseudo-tetragonal configuration. The 
structure revealed that the drug interacts with the central [AATT] region, covers the 
minor groove of DNA, displaces bound water and interacts with neighboring DNA 
molecules as a cross-linking agent.  
Finally, a functional analysis has been performed on the effect of different bis(2-
aminoimidazolines) on Trypanosoma brucei, which has a kDNA with higher than 70% 
AT base pair content. The main objective was to assess whether parasite DNA was a 
target for these compounds inside the cell. The in vitro effect of these drugs against T. 
brucei was evaluated. By a combination of flow cytometry and imaging techniques 
such as fluorescence microscopy and transmission electron microscopy, it was 
demonstrated that these compounds have a clear effect on the S-phase of T. brucei 
cell cycle by inflicting specific damage on the kinetoplast. It can be concluded that the 
studied DNA binding bis(2-aminoimidazoline) compounds FR60 and JNI18 are powerful 
trypanocides that act directly on the kinetoplast DNA. As the compounds show 100% 
curative activity in a mouse model of T. b. rhodesiense infection, they are potentially 
an effective chemotherapeutic agent for the treatment of sleeping sickness.
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RESUMEN 
Las secuencias ricas en adeninas (A) y timinas (T) le confieren al ADN propiedades 
únicas como un alto polimorfismo y flexibilidad. La abundancia de ADN rico en AT en el 
genoma de varios patógenos y la selectividad de unión a secuencias AT que presentan 
ciertas moléculas, han llevado al estudio de ligandos que interactúan con el surco 
estrecho de DNA con alto contenido en AT. De especial interés son los parásitos 
kinetoplástidos, como el Trypanosoma brucei, agente causante de la enfermedad del 
sueño, los cuales se distinguen por la presencia de una estructura de ADN mitocondrial 
muy rica en AT llamada kinetoplasto. 
Los ligandos de unión al surco estrecho han ofrecido información primordial sobre el 
reconocimiento molecular del ADN, proporcionando estrategias clínicamente útiles 
para combatir enfermedades. Por ello, se ha elegido como objeto de estudio la afinidad 
de unión y las características estructurales de complejos de oligonucleótidos ricos en 
AT con diferentes ligandos, específicamente con proteínas HMG y con compuestos 
bisimidazolinio. 
Las HMG (High Mobility Group) son una familia de proteínas arquitectónicas que se 
unen al ADN e influyen en numerosos procesos celulares esenciales. Este trabajo de 
investigación se ha centrado en dos subfamilias de las HMG: las HMGA y las HMGB. 
Ambas se unen al surco estrecho del ADN pero mediante diferentes motivos de unión: 
AT-hook (HMGA) y HMG-box (HMGB). Se ha expresado y purificado un fragmento de 
HMGA1a que contiene los AT-hook II y III, así como la HMGB1 box B y la HMGB1 box 
AB. Por medio de experimentos de resonancia de plasmón superficial (SPR), se ha 
encontrado para ambas proteínas una afinidad de unión alta y similar hacia un 
oligonucleótido rico en AT conteniendo la secuencia [AATAAT_ATTATT]. Se cristalizó un 
complejo de la HMGB1 box B con el oligonucleótido d[CCAATAATCGCGATTATTGG]2. Los 
diagramas de difracción del cristal a una resolución de 2.68 Å presentaban reflexiones 
bien definidas que indicaban dos orientaciones preferenciales en el cristal. 
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Por otra parte, una serie de derivados difenilo bisimidazolinio basados en el compuesto 
FR60 [4-((4,5-dihidro-1H-imidazol-2-il)amino)-N-(4-((4,5-dihidro-1H-imidazol-2-il) 
amino)fenil)benzamida] han demostrado ser ligandos de alta afinidad por secuencias 
AT con respecto a GC, mostrando cierta preferencia hacia secuencias que contienen 
[AATT] comparado con [(AT)4] o [AATAAT_ATTATT]. Además, los ensayos de competencia 
han demostrado que el JNI18 compite con la HMGA1a y la HMGB1 en su unión al ADN 
y es capaz de desplazar a dichas proteínas de sus sitios de unión al ADN. Esta última 
interacción es de especial relevancia, ya que se han encontrado proteínas relacionadas 
que son esenciales en parásitos kinetoplástidos. 
La estructura del compuesto de bis(2-aminoimidazolinio) CDIV32 [4,4'-bis (1-hidroxi 
imidazolinilaminio)difenilamina] con el oligonucleótido d[AAATTT]2 ha sido 
parcialmente resuelta a una resolución de 3.10 Å. Se encontraron columnas de 
oligonucleótidos apilados formando una hélice pseudo-continua, empaquetada en una 
configuración de columnas cruzadas perpendicularmente. La presencia del fármaco 
CDIV32 modula la organización de las hélices de ADN.  
Por medio de cristalografía de rayos X se ha resuelto la estructura del complejo 
formado por el oligonucleótido d[AAATTT]2 y el compuesto líder FR60 a resolución 
atómica de 1.25 Å (PDB-ID: 5LIT). Se encontraron los oligonucleótidos apilados 
organizados en columnas infinitas y paralelas en una configuración pseudo-tetragonal. 
La estructura reveló que el fármaco interacciona con la región central [AATT], ocupa el 
surco estrecho del ADN, desplaza las moléculas de agua presentes e interactúa con 
moléculas de ADN vecinas como un agente entrecruzador. 
Finalmente, se ha realizado un análisis funcional del efecto de diferentes compuestos 
bis(2-aminoimidazolinio) en Trypanosoma brucei, el cual posee un kDNA con un 
contenido de AT superior al 70%. El objetivo principal ha sido evaluar si el ADN del 
parásito es una diana para estos compuestos dentro de la célula. Para ello se ha 
estudiado su efecto in vitro mediante una combinación de citometría de flujo y 
técnicas como microscopía de fluorescencia y microscopía electrónica de transmisión. 
Los resultados permitieron demostrar que estos compuestos tienen un efecto claro 
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sobre la fase S del ciclo celular de T. brucei al dañar específicamente el kinetoplasto. Se 
ha podido concluir que los compuestos bis(2-aminoimidazolinio) FR60 y JNI18 son 
potentes tripanocidas que actúan directamente sobre el ADN del kinetoplasto. Ya que 
los compuestos muestran una actividad curativa del 100% en un modelo de ratón 
infectado por T. b. rhodesiense, representan un agente quimioterapéutico potencial-
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1 .1  The DNA 
Nucleic acids are biomolecules essential to all known forms of life. DNA 
(deoxyribonucleic acid) carries the genetic information used in all vital processes of 
every living organism, and transfers it from one generation to the next. 
The discovery of the DNA structure led to a revolution in biological science and to the 
foundation of molecular biology. The explanation of the structure of the DNA 
contributed dramatically to establish the interrelationship of its biological and 
chemical properties and functions, such as the elucidation of the genetic code (Crick et 
al., 1961), and thus establishing it as the key molecule of heredity, developmental 
biology and evolution.  
Structural determination of macromolecules has evolved to reach atomic resolution 
with the use of crystallography and single crystal diffraction, which has contributed 
significantly to increase the knowledge of properties and functions of nucleic acids 
over the last 60 years.  
1 .2  DNA Structure  
In molecular biology, DNA duplex, double-stranded DNA and double helix are used to 
describe the structure of the deoxyribonucleic acid molecule. DNA structure was first 
published by James Watson and Francis Crick (Watson & Crick, 1953) based upon the 
crucial X-ray diffraction patterns of DNA obtained by Rosalind Franklin and Maurice 
Wilkins. They described the double helix as two intertwined helical phosphate-sugar 
backbones, with the heterocyclic DNA bases projecting inwards from each of the two 
strands. The two chains are antiparallel (running in opposite directions) and are held 
together by hydrogen bonds formed between complementary nitrogen base pairs.  
DNA is the most important biopolymer for life and consists of repetitive units, called 
nucleotides (deoxyribonucleotides). Nucleotides are composed of a phosphate group 




is linked to a nitrogenous base (Figure 1-1a). DNA encodes information through the 
order, or sequence, of the short segments of nucleotides called genes, along each 
strand. Four nitrogenous bases or nucleobases establish the DNA sequence: adenine (A), 
guanine (G), cytosine (C) and thymine (T).  
A DNA strand is a string of nucleotides joined together. Nevertheless, DNA does not 
usually exist naturally as a single strand molecule. Instead, two strands running in 
opposite directions are coupled in a double helix structure creating generally very large 
polynucleotide chains (Figure 1-1b).  
 
Figure 1-1. Schemes of (a)  the three elements of a nucleotide and (b)  the DNA 
double hel ix .  
DNA is well-suited to perform its biological function because of its molecular structure. 
DNA geometric properties and configuration determine the base paring interaction, the 
helix conformation with a major and a minor groove, and the backbone charge 
distribution, among others (as presented in following sections).  
The acidic character of nucleotides is due to the presence of the phosphates, which 
dissociates at the pH found inside cells, freeing hydrogen ions and leaving the 
phosphate negatively charged. In the cell, the negative charge of DNA is shielded by its 
association with positive proteins. It also allows the interaction with other ligands, 
such as small molecules that bind the DNA helix.  




1 .2.1  Base Paring and Stacking 
The reasons behind the stability of the three-dimensional structure of DNA double 
helix are mainly the base pairing between complementary strands and the stacking 
between adjacent bases (Yakovchuk et al., 2006). 
 
Figure 1-2. Chemical structures and classif ication of the DNA nucleobases.  Red 
dotted l ines show the hydrogen bonds between adenine and thymine (AT) and 
guanine and cytosine (GC).  
DNA base pair complementarity is achieved by interactions between nucleobases. 
These bases are heterocyclic compounds with the rings containing nitrogen and carbon 
(Figure 1-2). Adenine and guanine belong to the purine group, while thymine and 
cytosine are pyrimidines. Both types of molecules complement each other with the 
opposing type of nucleobase, held together by hydrogen bonding. For an H-bond to 
occur there must be a donor group (-NH2 or –NH) and an acceptor group with at least 
one lone pair of electrons (C=O or N). Thus, the base complement adenine and thymine 
(AT) shares two hydrogen bonds, while the base pair guanine and cytosine (CG) has 
three hydrogen bonds (Yakovchuk et al., 2006) (Figure 1-2).  
DNA denaturation occurs when hydrogen bonding between nucleotides is disrupted by 
applying mechanical force, high temperature, or chemical treatment, among other 
factors. This results in the separation of previously annealed strands into two single 




such as DNA replication, transcription and DNA repair (Sicard et al., 2016). However, 
this process is reversible. DNA can be recovered as the fully base-paired duplex. 
Figure 1-2 shows the Watson-Crick (WC) base pairing, which is the most common base 
pairing configuration. Nevertheless, there are different types of base pairing dictated 
by specific hydrogen bonding patterns, such as the Hoogsteen base pair (Hoogsteen, 
1963; Abrescia, 2002; Abrescia, 2004; Acosta-Reyes et al., 2015) and Wobble (Crick, 
1966; Varani & McClain 2000), which can be formed under specific circumstances.  
The base stacking is due to pi bonding (π-π), which involves interactions between 
delocalized electrons in p-orbitals of the aromatic rings of the nucleobases. This 
includes a combination of van der Waals and dipole-dipole interactions between the 
bases. These hydrophobic, electrostatic interactions in which two or more bases are 
positioned with the planes of their rings parallel are the other essential mode of 
collaboration between bases in DNA. Undoubtedly, base stacking interactions are 
important contributors to duplex stability and also significantly contribute to the 
dependence of the duplex stability on its sequence, as well as its flexibility (Travers, 
2004).  
Pi stacking plays an important role in DNA crystal structures, stabilizing the typical 
configuration of columns in a helical arrangement of stacked oligonucleotides (HASO) 
(Campos et al., 2006). Base stacking interactions also contribute to the interactions 
between small-molecules and proteins. As a result, pi-pi and cation-pi interactions are 
important factors in rational drug design (Babine et al., 1997). 
1 .2.2  Minor and Major Groove 
In the duplex structure, the bases of one strand are paired with the complementary 
ones and are localized in the cavity left between the two backbones. In the common 
conformation of DNA, the backbones of the two strands exhibit two helical grooves 
because of their antiparallel arrangement. They are closer together on one side of the 
helix than on the other due to the glycosidic bond formed between the ribose group 




and a nitrogen base group in both nucleobases of the base pair, exposing different 
parts of the nitrogenous bases. 
The major and minor grooves are opposite to each other, and each runs continuously 
along the entire length of the DNA molecule. The major groove has 22 Å of width while 
the minor groove has12 Å. In B-DNA, the height of one helical turn measures 34 Å, 
equivalent to 10.5 base pairs (see Figure 1-1b).  
 
Figure 1-3. The minor and major grooves for B-form DNA for the base pairs GC ( left)  
and AT (r ight) .  A ,  acceptor;  D,  donor;  H, hydrogen; and M, methyl .  
The sides of each base pair are exposed so the minor and the major grooves generate 
patterns of donors and acceptors for hydrogen bonds and van der Waals interactions 
specific to each base pair (Figure 1-3). The codes of chemical groups A-A-D-H and its 
reverse pattern, H-D-A-A in the major groove specify the identity of the GC and CG 
pairs of bases respectively. Similarly, the patterns A-D-A-M and M-A-D-A uniquely 
identify AT and TA base pairs, respectively. This allows DNA binding proteins involved in 
biological processes to unequivocally recognize a DNA sequence. However, the minor 
groove’s codes A-D-A and A-H-A don’t display such explicit information. Nevertheless, 
it appears that minor groove electronegative potential may contribute significantly in 
guiding proteins to their binding sites in the genome (Lindemose et al., 2011). 
The grooves’ parameters change in every DNA type (see section 1.2.3). However, 
changes are also function of the base paring and sequence composition. These 
sequence specific variations and parameters of the DNA grooves play a vital role in 




DNA-ligand interactions through the major groove mainly tend to associate with 
proteins and through the minor groove with small molecules; since the minor groove is 
assumed too narrow to accommodate protein structures without energetically costly 
distortions. While the major groove dimensions remain very similar in free and bound 
DNA, the minor groove is particularly variable in complexes (Oguey et al., 2010). 
However, the importance of the minor groove in DNA-protein complexes has risen by 
the increasing number of X-ray structures found (Morávek et al., 2002).  
1 .2.3  DNA Parameters 
In DNA, the 2-deoxirybose is a five-carbon sugar linked to the phosphate group by 
phosphodiester bond to the third and fifth carbons of the adjacent sugars. This 
irregular bonding to C3’ and C5’ confers specific orientation of the bases on each DNA 
strand. Thus, a 5'-end of a strand means that only a phosphate group is attached to 
the fifth carbon atom of the pentose sugar of that nucleotide. On the other hand, 3'-
end of a strand is when the third carbon atom of the pentose sugar of the terminal 
nucleotide ends with a hydroxyl group. The antiparallel disposition between the two 
strands of the DNA duplex confers its directionality: one strand runs 5’ to 3’ while the 
other one runs 3’ to 5’. DNA can only be synthesized in vivo in the 5’ to 3’ direction. 
DNA folding and structural conformation is determined by a set of backbone 
parameters, including the six main chain torsion angles (α, β, γ, δ, ε, and ζ) around the 
covalent bonds and one more (χ) related to the glycosidic bond (Figure 1-4a). The five 
endocyclic torsion angles for the bonds of the sugar pucker are denoted by the symbols 
ν0, ν1, ν2, ν3, and ν4, (Figure 1-4b). All these torsional angles confer a large number of 
degrees of freedom to the DNA single strand, which are limited when the double helix 
takes place. The permissible values depend on the adopted conformation (Schneider et 
al., 1997; see section 1.2.4). The backbone torsion angles are defined in Table 1-1. 
The sugar group occupies a crucial position in the nucleotide unit because it forms part 
of both the backbone and the side chain. Since the sugar ring is non-planar and 




flexible, it can adopt different configurations, being the C3’-endo for A-DNA and the 
C2’-endo for B-DNA the most common ones.  
 
Figure 1-4. (a)  Torsion angles for backbone conformations of the i  th nucleotide in 
polynucleotide chains .  (b)  DNA sugar group and its torsion angles ν0,  ν1,  ν2,  ν3,  and 
ν4.  
The intrinsic flexibility of the DNA allows it to bend on local scales to facilitate 
genome-based processes such as transcription, DNA repair and replication (Garcia et 
al., 2007). Besides, in the highly packed state, genomic DNA is bent substantially to fit 
into the volume of a cell or cell nucleus, employing small architectural proteins that 
bend the DNA to compact the genome (Luijsterburg et al., 2008).  
The mechanical properties that give DNA its flexibility are sequence dependent (Sarai, 
et al., 1989). The physical and chemical properties of each nucleotide will define the 
base step interactions with torsional and bending specific parameters.  
Table 1-1. Atoms involved in the backbone and sugar torsion angles .  
α : O3’(i-1) – P – O5’ – C5’ β : P – O5’ – C5’ – C4’ 
γ : O5’ – C5’ – C4’ – C3’ δ : C5’ – C4’ – C3’ – O3’ 
ε : C4’ – C3’ – O3’ – P(i+1) ζ : C3’ – O3’ – P(i+1) – O5’(i+1) 
χpyrimidines : O4’ – C1’ – N1 – C2 χpurines : O4’ – C1’ – N9 – C4 
ν0 : C2’ – C1’ – O4’ – C4’ ν1 : C3’ – C2’ – C1’ – O4’ 
ν2 : C4’ – C3’ – C2’ – C1’ ν3 : O4’ – C4’ – C3’ – C2’ 






Figure 1-5. Base pair  parameters classif ication by rotations and translations.  (a)  
Local base pair  parameters ,  (b)  local base pair  hel ical  parameters ,  and (c)  local base 
pair  step parameters .   




DNA capacity to adopt a particular conformation entails important biological 
consequences (Travers, 2004). The formation of a DNA-protein complex not only can be 
achieved by the recognition of a particular sequence, but also by the identification of 
specific configurations of torsion and bending when nonspecific binding proteins have 
preference for certain DNA structural features (Heddi et al., 2010).  
DNA molecules do not have a perfect double helix. There are various structural 
variations of the strands and helices according to every individual base pair, as well as 
the neighboring base pairs along the duplex. The study of the morphology of the bases 
allows the knowledge and identification of many features and deformations of nucleic 
acids structures related to the sequence. In order to standardize those variations, a set 
of parameters was defined according to the Cambridge convention (Dickerson, 1989; 
Lu & Olson, 2003): 
§ Parameters for individual base pairs: 
- Local (or complementary) base pair parameters: the relative position and 
orientation between bases of a base pair (Figure 1-5a). 
- Local base pair helical parameters: the position and orientation of a rigid 
body formed by one base pair (Figure 1-5b).  
§ Parameters for local base pair step: the relative position and orientation from 
one base pair to its adjacent (Figure 1-5c).  
1 .2.4  DNA Double Helix Forms 
Previous sections have described the most common DNA-form described by Watson 
and Crick, called B-form. Nevertheless, there are other theoretical DNA conformations 
such as A, C, D, Z. However, only forms A, B and Z exist within the cells of living 
organisms (Figure 1-6).  
The helical structure of DNA is variable and depends, among other factors, on the 
nucleotide sequence, hydration, chemical modifications and superhelical tension. 




local environment, with DNA-ligand interactions that often lead to a change of 
conformational state (Lu & Olson, 2003). 
 
Figure 1-6. Top and side views i l lustrating the characterist ic features of regular 
hel ical  structures of DNA forms A, B and Z.  Generated by parameters reported in (Lu 
& Olson, 2003) .  
Table 1-2 lists the structural parameters for the three structural families of DNA helical 
conformations. B-DNA is the term given for the canonical DNA helix and consists, as 
mentioned before, in a double helix made of two antiparallel strands that are held 
together via hydrogen bonding in the AT and GC base pairs. In B-DNA the distance 
between the bases (rise) is 3.4 Å and the diameter of the helix is 20 Å (Figure 1-1b). 
However, crystallographic studies of oligonucleotides had shown significant sequence-
dependent flexibility of the parameters on B-DNA helix listed in Table 1-2. The A- and 
B-DNA families are right-handed (dextrorotatory) helices, while the Z-DNA family has 
a left-handed orientation of the helix (levorotatory). 
The A-DNA form has eleven base pairs per helical turn, a tilt of about 20 Å with 
respect to the helical axis and an average rise of 2.55 Å, resulting in a shorter and 
more compact helix where the base pairs are not perpendicular to the helix-axis as in 
B-DNA. The major groove of A-DNA is narrower and deeper, while the minor groove is 
wide and slightly shallower. The sugar pucker is C3' endo compared to C2' endo for B-




DNA and the base pairs are shifted to the helix edge, which generate a 9 Å hole in the 
centre of the helix.  
In 1952, Rosalind Franklin discovered and named the A and B form, and she also 
established that A-DNA conformation occurs in non-physiological dehydrating 
conditions (Franklin & Gosling, 1953). This explains the incidence of A-DNA structures 
found by X-ray crystallography; as such conditions are commonly used to form crystals. 
However, A-DNA form has been identified as the most biologically active non-B-DNA 
conformation.  
Table 1-2. Structural  parameters of DNA configurations.   
Structural Parameter A-DNA B-DNA Z-DNA 
Direction of helix rotation Right handed Right handed Left handed 
Residue per helical turn 11 10.5 12 
Axial rise per residue 2.55 Å 3.4 Å 3.7 Å 
Pitch (length) of the helix 28 Å 33.2 Å 44.6 Å 
Base pair tilt 20° -6° 7° 
Rotation per residue 32.7° 34.3° -30° 
Diameter of helix 23 Å 20 Å 18 Å 
Configuration dA, dT, dC anti anti anti 
of glycosidic bond dG anti anti syn 
Sugar Pucker dA, dT, dC C3' endo C2' endo C2' endo 
dG C3' endo C2' endo C3' endo 
Values from Potaman & Sinden, 2013. 
The B- to A-DNA conformational transition in vivo is reversible, cooperative and comes 
from many different aspects including the sequence, the hydration level and the 
interactions with enzymes, ions and ligands involved in biologically relevant reactions 
(Whelan et al., 2014). This helical conformation occurs in double-stranded r ibonucleic 
acids (dsRNAs), and in DNA-RNA hybrid double helices. Specific sequence repeats such 
as 5’-CC-3’ and 5-’ACT-3’, that present predisposition to adopt an A-DNA have been 
found (Feig & Pettitt, 1998). Other authors found preference for CG-rich sequences to 
assume A-form most easily, attributed to the ability of cytosine to switch to C3’ endo 
and have been confirmed by quantum mechanics calculations and nuclear magnetic 




experimental and theoretical studies have confirmed that some sequences as the A-
tracts can generate intermediate DNA conformations with specific structural 
parameters like the *B-DNA (Hud & Plavec, 2003). 
The third active form of duplex DNA has an outstandingly different, left-handed helical 
structure with a pronounced zig-zag pattern in the phosphate-sugar backbone (Wang 
et al., 1979). Z-DNA is formed by short stretches of alternating purines and pyrimidines, 
particularly poly(dG-dC)2, in negatively supercoiled DNA, or at high salt concentrations. 
The sugar of the G nucleotide is in the C3’ endo conformation, but the guanine base is 
in the syn conformation, positioned the guanine back over the sugar ring; while in A- 
and B-DNA guanine adopts the common and most favoured anti orientation (Figure 
1-7). This syn conformation is the responsible for the laevorotatory structure. Z-DNA 
has twelve bases per turn with a rise of 3.8 Å; the grooves, unlike A- and B-DNA, show 
little difference in size. 
 
Figure 1-7. Structures of anti  and syn  guanine nucleoside conformations.  
Z-DNA only exists in a small amount of the DNA, and is difficult to study due to its 
instability. Although its biological role has not been fully elucidated, proteins involved 
in transcriptional activity that recognize and bind Z-DNA with great specificity have 
been found (Oh et al, 2002). 
The transition from B- to Z-DNA occurs, despite it is a higher energy conformation, 
under physiological salt conditions when cytosine is methylated (Behe & Felsenfeld, 
1981). This transition can also form an intermediate called B-to-Z junction box, which 
is involved in the base pair extrusion (De Rosa et al., 2010; Martinez de Ilarduya et al., 
2010).  




1 .2.5  DNA Structural Scales 
The elaborate three-dimensional shape of biomolecules can be explained at any of 
several organization levels starting from the level of individual atoms until complex 
organizations between two or more biopolymers. The DNA structural scale 
classification is expressed in four levels: primary, secondary, tertiary and quaternary 
(Figure 1-8).  
Primary Structure 
The primary structure of a nucleic acid describes the detailed atomic composition and 
the chemical bonds connecting those atoms. Hence, DNA primary structure refers to 
the exact sequence of nucleotides and the phosphodiester bonds that comprise the 
chain starting from the 5’ end to the 3’ end.  
Secondary Structure 
The secondary structure defines the pattern of hydrogen bonds in a biomolecule. In 
DNA, it is determined by the intramolecular H-bonds between the nucleobases of one 
strand with its complementary one. This structural level described the double helix of 
the DNA molecule formed by two strands of nucleotides in antiparallel position, held 
together by the formation of the hydrogen bonds between nucleobases associated to 
both strands, where the base pairing geometry and helical parameters variations can 
create different arrangement of DNA as A, B, Z, and others (see section 1.2.4).  
These interactions between bases occur only when a purine pairs a pyrimidine (see 
section 1.2.1). Besides the canonical Watson-Crick base pairing, where CG base pairs 
are bound by three hydrogen bonds whilst AT base pair forms two H-bonds, variations 
between the base pairing conformation can generate alternate hydrogen bonding 
patterns, such as the Wobble base pair and Hoogsteen base pair. Moreover, DNA can 
adopt other secondary structures by the presence of mismatches or changes in the 





Tertiary Structure  
The tertiary structure of a DNA molecule comprehends its three-dimensional structure, 
as defined by the atomic coordinates in space. The ability of DNA to fold into highly 
compact and extremely ordered 3D forms leads to this structural scale.  
Both linear and circular DNA molecules can rotate, twisting around each other, to 
adjust to changes of various dynamic processes in the cell triggering supercoiled DNA, 
which is the tertiary structure of DNA (Figure 1-8). Supercoiling, specifically the 
negative one, can cause B-DNA to adopt a four-armed, cruciform structure that 
resembles a Holliday junction, or stabilize three-stranded triplex DNA (Bochman et al., 
2012). Macro helices and other non-canonical structures like triplexes and 
quadruplexes formed in telomeres are also included in the tertiary level of structure.  
 
 
Figure 1-8. The four structural  scales in DNA.  
 




The Quaternary Structure 
The quaternary structure is the higher level of organization and it refers to the 
interactions between two or more nucleic acid molecules, or between nucleic acid 
molecules and proteins. The most commonly seen form of this DNA structural scale is 
the interaction with the nuclear proteins histones to create nucleosomes when DNA 
packing in eukaryotic chromatin takes place (Figure 1-8). DNA quaternary structures 
change constantly according to the regions of genes needed to be transcript or during 
DNA replication.  
1 .3  AT-Rich DNA 
High AT-content in the range of 70% or more is called AT-rich DNA. AT-rich sequences 
can form motifs located strategically in the genome to perform a particular function. 
These repeated sequences are present in the sites for DNA replication initiation in both 
eukaryotic and prokaryotic replicons, as binding places or regulatory factors for the 
appropriate replication initiation protein. The AT-rich fragment of the replication origin 
represents the most ubiquitous conserved structural element identified in all replicons 
(Rajewska et al., 2012). This AT-rich sequence contains the DNA unwinding element 
(DUE), where the initial DNA helix destabilization (unwinding) occurs during the 
process of replication initiation (Kowalski & Eddy, 1989; Carr & Kaguni, 2001). 
The AT-rich regions constantly play an important role in the regulation of gene 
transcription through the ability to influence transcription factors (TFs) and chromatin 
proteins. The TATA box is an AT-rich DNA sequence found in the promoter region of 
genes that facilitates easy unwinding and bending of the DNA double helix during the 
process of transcription by the TATA binding protein (TBP; Roeder, 1996). The matrix 
attachment regions (MARs) are AT-rich DNA sequences that could facilitate dynamic 
processes in chromatin structure allowing accessibility to transcription factors at their 
binding sites (Hart & Laemmli, 1998; Petersen el al., 2002), such as the transcriptional 
regulation protein SATB1, which recognizes and binds specific regions of MARs in order 




H1 histone preferentially binds AT-rich DNA to repress their transcription and 
therewith to contribute to chromatin condensation (Roque el al., 2004, Flickinger, 
2015). The chromatin proteins called HMGA (High mobility group A) are able to bind 
DNA in AT-rich regions and regulate gene expression by acting as architectural 
proteins (see section 1.5.1.1; Baldassarre et al., 2005). 
In spite of the identification of many AT-rich motifs, the fully knowledge about the AT-
rich regions is limited. Nevertheless, it is important to emphasize the strong 
relationship between the two main functions of the AT-rich sequences in the genome: 
the protein recognition and the structural peculiarities. These structural distinctions 
have been specially studied within the A-tracts. Formed by four adenine and/or 
thymine nucleotides, the A-tracts are a universal DNA element in regulatory regions of 
many organisms (Haran & Mohanty, 2009). When they are inserted in phase with the 
helical periodicity, these motifs present a narrow minor groove and an unusual DNA 
form due to its flexibility, giving rise to a global curvature of the DNA double helix and 
increasing stability of the DNA complexes with architectural proteins (Hizver et al., 
2001; Tolstorukov et al., 2005).  
1 .3.1  Non-coding DNA 
Firstly called “junk DNA” because its supposed lack of biological functions for the 
organism, the non-coding DNA are sequences in the genome that do not encode 
protein sequences. Although the functions of the non-coding sequences are not 
completely clear yet, researchers have shown that a large fraction of this DNA is 
transcribed and plays an important role in the regulation of differential gene 
expression by the transcription of non-coding RNAs (Mattick, 2009). Other sections of 
non-coding DNA provide regulatory sites (i.e., binding sites where transcriptional 
proteins can bind to enhance or inhibit transcription), or act as structural elements 
involved with chromatin and other architectural DNA components (Narlikar & 
Ovcharenko, 2009).  




Non-coding DNA corresponds to the vast majority of the entire genome and is 
composed by repeated sequences, usually regions that contain an above average 
number of adenine and thymine bases (Campos et al., 2006).  
The distinctive features of AT-rich DNA are based on its structural and mechanical 
properties. The low thermodynamic stability of AT-rich regions causes the relatively 
easy melting of the double helix, but provides also flexibility and high degree of 
polymorphism. 
1 .3.2  AT-Rich Organisms 
The ratio between the four nucleotides in organism genomes is not equal and the shifts 
to very high AT or CG content levels can occur in many different proportions for every 
living system. Hence, Dictyostelium discoideum is an example of AT-biased genome 
with 78% of AT content, while Streptomyces ceolicolor A3(2) with only 28% of AT 
content is an example of a CG-rich genome. Shifts to very high AT or GC levels can 
occur in several distinct branches of the tree of life. The underlying reasons for these 
shifts therefore may be of different origin (Szafranski at al., 2005). 
The singular properties of the AT-rich DNA and the necessity to understand the 
unknown biological functions of certain AT-rich sequences encourage our interest on 
organisms with high AT content. This includes various parasites, like the human malaria 
parasite Plasmodium falciparum, which has a genome with extremely high AT content 
(80%) and numerous repetitive sequences (Gardner et al., 2002). Another example are 
species of kinetoplastid parasites, such as the genus Trypanosoma present a kinetoplast 
(see section 1.7.2) with high content of adenines and thymines (around 70%). 
The reason why the DNA of these organisms is constituted mainly by AT is not clear. 
Comparison of the genomes of P. falciparum and D. discoideum shows that the slightly 
higher AT content of P. falciparum genome compared to D. discoideum (80.1 versus 
77.4%) is not achieved by increased AT richness in intergenic regions. Instead, both the 




intergenic regions make an equal contribution to the higher AT content in this 
organism (Szafranski at al., 2005). 
1 .3.3  Importance of AT-Rich Regions in Target Site 
Recognition 
Previous sections have listed several AT-rich regions that are implicated in gene 
regulation and DNA folding processes. Those regions act as specific binding sites for 
certain proteins and their accessibility is crucial to achieve the protein-DNA binding 
and thus, the right performance of DNA functions. Therefore, the ability to disrupt or to 
direct changes in gene activity and replication functions can be performed by other 
molecules such as drugs that specifically target these sequences. 
An example is the nucleosome disruption by the DNA binding drug DAPI (Fitzgerald & 
Anderson, 1999). DAPI specificity for AT sites creates a DNA-drug interaction that 
prevents the nucleosome from forming on the DNA bending, leading to a histone-free 
DNA during the assembly reaction. Opposite structural changes in the chromatin 
structure are caused by distamycin A, a drug that preferentially binds to AT-rich DNA 
(Radic, Lundgren, & Hamkalo, 1987). In this case, the drug distamycin A induces the 
compaction of the chromatin by two mechanisms: linker DNA bending and 
internucleosomal angle contraction. Changes in chromatin packing may directly affect 
protein binding, altering the recognition of genes towards transcription factors 
(Majumder & Dasgupta, 2011).  
Some other AT-rich DNA-protein interactions could be not favourable for the cell 
health. This research works focuses on the subfamily of proteins HMGA, which binds 
preferentially to AT-rich DNA regions of the chromatin and their overexpression is a 
hallmark of several metastatic cancers (Hock et al., 2007) (explained in detail in 
section 1.5.1.1). Studies on the use of drugs to directly interfere with the DNA-HMGA 
binding have found that the drugs distamycin (Smith & Buchmueller, 2011) and 
netropsin (Miao et al., 2008) cause a displacement of HMGA protein motifs from the 
DNA, acting as competitors for the same binding site. Furthermore, the DNA-




intercalator drug cisplastin seems to enhance sensitivity in mouse embryonic stem cells 
with high expression levels of HMGA1 proteins (Baldassarre et al., 2005).  
One of the main focuses of this research work is the study of the DNA as a biological 
target for antiparasitic drugs, particularly against Trypanosoma brucei, the causative 
agent of African sleeping sickness. The kinetoplast of this parasite is particularly AT-
rich, with about 73% of AT content (Chen & Donelson, 1980) and thus, presents a 
likely target for diamidines who bind the minor groove of parasitic DNA (Scott et al., 
2016). DNA-binders with preference for AT sequences as the aromatic dications 
pentamidine, diminazene, furamidine and several derivatives are being used against 
different strains of T. brucei, showing high efficiency but, in some cases, toxic side 
effects (Wilson et al., 2008; Scott et al., 2016). 
1 .4  DNA-Ligand Binding  
In DNA-ligand binding studies, the ligand can be a drug (small molecule), an ion or a 
protein, which binds to the DNA duplex. The interaction between the DNA and the 
ligand may be function of charge, hydrophobicity or structural features, and occurs 
generally by intermolecular forces, such as ionic bonds, hydrogen bonds and van der 
Waals forces. When the DNA-ligand binding occurs, it may induce conformational 
changes in the DNA, the ligand or both. 
The tendency or strength of a ligand to interact with its binding sites can be measured 
in terms of a binding affinity. In addition to the DNA and the ligand, the solvent plays 
a very important role in binding recognition and affinity since it provides the 
environment to drive or reject the binding (Baron, et al., 2010). 
1 .5  DNA-Protein Interactions 
DNA-protein interactions control a number of important cellular processes: 
transcription factors modulate the process of transcription; various enzymes including 




chromosomal proteins such as histones or HMG proteins are involved in chromosome 
packaging. 
Some DNA-protein interactions are mediated by DNA flexibility, particularly when 
architectural proteins are involved. Factors like temperature and nucleotide sequence 
contribute in the DNA intrinsic flexibility (Driessen et al., 2014; Geggier & Vologodskii, 
2010).  
The binding can occur to specific sequences or through non-specific DNA-binding 
proteins, and they could present affinity for either single or double stranded DNA. 
Nevertheless, all DNA-binding proteins are composed of domains where the binding 
takes place. Most of the binding proteins interact with the major groove of the DNA 
helix. However, the HMG proteins bind to the minor groove of the double helix. 
Basically every biological function of DNA depends on site-specific DNA-binding 
proteins finding their targets (Halford & Marko, 2004).  
1 .5.1  HMG proteins 
The ‘High Mobility Group’ (HMG) is a family of ubiquitous and abundant non-histone 
nuclear proteins. The main function of HMG proteins is to coordinate and facilitate 
DNA-directed nuclear processes by producing structural changes in the structure of 
DNA and in the organization of the chromatin fiber (Bustin, 1999; Reeves, 2010). 
Discovered in the early 1970s, the HMG proteins receive their name according to their 
electrophoretic mobility in polyacrylamide gels. They were characterized by having low 
molecular weight and high content of positively charged amino acids (Goodwin, 1973). 
According to their DNA binding motifs, HMG proteins are classified into three families 
(Table 1-3): HMGA, HMGB and HMGN, previously called HMG-I/Y, HMG-1/2 and HMG-
14/17 respectively. The members of each family are ubiquitously and abundantly 
expressed in most eukaryotic cells. Although they display different binding domains 
and structures, all of them act as architectural factors (Štros, 2010).  




The execution of vital cellular processes involves multiple changes in gene expression 
where the structure of the nucleosome and the chromatin play a central role. Therefore 
proteins like the HMG family, which contribute in remodeling the assembly of 
chromatin, are crucial mediators of proper or abnormal cellular development (Hock et 
al., 2007).  
HMG proteins are involved in many biological processes such as cellular differentiation, 
embryonic development, transcription regulation and DNA repair modulation. However, 
each HMG family influences different sets of those processes.  
Table 1-3. The three HMG protein famil ies and their  main characterist ics .  











Bind into the minor groove of DNA with 






Bind inside Nucleosomes, between DNA 
spires and the histone octamer 
The main structural features, size and DNA binding specificities of HMGs are shown in the table. 
HMGAs contain three AT-hooks (green) and HMGB have two HMG-boxes (orange), both contain an 
acidic C-terminal end (purple). HMGN includes a Nucleosomal Binding Domain (NBD, red) and a 
negatively charged C-terminal region named chromatin unfolding domain (CHUD, purple).  
The HMGA family is constituted by four members: HMGA1a, HMGA1b, HMGA1c and 
HMGA2. All of them contain three AT-hook motifs, except the HMGA1c which contains 
only two. The AT-hooks are segments of seven to nine amino acids unstructured in 
solution, which bind to the minor groove of AT-rich DNA regions. In mammalians, the 
members of the HMGB family are: HMGB1, HMGB2, HMGB3 and HMGB4. Each of 
them contains two HMG-boxes and an extended acidic C-terminus. The HMG-box 
domain presents about 75 amino acids and binds also to the minor groove of DNA but, 
in this case with limited or no sequence specificity. The third and last family is the 
HMGN composed by six members: HMGN1, HMGN2, HMGN3a, HMGN3b, HMGN4 and 




presence of a positively charged nucleosomal binding domain (NBD) with 30 amino 
acids through which they bind specifically to the nucleosome core. 
HMG proteins interactions with DNA and other proteins are highly regulated by 
extensive post-translational modifications (PTMs). Essential participants in the 
performance of nuclear functions, PTMs in HMG proteins include phosphorylation, 
acetylation, methylation, glycosylation and ADP-ribosylation (Zhang & Wang, 2010). 
The mechanisms by which HMG proteins alter the chromatin structure vary according 
to each member of the family. HMGAs and HMGBs can facilitate the binding of 
additional proteins (as TFs) by DNA bending activity (Reeves, 2001; Bianchi & Agresti, 
2005). On the other hand, the DNA-HMGN complex is able to either prevent or assist 
the access of modulating factors to chromatin (Lim et al., 2005). HMGA proteins as 
HMGNs, bind to nucleosomes and as part of regulatory multiprotein complexes can 
modulate the nucleosome flexibility, compacting or unfolding the chromatin. HMGA 
competes with histone H1 for binding sites in the chromatin. The interactions HMGA-
H1-nucleosome provide flexibility to the chromatin structure affecting its functions 
(Bianchi & Agresti, 2005). 
As specific modulators of chromatin, HMG proteins impact various cellular functions 
and affect the development and diseases. HMGs are present during embryonic 
development and most of them are gradually down-regulated until their absence or 
low expression in adult tissues (Fusco & Fedele, 2007). Overexpression of HMG proteins 
alters the cellular phenotype and may lead to anomalies such as developmental defects, 
diseases and cancer. Hence, high levels of expression of some HMGAs and HMGBs 
represent a feature (biomarker) of malignant tumours and are strongly related to 
neoplastic cell transformation (Fusco & Fedele, 2007; Shah & Resar, 2012).  
1.5.1.1 HMGA	
The human high mobility group A (HMGA) proteins comprise two types of proteins 
(HMGA1 and HMGA2) produced by different genes. The first group includes three 
proteins encoded by alternative splicing of the same gen: the two abundant variants 




HMGA1a and HMGA1b, and one unusual variant, the HMGA1c. The HMGA2 protein is 
encoded by a different gene (Figure 1-9). 
The HMGA1a protein is composed of 107 amino acids, HMGA1b has 96, HMGA1c 179 
and HMGA2 comprises 109 residues. All HMGAs have a similar structure and are 
conserved during evolution. Each protein contains three domains named AT-hooks 
(except HMGA1c which only has two), through which they bind the minor groove of 
DNA, and an acidic carboxy-terminal tail which role is still unknown although it may 
be important in modulating protein-protein interactions (Cleynen & van de Ven, 2008) 
(Figure 1-9). AT-hook motifs bind AT-rich sequences but, rather than be sequence-
specific DNA binding proteins, the HMGA proteins recognize particular structures of 
the DNA helix.  
 
Figure 1-9. Schematic representation of the HMGA human protein-coding gens.  
Black arrows indicate the direction of the gene in the chromosome and their  boxes 
i l lustrate their  respective exons.  Dark blue boxes represent the exons transcribed in 
mRNA and code for HMGA proteins .  AT-hooks are shown in green and acidic C-
terminal region in red.  Adapted from Fusco & Fedele ,  2007.  
Figure 1-10 shows the primary structure of the HMGA proteins. The AT-hook motif is a 
positively charged nine amino acid tract with a central repeat Pro-Arg-Gly-Arg-Pro 
(AT-hook I contains a glycine instead of the first proline), flanked by flexible and 
positively charged residues. Furthermore, at their C-terminal end, the HMGA proteins, 
except for HMGA1c, have a high content of negatively charged acidic residues. 
Secondary and tertiary structures of HMGAs in solution are not defined since they 




fixed or ordered three-dimensional structure. However, the central element of the AT-
hook induces structure formation upon binding with DNA (Slama-Schwok et al., 2000). 
In reality, the structural changes are induced in both, protein and DNA when the 
interaction occurs (Dunker et al, 2008).  
 
Figure 1-10. Amino acid al ignment of human HMGA proteins .  Unique sequences are 
indicated by lowercase letters .  AT-hook central  invariant repeat R-G-R-P is  shown 
in green boxes and C-terminal acid tai l  in purple boxes.  BLAST 
[http://blast .ncbi .nlm.nih.gov/Blast .cgi#] .   
Hence, the study of DNA-HMGA interactions through structural studies has been 
challenging. A couple of decades ago, NMR studies have revealed the structure of a 
complex between a truncated form of HMGA protein (from the residue 51 to the 90), 
containing the II and III AT-hook motifs with the DNA dodecamer GGGAAATTCCTC 
(Figure 1-11a). There, it was shown how the central fragment RGR (Arg-Gly-Arg) of the 
AT-hook adopts an ordered and well-defined conformation that adapts perfectly to the 
minor groove of the oligonucleotide (Geierstanger et al., 1994; Huth et al., 1997). For a 
better understanding of the complex stabilization, the AT-hook motif structure can be 
divided into three segments: the central RGR core with an extended conformation deep 
in the minor groove, the residues lysine and arginine at either end of the central core 
provide electrostatic and hydrophobic interactions with the DNA backbone, and in the 
II (but not the III) domain, the six C-terminal residues next to the core interact with 
the backbone on the edge of the minor groove (Huth et al., 1997).  
However, it was not until 2012 when a member of our research group (MACROM), 
could crystallize and solve the first crystal structure of an AT-hook (Fonfría-Subirós et 




al., 2012). The structure shows the III AT-hook peptide in complex with the AT-rich 
oligonucleotide CGAATTAATTCG and exhibits in detail the interaction of the AT-hook 
domain in the minor groove of the double helix (Figure 1-11b). The inner PRGRP 
sequence of the AT-hook peptide interacts with one of the AATT regions of the DNA 
dodecamer and fully occupies its minor groove. In the binding region, the minor groove 
is 4 -5 Å wider than the free minor groove.  
 
Figure 1-11. Top and front views of AT-hook interactions with DNA. (a)  NMR 
structure of the complex of DNA dodecamer and the I I  AT-hook (PDB ID: 2EZD).  (b)  
Crystal  structure of a complex of AT-r ich ol igonucleotide with the I I I  AT-hook of 
HMGA (PDB ID: 3UXW). The DNA dodecamers (a)  GGGAAATTCCTC and (b)  
CGAATTAATTCG shown as partial ly transparent objects are drawn with Pymol .   
HMGA proteins act as architectural elements positively and negatively regulating the 
transcription of a variety of genes by changing the DNA conformation or by interacting 
with several transcription factors (Ozturk et al, 2014). In this way, they are involved in 
multiple nuclear processes including cell growth, proliferation, differentiation and 
induction of apoptosis (Fujikane et al., 2016). The mechanism of action of the HMGA 
proteins according to the substrates with which they interact, can be summarized in 
the following list:  
§ HMGAs direct interactions with DNA. They can bind to specific structures in 




consequently facilitating the binding of transcription factors, giving rise to 
multiprotein stereospecific complexes bound to DNA (Figure 1-12a).  
§ HMGAs direct interactions with TFs. They can bind to a variety of 
transcription factors, changing its conformation and thus enhancing its DNA 
binding affinity (Figure 1-12b). 
§ HMGAs interactions with chromatin. They can be associated with specific 
segments of genomic AT-rich DNA that have affinity for nuclear MAR and 
SAR (matrix- and scaffold-associated regions), and de-represses transcription 
by displacement of histone H1 from the chromatin structure (Figure 1-12c). 
§ HMGAs as co-factor in virus integration and expression. They can facilitate 
the integration of the double-stranded linear cDNA copies of virus genomes 
into host cell chromosomes (Li et al., 2000). 
 
Figure 1-12. HMGA proteins interactions with (a)  DNA, (b)  other proteins such as 
transcription factors (TF) ,  and (c)  the chromatin structure.  Fusco & Fedele ,  2007. 
The first example of HMGA interactions was described with the interferonß (IFN-ß) 
promoter. HMGA1 stimulates the binding of a specific isoform of the activating 
transcription factor 2 [ATF-2(195)] but also inhibits the binding of ATF-2(192) to the 
IFN- ß gene promoter (Du & Maniatis, 1994). The activation of the ATF-2(195) is 
stimulated by the bending of the DNA caused by the HMGA.  




Another kind of interactions with DNA occurs when HMGA proteins alter the 
chromatin structure by forming a higher order transcriptional complex 
“enhanceosome”. After binding DNA, the HMGA is able to coordinate the assembly of 
additional TFs, altering the expression of specific target genes (Shah & Resar, 2012). 
Both HMGA1 and HMGA2 genes are highly and ubiquitously expressed during 
embryogenesis in undifferentiated or rapidly proliferating cells, and very low expressed 
or non-expressed in normal adult tissues (Reeves, 2001; Macrì et al., 2016).  
HMGA proteins may play a significant role in human disorders, particularly in 
tumorogenesis. After the embryogenesis, there is a generalized de-repression of 
HMGA1 and frequently HMGA2 expression in tumor cells. Overexpression of HMGA1 
has been found in various types of malignant epithelial tumors in organs such as 
prostate, colorectum, lung, breast, pancreatic, gastric, cervical and thyroid (Shah & 
Resar, 2012). In every instance, a correlation between the concentration of HMGA1 
and the degree of malignancy or metastatic potential has been found (Fedele & Fusco, 
2010). HMGA2 overexpression is also observed in breast cancer, sarcomas, pancreatic 
neoplasms, oral squamous cell carcinomas, and non-small cell lung cancer (Cleynen & 
van de Ven, 2008). The strong and consistent association between levels of expression 
of HMGA proteins and human cancers arising from diverse tissues suggests them as 
potential biomarkers for neoplastic transformations (Shah & Resar, 2012). 
Aberrant expression of HMGA proteins is related to other human pathologies besides 
cancer. Examples of serious diseases where HMGA proteins play important roles are 
type 2 diabetes mellitus (Chiefari et al., 2011), obesity (Anand & Chada, 2000) and 
idiopathic pulmonary fibrosis (Pandit et al., 2010). Moreover, HMGA1 proteins are 
critical cellular factors required for the formation of functional HIV-1 preintegration 
complexes, its integration in the host genome and the viral gene transcription (Slama-
Schwok et al., 2000). 
The canonical HMGA proteins are not only expressed in mammalians, but also in other 
vertebrates such as the African clawed frog Xenopus laevis. This species has two allelic 




al., 2006; Macrì et al., 2016), and the gene Xhmgax, which encodes a highly divergent 
HMGA with eight AT-hooks (Vignali et al., 2008). Most plants and invertebrates also 
express variants of HMGAs. An example is the fly Drosophila melanogaster that 
expresses the D1 protein, orthologue of HMGA, presenting ten repeated AT-hook 
motifs (Aulner et al., 2002). 
In fact, studies have reported on the existence of more than 100 proteins from 
different species containing the AT-hook DNA-binding domain, including Aspergillus 
nidulans, Arabidopsis thaliana, Gallid herpesvirus 1, Saccharomyces cerevisiae (Aulner 
et al., 2002; Aravind & Landsman, 1998), as well as many species of Leishmania (Kelly 
et al., 2011).  
1.5.1.2 HMGB	
The mammalian high mobility group B (HMGB) comprises four types of proteins 
encoded by distinct genes: HMGB1 with 215 amino acids, HMGB2 with 209, HMGB3 
contains 200 amino acids, and the recently discovered HMGB4 is composed of 186 
residues. The canonical HMGB1-3 proteins share more than 80% identity. HMGB4 
presents a lower molecular mass and lacks the C-terminal tail (Štros, 2010). 
Nevertheless, all members of the HMGB family contain two DNA-binding domains 
called HMG-boxes A and B (Figure 1-13). The two boxes are structurally similar, and 
their motions are completely independent (Bianchi & Agresti, 2005).  
HMGB proteins exhibit not only high mobility in polyacrylamide gels like the rest of the 
HMGs, but they also show it in the nucleus, being the most dynamic nuclear proteins 
in cells (Scaffidi, et al., 2002).  
All members of the HMGB family share a great similarity in the primary structure as 
shown in the amino acid sequence alignment of the HMGB proteins in Figure 1-13. The 
distinction is basically the acidic C-terminal tail length and in the case of the HMGB4, 
the lack of it. In contrast to the HMGAs, the two tandem highly homologous HMGB 
group motifs, HMG-boxes A and B, have a well-defined secondary and tertiary 
structure, while the acidic tail seems to be unstructured (Bianchi & Agresti, 2005). 




Each HMG-box domain contains approximately 75 amino acids and is composed of 
three α-helices folded up into a typical wedge shape (Weir et al., 1993). This 
characteristic L-shape architecture from the tripartite structure of the HMG-box forms 
a concave surface that can delve into the minor groove of DNA with little or null 
apparent sequence specificity.  
 
Figure 1-13. Amino acid al ignment of human HMGB proteins.  Residues contained in 
HMG-boxes are highlighted in brownish and C-terminal acid tai l  in purple.  [*]  
Residues identical in al l  sequences in the al ignment; [ : ]  conserved substitutions; 
and [ . ]  semi-conserved substitutions.  Al ignment created by UniProt 
[http://www.uniprot .org/al ign/] .  
The HMG-box motif has been identified in more than 150 different proteins in a large 
variety of organisms including human, bovine, rat, mouse, chicken, Drosophila, 
Arabidopsis, Xenopus, Saccharomyces cerevisiae, Trypanosoma brucei (see section 
1.7.2.1), among others (Baxevanis & Landsman, 1995). According to the evolutionary 
and functional conservation, abundance, and DNA specificity, the HMG-box-containing 
proteins are grouped into two families. The first one, the most abundant, has little or 
no DNA sequence specificity and can present either a single motif such the Drosophila 
proteins HMGD/Z and the S. cerevisiae proteins Nhp6A/B; two in tandem like the 
human HMGB proteins and the mitochondrial transcription factor A (TFAM; Ngo, et al., 
2011); or more than two DNA binding domains like the Xenopus laevls transcription 
factor xUBF with 5 tandemly repeated HMG-boxes (Bachvarov & Moss, 1991). The 
second family of HMG-box-containing proteins is able to recognize and bind specific 
DNA sequences and includes a few sequence-specific transcription factors such as the 




The structures of the mammalian HMG-boxes A and B have previously been 
determined individually by NMR structural studies (Figure 1-14) (Hardman, et al. 1995; 
Weir et al., 1993). The conserved fold structure of the three α-helices in the HMG-box 
forms an L-shape with an angle of approximately 80° between the long and the short 
arms. Helix III and the extended N-terminal part create the long arm, while the short 
arm is composed of helices I and II (Štros, 2010).  
 
Figure 1-14. Domain structures of HMGB1 protein.  Schematic representation of the 
HMGB proteins and the α-helices within the HMG-boxes A (orange; PDB ID: 1AAB) 
and B (blue; PDB ID: 1HME) as determined by NMR microscopy (Hardman, et al .  
1995; Weir et al . ,  1993) .   
The tertiary structure of the HMGB1-3 proteins shows the conserved Cys23 located at 
the centre of helix I and Cys45 at helix II, opposing each other and at a distance 
capable to form a disulphide bond under appropriate oxidative conditions. HMGB4 
lacks the Cys23 (Barreiro-Alonso et al., 2016).  
NMR structures of the HMG-boxes of HMGD (Drosophila HMGB1-like protein), Nhp6A 
(yeast HMGB1-like), the transcriptional activators SOX-2, SOX-4 and SOX-17, and the 
human UBF HMG-boxes are also published in the PBD (Protein Data Bank). SOX-17 
(Gao et al., 2013), the human mitochondrial transcription factor A box B (PDB ID: 3FGH; 
Gangelhoff et al., 2009) and UBF HMG-box 5 (PDB IDL: 2HDZ; Rong et al., 2007) has 
also been determined by X-ray crystallography. 




The homologous structures of the HMG-boxes A and B in mammalians differ slightly. 
Box A presents a shorter and straighter helix I, has a longer length of the loop between 
helices I and II, and more positive charge in the helices I and II as compared to box B 
(see Figure 1-13 & Figure 1-14). This distribution of charged surface residues of box A 
gives it significantly greater affinity for unusual or distorted DNA configurations such 
as four-way junctions (Teo et al., 1995).  
Significant age-dependent changes of HMGBs expression have been identified in many 
organisms. In mice for example, HMGB1-3 proteins are expressed in early embryos, but 
HMGB2 and HMGB3 are down regulated during embryogenesis (except for the HMGB2, 
which remains highly expressed in lymphoid organs and testes). On the other hand, 
HMGB1 is expressed during embryogenesis and continues in adult cells (Hock et al., 
2007).  
The evolutionarily highly conserved HMGB proteins participate in divergent biological 
tasks by means of two different roles: intracellular and extracellular. In the nuclear role, 
they may act as architectural factors through the following mechanisms:  
§ Acting as a DNA chaperon protein, binding the chromatin, altering the DNA 
configuration while: 
- Enhancing accessibility to transcriptional protein assemblies (Tang et al., 
2010; Bianchi & Agresti, 2005) on specific DNA targets (Figure 1-15a).  
- Stabilizing a partner protein on its target and in some cases, augmenting 
the affinity of other DNA binding proteins (Figure 1-15b; Hock et al., 2007), 
e.g. the interactions with the TBP (TATA-binding protein)/TATA-box complex 
affect the recruitment of other transcription factors (Štros, 2010). 
§ Relaxing the structure of the nucleosome by inducing a shift between core 
histones and remodeling the chromatin (Figure 1-15c) 
§ Interacting with specific nuclear elements by protein-protein interactions, 






Figure 1-15. HMGBs intranuclear activity .  (a)  HMGB bends DNA and enhances the 
binding of specif ic transcription factors .  (b)  HMGB-TF1 complex binds and bends 
DNA and HMGB-TF1-DNA may promote the binding with other TFs .  (c)  HMGB 
induces chromatin unfolding by displacing histone H1. (d)  HMGB promotes 
formation of complex nucleoprotein structures .  Nucleosome structures are 
i l lustrated in grey cyl inders .  TF1/TF2 are examples of transcription factors (green 
and purple) ,  NP1-3 are nuclear proteins (mint ,  aqua and pink) .  H1 in red simulate a 
histone.  
In this way, the HMGB proteins are involved in numerous activities, including 
transcription, recombination, replication, telomere maintenance and a series of 
mechanisms of DNA repair (Barreiro-Alonso et al., 2016; Hock et al., 2007). Allosteric 
transitions of DNA such as DNA bending, kinking and unwinding can be promoted by 
binding of the HMG-boxes, causing greater distortions than AT-hooks (Bianchi & 
Agresti, 2005). All HMGBs are able to bend the DNA from 60° to 110° by binding to 
the minor groove in a number of different DNA structures. Besides supercoiled, single-
stranded DNA and B- and Z- forms, it binds preferentially DNA minicircles and other 
non-canonical structures like four-way junctions, loops, hemicatenated DNA and 
triplex (Tang et al., 2010). HMG-box B presents superior ability than box A to bend 
linear DNA (Štros, 2010; Sánchez-Giraldo et al., 2015).  




Although HMGB boxes A and B can bind DNA individually, the binding affinity 
improves when both domains remain attached. The major characteristic of the HMG-
box/DNA interaction is the DNA dramatic distortion and bending. The basis of this DNA 
bending, demonstrated in published HMG-box/DNA structures (Sánchez-Giraldo et al., 
2015; Ngo et al., 2014; Stott et al., 2006), is the intercalation of bulky hydrophobic 
amino acid residues of the HMG-box between consecutive base pairs within the minor 
groove of the DNA, complemented with a partial unwinding of the minor groove and 
bending towards the major groove. The box B first intercalated residue Phe102 is 
located in the helix I and the second intercalated amino acid Ile121 in the helix II; 
both flanked by conserved basic residues that bind to the phosphodiester bond of DNA 
and stabilize the complex. Box A only contains one intercalating residue, Phe37, in the 
helix II (Štros, 2010). 
The structure of HMGB1 protein with both HMG-box domains in complex with DNA 
has not been solved so far. Yet, the crystal structure of the HMG box A binding a 
previously distorted DNA (distortion caused by the drug cisplatin) has been determined, 
producing a bend of 60° on the DNA (Ohndorf et al., 1999). 
Moreover, structures of the human mitochondrial transcription factor TFAM in complex 
with different DNA sequences have been solved (Ngo et al., 2014; Ngo et al., 2011; 
Rubio-Cosials et al., 2011). Although TFAM differs in amino acid sequence from 
HMGB1 protein, it also has two tandem HMG-box domains (A and B). Crystal 
structures show two sharp ~90° kinks, each caused by one HMG-box, generating an 
overall U-turn of ~180° (Figure 1-16a).  
Recently, the crystal structure of the HMG-box A bound to a linear AT-rich DNA has 
been solved by a member of the MACROM research group (Sánchez-Giraldo et al., 
2015). The 2 Å resolution structure comprises in the asymmetric unit two 
oligonucleotides d[ATATCGATAT]2: one unbound straight DNA duplex and one bent 
DNA duplex bound by two boxes A acting together. These two domains enclose, 





Figure 1-16. Crystal  structures of HMG-box bound to DNA. (a)  The domain structure 
of mature TFAM in complex with a mitochondrial  DNA fragment.  HMG-box motifs ,  
shown in blue and green, are forming a complex with the 28 base pair  DNA (grey) ,  
and bending the DNA into a U-turn (Ngo et al . ,  2011; PDB ID: 3TMM). (b)  The two 
near-symmetric box A domains (purple and cyan) of HMGB1 protein col laborate to 
bend the AT-r ich DNA decamer (orange) (Sánchez-Giraldo et al . ,  2015; PDB ID: 
1CKT) .  DNA sequences are given below each structure.   
HMGB proteins are extensively modified after translation. Post-translational 
modifications such as phosphorylation of HMGB1 are required for proper folding and 
stability, as well as to influence the transcription factor activity and acquire DNA-
binding affinity. Besides, acetylation within the HMG-boxes is crucial for DNA binding 
and histone interaction. Several studies have shown that phosphorylation, acetylation 
and methylation modifications of the HMGB1 are involved in nucleo-cytoplasmic 
translocation and subcellular localization. Besides, the acetylation of certain lysine 
residues prevents a re-entry to the nucleus and participates in extracellular secretion 
(Erlandsson Harris & Andersson, 2004; Štros, 2010). The regulation of the HMGB1 
translocation, release, and activity in diseases are also triggered by redox modifications 
(Kang et al., 2013).  
After these post-translational modifications, some members of the HMGB family can 
be transported from the nucleus to the cell surface membranes, cytosol and 
mitochondria, and be released into the extracellular space. HMGB1 and HMGB2 shuttle 
frequently form the nucleus to the cytoplasm by passive diffusion across the nuclear 




pores due to their relative small size, or by active transport mechanisms including 
direct binding to β–related nuclear transport receptors (Štros, 2010). 
The levels of expression in nuclei and cytoplasm correlate with the organism’s tissue 
and with the differentiation stage of cells (Erlandsson Harris & Andersson, 2004). High 
levels of HMGB proteins are found in undifferentiated cells as well as in the cytoplasm 
of most tumor cells.  
HMGB1, the most studied member of the HMGB family, develops numerous biological 
functions inside as well as outside the cell. It also plays pathological effects in 
inflammatory diseases including sepsis and arthritis, in several cancers (Lotze & Tracey, 
2005), and in human epilepsy (Maroso et al., 2010).  
In the extracellular role, HMGB1 (and possibly HMGB2) acts as a signaling molecule 
during inflammation, cell differentiation, cell migration, tissue degeneration, 
metastasis and apoptosis (Banerjee et al., 2011). HMGB1 is released to the cytoplasm 
from necrotic, inflammatory or apoptotic cells. It is then secreted to the extracellular 
medium by macrophages, natural killer cells and dendritic cells alone, interacting with 
diverse proteins including the receptor for advanced glycation end-products (RAGE), 
TLR-2/4, CD24 and others DAMP (Damage-associated molecular patterns) receptors, or 
forming heterocomplexes with other immune coactivators (Kang et al., 2013; Barreiro-
Alonso et al., 2016; Tang et al., 2010).  
Alterations in HMGB1 location, abundance, and levels are associated with the principal 
cancer hallmarks and linked to poor prognosis in several tumors. The released HMGB1 
indicates tumor cell stress or death and a warning of danger over the cells in the 
microenvironment. In cancer cells, this alert contributes to tumor cell survival by 
inhibition of apoptosis and the development of metastasis (Tang et al., 2010). Also, 
HMGB1 can act as pro-apoptotic protein by activating the apoptotic response to 
genotoxic stress caused by anticancer drugs (Štros, 2010). However, the role of HMGB1 
in many types of cancer such as colon, prostate, breast, gastric, and other tumors is 
clearly related to both nuclear and extracellular performing of the protein (Hock et al., 




1 .6  DNA-Drug Interactions 
The distinctive structural features characteristic of DNA such as the regular helical 
grooves and the arrays of hydrogen bond donors and acceptors specific to each 
individual base pair (Figure 1-3), set it as an interesting target for drug design where 
small molecule ligands can recognize specific sequences and/or structures, and 
produce a predetermined biochemical response (Wemmer & Dervan, 1997). 
Small molecules that bind to DNA generally alter the normal transcription and 
replication dynamics of the cell. Thus, the design of drugs targeting DNA has become 
an attractive strategy to obtain novel potent molecules for modulating gene expression 
(Fitzgerald & Anderson, 1999; Waring et al., 2005). For this reason, in the last few 
decades, remarkable effort has been devoted to studying DNA-drugs interactions and 
describing mechanisms by how small molecules promote these changes in the cell.  
Hence, DNA is the molecular presumed target for diseases treatment of many clinical 
anticancer, antibacterial, antiviral and antiparasitic agents due to the inhibition of a 
series of downstream biological processes including not only transcription and 
replication but also cell cycle arrest and DNA repair mechanisms, leading eventually to 
cell death (Sheng et al., 2013).  
However, modern drug discovery is complex and requires integrated understanding of 
the biological, biochemical and structural properties of the target, the ligand, the 
binding site and the complex. In this way, advances in structural biology (nucleic acid 
crystallography and NMR) are required to provide detailed 3D information of the drug 
target and the interactions between the target and the small molecule ligand, offering 
models to rationally design DNA-binging molecules. Subsequently, optimized 
compounds with better properties can be developed (Gurova, 2009; Bailly, 2003). 
1 .6.1  Types of DNA-Binding Drugs  
By understanding the different chemical and structural modes of interaction between 
small molecules and DNA, it is possible to predict the potential biological 




consequences of such interactions in the cell, and consequently in the organism to be 
treated. DNA-binding agents can be classified into three groups according to the 
general type of binding: intercalators, groove binders (minor or major) and covalent 
binders (Gurova, 2009). DNA intercalators may present covalent or non-covalent mode 
of DNA binding. 
Small molecules forming covalent bonds with DNA can produce direct damage on the 
double strand by forming various types of DNA crosslinks capable of altering DNA 
conformation and stopping interactions with related proteins, thereby blocking 
biological processes such as replication or transcription (Wang et al., 2016; Hofr et al., 
2001). This category includes many chemotherapeutic anticancer agents like various 
platinum-containing compounds (Sheng at al. 2013), such as cisplatin or cis-
diamminedichloroplatinum (II), the most widely used and effective anticancer drug. 
However, because cisplatin acts on both cancer and normal cells, it is associated to 
substantial side effects (Dasari & Tchounwou, 2014). Cisplatin produces a direct and 
rigid kink into the major groove of DNA, which promotes recognition by HMG domain 
proteins (Hofr et al., 2001). In addition to Pt-containing compounds, other small 
molecules have been discovered to covalently bind DNA duplex, including nitrogen 
mustard drugs, mitomycin C and psoralen, which are used as anticancer drugs due to 
their high cytotoxic activity, mainly caused by the non-specific DNA cross-linking 
(Sheng et al., 2013).  
Non-covalent DNA-drug interactions are generally stabilized by a combination of 
hydrogen bonds and other electrostatic interactions such as van der Waals forces. 
These bonds may change the conformation of DNA and/or cause indirect DNA damage 
by altering the normal activity of the DNA-binding enzymes. In any case, non-covalent 
binding is a reversible process beneficial for applications that require a controlled 
binding such as in gene regulation (Almaqwashi et al., 2016). There are two main 
modes of non-covalent DNA interactions: 
§ DNA–intercalator: a planar aromatic moiety is non-covalently inserted between 




sequences (Paul & Bhattacharya, 2012) and is usually stabilized by the 
formation of strong stacking bonds between the aromatic chromophores of the 
ligand and the nucleobase (Berman & Young, 1981). Typical examples are 
ethidium bromide; the antimalarial drug quinacrine; and the natural antitumour 
and antiviral compound variolin B (Canals et al., 2017).  
§ DNA- groove binder: small molecules interacting with both the major or minor 
groove of double-stranded DNA by H-bonds between their functional groups 
and the adjacent base pairs. Due to the grooves’ dimensional difference (see 
section 1.2.2), targeting them requires enormous dissimilar sized and shaped 
molecules. Major groove binders are necessarily much larger molecules. Thereby, 
it is the binding site of most of the DNA-interacting proteins. Added to this, 
there are also various carbohydrate compounds including neocarzinostatin, 
nogalamycin, and neomycin that interact with the major groove due to their 
size and distribution of hydrophobic and hydrophilic moieties (Sheng et al., 
2013). Natural compounds such as pluramycins, aflatoxins, azinomycins and 
leinamycin also bind the DNA major groove, although they target DNA primarily 
by intercalation between DNA base pairs (Hamilton & Arya, 2012). Specific 
DNA-drug interactions through the major groove can alter recognition and 
binding of proteins with DNA. On the other hand, an extensive variety of small 
molecules can bind within the minor groove of DNA, preferentially at AT-rich 
regions (Wemmer & Dervan, 1997). Netropsin, Hoescht 33258, diminacyn, 
pentamidine and DAPI are typical examples of minor groove binding drugs 
(MGBD). 
1.6.1.1 Minor	Groove	Binding	Drugs	(MGBD)	
Specific recognition of DNA sequences by small organic molecules is important not 
only for the targeting of specific genes in a genome, but also for chemotherapeutic 
purposes as antibacterial, antiprotozoal, antiviral and antitumor agents (Bailly, 2003; 
Sheng et al., 2013). A large variety of such compounds have been developed, 
emphasizing the study of compounds that bind the minor groove of the DNA. 




The molecular recognition elements of the minor groove binders are the electrostatic 
interactions with the negative potential in the groove, specific hydrogen bonds of 
functional groups in the ligand (donor) with the atoms of the nucleobases (acceptor), 
and van der Waals contacts and other hydrophobic interactions within the minor 
groove (Rentzeperis et al., 1995). MGBD display a degree of sequence specificity, 
preferentially to high AT-content sequences due to the higher electrostatic potential in 
AT-rich grooves than CG-rich grooves, and the formation of greater van der Waals 
interactions by small molecules with the narrower, deeper and easy to fit minor groove 
at AT sites (Tidwell & Boykin, 2003). 
 
Figure 1-17. Diverse structures of minor groove binding drugs.  
Although neutral, mono- or multi-charged ligands have been found, the 
electronegativity of the DNA minor groove makes it more appropriate target for 
cationic molecules. In addition, MGBD share several structural features to fit and 
follow the narrow groove, including aromatic rings and relative flexibility to let it form 
an overall curvature that matches with the DNA twist (Wemmer & Dervan, 1997). 
Therefore, minor groove binders are commonly polyamides and heterocyclic dications 




A series of structural studies of small molecules in complex with various 
oligonucleotide duplexes containing stretches of AT base pairs via minor groove have 
been reported. Examples of these studies determined by X-ray crystallography include 
Hoechst 33258 in complex with DNA d[CGCGAATTCGCG]2 (Pjura et al., 1987; PDB ID: 
8BNA); the complex between netropsin and the DNA dodecamer d[CGCGATATCGCG]2 
(Coll et al., 1989; PDB ID: 1VTJ); the complex with d[GTATATAC]2 and distamycin A 
(Mitra et al., 1999; PDB ID: 378D); among others. 
The special interest of the MACROM research group for a better understanding of 
DNA-drug interactions through the minor groove of AT-rich oligonucleotides has also 
rendered two crystal structures at atomic resolution of DNA-MGBD complexes. First, a 
new mode of interaction of the drug pentamidine with the DNA duplex 
d[ATATATATAT]2 was demonstrated (Figure 1-18a) containing a mixed structure 
Watson-Crick and Hoogsteen base pairs and interacting with neighboring molecules in 
the crystal to stabilize the coiled-coil structure of the stacked duplexes (Moreno et al., 
2010). Lately, the crystal structure of the complex of the DNA duplex d[AAAATTTT]2 
with the dicationic drug 4,4’-bis(imidazolinylamino)diphenylamine (CD27) has been 
presented (Figure 1-18b; Acosta-Reyes et al., 2014). The CD27 molecules cover 
completely the minor groove of the oligonucleotide and act as a cross-linking agent by 
the interaction with neighboring molecules.  
The amenability of the minor groove to bind with drugs is not only related to the 
narrowness and more attractive dimensions of the groove for small molecules, but also 
minor-groove binding generally involves greater binding affinity and higher sequence 
specificity than intercalator or major-groove binding (Paul & Bhattacharya, 2012). 
Hence, MGBD are extensively studied and are considered great promises for treating 
diseases at the DNA level.  
There are only a few minor groove binders approved for treatment due to the initial 
significant toxicities they presented. Nevertheless, there has been renewed interest in 
MGBD over the past years through the development of new improved compounds (Cai 
et al., 2009). The major contributions of minor groove binders have been in the 




discovery and development of anticancer agents. Nevertheless, they have demonstrated 
a wide range of applications such as antiviral, antiparasitic, antifungal and 
antibacterial. This research work has focused on MGBD as antiprotozoal agents. 
 
Figure 1-18. Crystal  structures of MGBD with al l-AT DNA. (a)  Asymmetric unit of 
the crystal  containing pentamidine-d[ATATATATAT]2 complex.  The drug interacts 
through the minor groove at the centre of the sequence.  (Moreno et al . ,  2010; PDB 
ID: 3EY0) .  (b)  The different crystal lographic units of the CD27-d[AAAATTTT]2 
complex .  The black lozenge indicates one of the dyad axes (Acosta-Reyes et al . ,  
2014; PDB ID: 4OCD).   
1 .6.2  Structure-Based DNA-Targeting Strategies for 
Drug Discovery 
Nucleic acids have usually been less attractive as drug targets in structure-based drug 
design as compared with proteins. This is mainly due to the limited structural 
information existing on nucleic acids complexed with potential drugs (Sheng et al., 
2013). However, over the past years, a number of structures of diverse complexities 
have been determined and more than 300 structures with small molecules binding 
nucleic acids have been deposited in the Protein Data Bank (PDB; www.rcsb.org) since 
2004.  
DNA is the primary molecular target of some clinical drugs, including anticancer and 




molecules targeting DNA, scientists have developed different strategies including 
virtual screening, molecular modeling, and structure-based drug design (Sheng et al., 
2013). These techniques depend mainly on the availability of the DNA-drug complex 
3D structure, especially the high-resolution crystal structure. By extracting the key 
features from this structural information it is possible to define the optimum geometry 
and distance for binding site recognition, or to identify the right position of the 
functional groups in the ligand for better interaction. Moreover, structure-based 
approaches are also applied to integrate properties into compounds to create 
alternative molecules less likely to show resistance mechanisms (Hol, 2015).  
Due to the high toxicity and side effects that unspecific DNA-targeted therapies have 
faced during the past decade, new approaches are being investigated for individualized 
therapies that target specific genes and/or displace key proteins interacting with DNA 
in determined regions of the genome causing pathogenic effects. These approaches 
have progressed immensely thanks to the advances in nucleic acid chemistry, 
molecular biology and structural biology. 
In the complex process of drug discovery, the challenge is to identify the right DNA 
ligand for a given pharmacological action. That is, a balance of affinity, selectivity, 
specificity, effectiveness and minimum side effects. Selective targeting of a specific 
sequence is a major challenge when designing nucleic acid ligands. Models to enhance 
specificity of DNA binding agents have been developed and thereby, the design of 
compounds that can minimize the off-target effects by the recognition of particular 
regions, specific genes or certain configurations of DNA has allowed new therapeutics 
and gene-specific probes (Paul et al., 2015).  
Currently available structural information has enriched enormously the understanding 
and knowledge of the molecular binding mechanisms, specific DNA-ligand interactions, 
particular configurational changes, and topological deformations of DNA caused by 
binding with small molecules (Smith & Buchmueller, 2011). Nevertheless, more 
research and information on DNA-drug interactions is needed to help rationalized drug 
design. 




1 .6.3  DNA-Binders Targeting Parasit ic Diseases 
Infectious diseases caused by protozoan pathogens represent a global health, social 
and economic problem which rank among the top leading causes of mortality, resulting 
in more than one million deaths world-wide every year and threaten the health of 
millions more (Andrews, et al., 2014; WHO, 2015). This enormous burden has been 
aggravated by the lack of preventive chemotherapy and suitable treatments for many 
of the diseases these parasites cause, added to the already existing challenge of 
controlling the growing threat of drug resistance. In addition, the low economic status 
of the majority of people living in the endemic countries aggravates the situation, 
making the pharmaceutical market for the development of new drugs financially 
unattractive to the private-research sector (Ndjonka, 2013).  
Discovering and developing safe and affordable treatments to respond the neglected 
tropical diseases is an urgent need. Notable progress in the development of new 
antiparasitic drugs has been made in the last two decades using rational drug design 
including new targets or the use of natural sources (Ndjonka, 2013; Scott et al., 2016). 
Furthermore, many efforts have been devoted on creating chemotherapeutic 
treatments targeting parasitic DNA as a safe, selective, and effective antiparasitic 
strategy. 
The DNA of protozoan organisms differs tremendously between species. However, 
common trends such as a high AT content are observed in species such as P. falciparum, 
(80% overall at content) (Carlton et al., 2002) or Trypanosoma brucei [about 73% AT 
content in its mitochondrial DNA (mtDNA)]. Due to these AT rich genomes, parasites’ 
DNA appears as a suitable target for minor groove binders, particularly for aromatic 
diamidines (Barrett et al., 2013). 
Minor groove binding drugs (MGBD) have been extensively used as antiprotozoal 
agents to fight diseases like American trypanosomiasis (Chagas disease) caused by 
Trypanosoma cruzi; human African trypanosomiasis (HAT or sleeping sickness) caused 




leishmaniasis caused by several species of Leishmania; and trichomoniasis caused by 
Trichomonas vaginalis (Montalvo-Quirós et al., 2015; Soeiro et al., 2013; Scott et al., 
2016; Wilson et al., 2008; Acosta-Reyes et al., 2014). 
Although widely studied, the precise mechanisms by which the minor groove binders 
act in protozoa remains unclear and seems to differ between different species (Scott et 
al., 2016). Still, high intracellular concentrations of dicationic drugs such as 
pentamidine, have been found in treated trypanosome and plasmodia cells. It was 
demonstrated that these compounds bind preferentially to AT-rich regions through the 
minor groove of DNA (see section 1.6.1.1). Then, the specific parasitic DNA-drug 
binding has been suggested as a potential mode of action of MGBD. This interaction 
would trigger a particular trypanocidal or trypanostatic activity (Barrett et al., 2013).  
Well-studied antiprotozoal compounds like pentamidine, diminazene, furamidine, 
berenil and others are MDBG have been used for years against Plasmodium spp., 
Leishmania spp., Trypanosoma spp., Toxoplasma gondii, Trichomonas vaginalis, 
Acanthamoeba spp., Balamuthia mandrillaris, Babesia microti, Cryptosporidium parvum 
and Crithidia fasciculata (Soeiro et al., 2013). Nevertheless, new antiprotozoal drugs 
are urgently required due to the appearance of drug resistant parasite strains. The high 
toxicity and significant side effects of current drugs, added to the complexity of 
treatment regimens (e.g. lack of oral bioavailability), the high cost, or the lack of 
supply are some of the main drawbacks that available antiparasitic treatments face.  
The search for efficient novel antiparasitic agents has led to the design and synthesis 
of small molecules that strongly bind to the minor groove of DNA, such as the 
diamidines (Soeiro et al., 2013; Scott et al., 2016). Among them, bis(2-
aminoimidazoline) compounds are considered promising due to the DNA sequence 
specificity to AT-rich sites and their in vitro and in vivo antimalarial and 
antitrypanosomal activity (Rodríguez et al., 2008; Nieto Garrido et al., 2011; Ríos 
Martínez et al., 2014). 




1 .7  Human African Trypanosomiasis  
Also known as sleeping sickness, human African trypanosomiasis (HAT) is a neglected 
tropical disease caused by infection with protozoan parasites belonging to the species 
Trypanosoma brucei. There are two forms of the disease in humans: the subspecies 
Trypanosoma brucei gambiense is found in West and Central Africa and causes the 
chronic form of HAT (98% of reported cases; WHO, 2017), whereas the less common 
form is an acute, rapidly progressive and mortal disease caused by Trypanosma brucei 
rhodesiense and is spread through East and South Africa (Figure 1-19). Both forms of 
HAT are transmitted to human by the tsetse fly vector (Franco et al., 2014). 
Approximately 55 million people distributed over a surface of 340,000 km2 in 33 sub-
Saharan African countries are estimated to be at different levels of risk of contracting 
sleeping sickness (WHO, 2016). Most of the affected populations live in remote rural 
areas with limited access to health services, which complicates the diagnosis and 
treatment of cases in Africa’s poorest countries.  
 
Figure 1-19. Distr ibution of human African trypanosomiasis worldwide in 2015. 
Number of reported cases caused by (a)  Trypanosoma brucei gambiense  and (b)  




The epidemiology of the disease is mediated by a painful bite of an infected blood-
feeding tsetse fly (genus Glossina) to humans, where metacyclic trypomastigotes 
present in the salivary fluid of the fly produce a primary lesion in the skin of the 
human host, called “trypanosomal chancre” that appears from 5 to 15 days after the 
bite (Nagle et al., 2014). Then, the clinical progression of sleeping sickness depends on 
the type of trypanosome infection. The incubation period for Rhodesian sleeping 
sickness is two to three weeks, and if left untreated, death generally occurs within a 
year. Gambian sleeping sickness (gambiense HAT) has an incubation period of several 
days to some weeks (Markell et al., 2006). During the incubation period, the parasites 
proliferate and spread to the blood where they start to disseminate throughout the 
body. 
In general, HAT clinically evolves in two stages. Initially, in the first or early 
hemolymphatic stage, the parasites dwell in the lymphatic system and bloodstream. At 
this point, patients experience nonspecific symptoms of intermittent fevers, malaise, 
arthralgias, and headaches (Franco et al., 2014). Besides the common symptoms, 
lymphadenopathy, the swelling of lymph nodes (especially in the posterior cervical 
nodes along the back of the neck) is exclusive and main sign of gambiense HAT and is 
termed Winterbottom’s sign (Nagle et al., 2014; Markell et al., 2006).  
The second stage of the disease begins when parasites penetrate the Central Nervous 
System (CNS), crossing the blood-brain barrier (BBB) from capillary vasculature in the 
brain. In rhodesiense HAT, this occurs a few weeks after infection, while in gambiense 
HAT, it can take several months or even years before evolving into a late period of the 
disease. In the late (meningoencephalitic) stage, symptoms include psychiatric, motor, 
and sensory disturbances, severe headaches, personality changes, apathy, and, for 
approximately three-quarters of patients, profound disorder of the sleep patterns 
which includes nocturnal insomnia and daytime somnolence, symptoms from which 
the disease name arises: sleeping sickness. Without treatment, patients eventually 
progress to a deepening coma and death (Lamb, 2012; Barrett et al., 2003). 




1 .7.1  Trypanosoma  brucei  
Trypanosoma brucei is a species of parasitic kinetoplastid belonging to the genus 
Trypanosoma and the class Kinetoplastida. There are three morphologically 
indistinguishable subspecies of Trypanosoma brucei: T. b. gambiense, T. b. rhodesiense, 
and T. b. brucei. In humans, T. brucei causes human African trypanosomiasis (sleeping 
sickness) and in cattle, horses, lions, antelopes, buffaloes, and others, it causes animal 
trypanosomiasis (nagana).  
Cell Structure 
T. brucei is a eukaryotic unicellular organism. Besides the typical eukaryotic organelles, 
i.e. nucleus, mitochondrion, endoplasmic reticulum, Golgi apparatus, lysosomes, and 
cell membrane, it has an unusual organelle called the kinetoplast composed of a mass 
of catenated DNA (kDNA) (Figure 1-20). Kinetoplast is localed within a specialized 
region of the mitochondrion, a single elongated organelle that extends from the 
posterior to the anterior end of the cell (Matthews, 2005). 
The trypanosome cell is asymmetric in shape, approximately 10 to 20 µm long, with 
clearly dissimilar anterior and posterior ends (Figure 1-20). It has a long slender shape 
with a single flagellum surrounded by its own membrane, which origins from the basal 
body near the posterior end of the cell. The flagellum exits the cytoplasm from a small 
invagination of the plasma membrane called flagellar pocket. This specialized 
compartment also participates in many cellular processes (Ralston & Hill, 2008; Field & 
Carrington, 2009). The flagellum is attached to the cell body along most of its length, 
holding together a thin layer known as flagellum attachment zone (a network of 
cytoskeletal and membranous connections) and drawing a left-handed helical path 
from posterior to anterior (Ralston & Hill, 2008). The movement of the cell body is 
strongly linked to flagellar wave propagation, giving the appearance of an “undulating 
membrane” (Hill, 2003).  
The cell membrane, called pellicle, consists of phospholipids, proteins, cholesterol, and 




covers the trypanosome surface to protect it from the mammalian immune response 
(Franco et al., 2014). 
 
F igure 1-20. Trypanosome cel l  architecture.  A s implif ied schematic representation 
of the location of the major organelles of the trypanosome cel l .  Adapted from 
Matthews, 2005. 
The characteristic cell body shape is defined by a stable and highly cross-linked 
subpellicular microtubule cytoskeleton, beneath the cell membrane. The single-copy 
organelles (flagellar pocket, flagellum, kinetoplast, mitochondrion and nucleus) are 
positioned specifically within the cytoskeletal corset and are concentrated between the 
center and the posterior end of the cell (Figure 1-20; Matthews, 2005). 
The kinetoplast and basal body are physically connected via a high-order 
transmembrane structure termed tripartite attachment complex (TAC) that must cross 
both the cell and the mitochondrial membranes (Figure 1-24). TAC includes a series of 
filaments providing guide ropes through which mitochondrial genome segregation is 
linked to replication and division of the basal body and flagellum (Ogbadoyi et al., 
2003) 
Life Cycle 
The organization of cell structure is fundamental to the trypanosome throughout its 
life cycle. Trypanosomes pass through five distinct forms: metacyclic trypanosomes, 




long slender bloodstream form, short stumpy bloodstream form, procyclic 
trypomastigotes and epimastigotes (Figure 1-21). The trypomastigote is the only form 
to be observed in the mammalian host, whereas the epimastigote form occurs during 
the development phase in the tsetse fly. The metacyclic form is the only stage that is 
infective to vertebrates.  
Trypanosomes undergo dramatic morphological and biochemical adaptions over their 
life cycle. Life-cycle stages alternates between bloodstream-form and insect-form to 
adapt and survive in the mammalian host and the insect vector, respectively (Ralston & 
Hill, 2008). They proliferate in the midgut of the fly as a procyclic trypomastigote form. 
After migration to the salivary glands, they progress into proliferative epimastigote 
forms and then to the non-proliferative metacyclic form that are ready for 
transmission to the next mammalian host (Akiyoshi & Gull, 2013).  
 
Figure 1-21. A general ized l i fe cycle of Trypanosoma brucei .  CNS: central  nervous 
system. Adapted from Langousis & Hil l ,  2014. 
Infection of the mammalian host starts when the bite of an infected tsetse fly 
introduces the metacyclic trypomastigote into skin tissue. The trypanosomes first 
multiply locally at the site of the bite before invading the lymphatic system, the blood 




Kennedy, 2004). Two different trypomastigote forms can be observed in the 
mammalian host: a long, slender proliferative (actively-dividing) form and a short, 
stumpy non-dividing form. Both trypomastigote forms can infect tsetse flies, but only 
the latter is able to develop into the proliferative procyclic trypomastigote form, 
completing the life cycle (Chappuis, 2005). 
Cell Cycle 
Like other eukaryotic organisms, the cell cycle of trypanosomes consists of distinct G1, 
S, G2 and M phases (Hammarton, 2007). The presence of single-copy organelles and 
the detailed morphology of the trypanosomes cells require a highly ordered process of 
organelle duplication and segregation at cell division (Woodward & Gull, 1990). 
 
F igure 1-22. Cel l  cycle regulation in Trypanosoma brucei .  Duplication of the major 
organelles and structures during the cel l  cycle is  i l lustrated,  indicating the stages 
G1, S phase,  G2 and M (mitosis) .  Kinetoplast (K) is  shown in red ovals and nucleus 
(N) in blue sphere.  
During the first gap phase G1 in procyclic form T. brucei, the cell prepares for entry 
into a new round of replication and cell division. The earliest detectable cytological 
events during this stage are the basal body and flagellum duplication: the probasal 
body (lying adjacent to the flagellar basal body) matures, daughter flagellum 
outgrowth starts, and new probasal bodies for each mature basal body are formed 




(Figure 1-22; Gluenz et al., 2011). Duplication of the Golgi apparatus commences just 
after basal body duplication (Hammarton, 2007). 
S phase separates two gap phases, G1 and G2, which are followed by mitosis (M phase). 
DNA is replicated during S phase. However, as mentioned before, trypanosomes have 
two DNA-containing organelles: a nuclear genome and an unusual mitochondrial 
genome that constitutes the kinetoplast (both of which must be replicated and 
segregated coordinated) (Gluenz et al., 2011). Kinetoplast S phase is much shorter than 
nuclear S phase and begins just prior to nuclear S phase (Woodward & Gull, 1990).  
The segregation of the two genomes takes place in a specific chronological order. Early 
in G2 phase, the replicated kinetoplast segregates, followed by nuclear mitosis and 
finally cytokinesis (Figure 1-22), resulting in the formation of two daughter cells that 
contain one kinetoplast and one nucleus. It has been suggested that entry to 
cytokinesis may be more dependent on kinetoplast division and segregation than on 
mitosis (Hammarton et al., 2003). However, it remains unknown how these temporal 
orders are established and regulated. Strictly controlled regulation of DNA replication, 
and kinetoplast and chromosome segregation is essential for maintenance of genome 
stability. 
1 .7.2  The Kinetoplast 
The mitochondrial DNA of Trypanosoma brucei is organized in a unique and complex 
structure called kinetoplast. The kinetoplast constitutes about the 5% of the 
trypanosome’s DNA and consists of an interlocked network of tens maxicircles (23 kb 
each) and several thousand minicircles (1 kb each). These circles are intercatenated 
into a single huge planar disk-shaped network that resides within a specialized region 
of the mitochondrial matrix near the flagellar basal body (Roy Chowdhury, 2010) 
(Figure 1-23). 
Maxicircles encode ribosomal RNAs and a few proteins involved in energy transduction, 
such as subunits of NADH dehydrogenase, cytochrome oxidase complexes I, II and III, 




the maxicircle precursor mRNAs (pre-mRNAs) would need to be modified post-
transcriptionally by a process called RNA editing in order to produce complete open 
reading frames. Minicircles encode small guide RNAs (gRNAs), templates for editing of 
maxicircle transcripts, which decode the encrypted information, specifying the site and 
number of uridine residues added or deleted during the RNA editing (Klingbeil & 
Englund, 2004; Szempruch et al, 2005). While maxicircles are homogeneous in 
sequence, minicircles are highly heterogeneous and different minicircles are required 
for editing different maxicircle transcripts (Beck et al., 2013). Therefore, both 
minicircles and maxicircles are essential for mitochondrial physiology. 
 
Figure 1-23. Kinetoplast DNA network structure.  (a)  E lectron micrograph of the 
periphery of an isolated kDNA network.  Loops represent interlocked minicircles 
(arrowhead indicates a clear example) .  Scale bar 500 nm. (b)  Schematic 
representation of the minicircles ’  organization. 1 .  Segment of an isolated network 
showing interlocked minicircles in a planar array.  2 .  Section through a condensed 
network disk-shaped in vivo  showing stretched-out minicircles .  The double-headed 
arrow indicates the thickness of the disk ,  which is  about half  the perimeter of a 
minicircle .  Adapted from Lukes et al . ,  2002. 
The replication of the kinetoplast occurs simultaneously to the duplication of the 
adjacent flagellum and just prior to the nuclear DNA replication. It is catalyzed by an 
enzymatic machinery located at defined sites flanking the kDNA disk (antipodal sites) 
(Figure 1-24) and consisting of at least six DNA polymerases, six helicases, two 




primasas, two ligases (Bruhn et al. 2011, Beck et al., 2013) and two topoisomerases: a 
topoisomerase II (Wang & Englund, 2001) and a topoisomerase 1A (Scocca & Shapiro, 
2008).  
Covalent closed minicircles are released from the network by a topoisomerase II before 
replication, so that they could be copied as free circular molecules (Szempruch et al, 
2005). The free detached minicircles replicate first as theta-structures. Then, the 
progeny minicircles, which contain nicks or gaps, are reattached to the network 
periphery (Figure 1-24). Maxicircles also replicate as theta-structures, but they remain 
linked to the network. However, exact mechanisms for maxicircle replication have yet 
to be determined in the same detail as minicircles’. When the network has doubled the 
size, the minicircles mismatches are repaired, and networks are segregated into two 
daughter kinetoplasts.  
 
Figure 1-24. The kDNA repl ication model of Trypanosoma brucei  showing the 
location of repl ication proteins and minicircle repl ication intermediates .  Pol ,  DNA 
polymerase; PAK, prol ine,  alanine and lysine-r ich; Topo, topoisomerase; SSE1, 
structure-specif ic endonuclease 1; UMSBP, universal minicircle sequence-binding 
protein.  Adapted from Englund et al . ,  2005. 
Minicircles make up over 90% of the mass of the network (Shapiro & Englund, 1995). T. 
brucei contains approximately 300 different minicircle sequences in different number 
of copies, as many maxicircle transcripts are extensively edited (Feagin, 2000). Besides 




conserved region containing the origin of replication, which is virtually identical in all 
minicircles of the network (Ray, 1989). They also have a single region of bent helix, 
composed of short A-tracts (4 to 6 residues each) spaced in phase about every 10 base 
pairs (Shapiro & Englund, 1995). The flexibility of A-tracts (see section 1.3) results in a 
substantial curvature of the DNA double helix. Moreover, T. brucei minicircles include 
up to 73% of AT-content. 
ATP production (through oxidative phosphorylation) is the most well-known function 
of mitochondria. Nevertheless, it has key roles in many other metabolic and cellular 
processes. The vast majority of mitochondrial proteins are encoded on nuclear genes 
and need to be imported from the cytosol and sorted to the mitochondrial outer 
membrane (OM), inner membrane (IM), intermembrane space (IMS) or matrix (Jensen 
et al, 2008). Mitochondrial enzymes, but also metabolites and other small molecules 
import, depend upon a membrane potential (ΔΨ) across the IM. To generate ΔΨ, T. 
brucei procyclic form uses the proton-pumping electron transport chain and 
bloodstream form uses the ATP synthase to hydrolyze ATP and thus pumping protons 
from the matrix to the IMS (Figure 1-25).  
The partial loss (dyskinetoplastidy, Dk) or complete loss (akinetoplastidy, Ak) of 
kinetoplast means that mitochondria cannot fully function due to a deficiency in 
maxicircles (Jensen et al., 2008). They can propagate only as bloodstream form. The 
tsetse fly is therefore eliminated from the life cycle and transmission between 
individual hosts becomes via mechanical or sexual means, allowing the parasite to 
spread outside the African tsetse belt (Lai et al., 2008). It was found that kDNA-
deficient T. brucei and several strains of T. equiperdum (dyskinetoplastid) and T. evansi 
(akinetoplastid) need a mutation in the nuclear gene encoding the γ-subunit of the F1 
portion of the F1F0-ATPase to survive the loss of their kinetoplast (Eze et al., 2016; Lai 
et al, 2008). The loss of proton-pumping membrane component (Fo) of the ATP 
synthase in the Dk and/or Ak trypanosomes leads to a release of the soluble, 
catalytically active domain of the synthase (F1) into the matrix. ATP hydrolysis by F1 
produces ADP, and the exchange of the ADP-3 for cytosolic ATP-4 via IM ADP-ATP 




carrier, re-establishes the mitochondrial membrane potential (ΔΨ) (Figure 1-25; 
Jensen et al, 2008).  
Pentamidine, diminazene and other trypanocidal diamidine-type compounds have been 
shown to collapse the mitochondrial membrane potential, but the mechanism through 
which these drugs exert their activity is still not entirely known (Lanteri et al., 2008). 
However, and just as MGBD (see section 1.6.1.1), they are expected to interact with 
parasitic DNA, both nuclear and kinetoplastid; nevertheless the rapid accumulation of 
these drugs within the mitochondrion of treated trypanosomes suggests the kDNA as 
the potential cellular target (Scott et al., 2016). 
 
Figure 1-25. Mitochondrial  inner-membrane potential  in T.  brucei .  The ATP synthase 
is  composed of Fo,  which is  embedded in the IM and translocates protons,  and F1,  
which can either synthesize or hydrolyze ATP. The ATP–ADP carr ier (AAC) mediates 
the exchange of ATP and ADP across the IM. (a)  In the procycl ic form, the electron 
transport machinery generates ΔΨ to drive ATP synthesis ,  in addit ion to protein 
import and metabolite transport (not shown).  (b)  In the bloodstream form, the ATP 
synthase runs backwards and uses ATP hydrolysis to pump protons across the IM to 
generate ΔΨ. (c)  In Dk or Ak trypanosomes,  the Fo portion of the ATP synthase is  
missing (e .g .  owing to a lack of the kDNA encoded subunit ,  A6) ,  but the F1 portion 
hydrolyzes ATP to ADP in the matrix .  The exchange of ADP−3 with ATP−4 from the 
cytosol establ ishes ΔΨ.  Adapted from Jensen et al ,  2008.  
The unusual structural features of kinetoplast, its particular location, its unique 
functions, its DNA composition and its sophisticated mode of replication, division and 
segregation, make this system an attractive target for antitrypanosomal drugs (Sela et 





The proper synthesis and function of kinetoplast are largely based on its structure 
integrity. This highly condensed network demands proteins or protein complexes in 
order to stabilize the disk architecture. Nevertheless, no information about such 
proteins was discovered in the kinetoplastid protozoan Trypanosoma brucei until 2014, 
when Wang and co-workers found the first trypanosomatid kinetoplast-associated 
protein (KAP) called TbKAP6 (Wang et al., 2014).  
Various KAP proteins had been previously identified in Crithidia fasciculate as small, 
basic and nucleus-encoded histone H1-like proteins, which were able to condense the 
isolated kDNA networks in vitro and colocalize with the kinetoplast disk in vivo (Xu et 
al., 1996). Moreover, they may also play a role in regulating kDNA gene expression 
(Avliyakulov et al., 2004). Trypanosoma cruzi also has TcKAP proteins characterized. 
They are similar to KAP proteins of C. fasciculata, implicated in kDNA packaging and 
architectural rearrangement (Cavalcanti et al., 2009).  
 
Figure 1-26. The HMG box-containing proteins TbKAP6 and HMGB1. Schematic 
comparison of two tandem HMG-boxes in TbKAP6 with those of human HMGB1. 
HMG-box A: green box; HMG-box B: blue box; C-terminal acidic tai ls :  hatched l ines .  
Structure comparison (below each diagram) of the HMG boxes A and B of TbKAP6 
constructed by SWISS-MODEL workspace [http://swissmodel .expasy.org/]  (Wang, et 
al . ,  2014);  and HMGB1 box A (green; PDB ID: 1AAB) and box B (blue; PDB ID: 1HME) 
as determined by NMR microscopy (Hardman, et al .  1995; Weir et al . ,  1993).   




The T. brucei TbKAP6 protein, which is homologous to CfKAP4 and TcKAP6, is involved 
in stabilizing the kDNA disk structure. It belongs to the HMG-box-containing proteins 
(see section 1.5.1.2) and presents two tandem HMG-boxes: a corrupt and shorter box A 
and a conserved box B (Figure 1-26). It lacks the acidic C-tail and binds directly to 
minicircles in the kDNA (Wang, et al., 2014). 
 
F igure 1-27. Amino acid al ignment of the two HMG-boxes of TbKAP6 and the box B 
of HMGB1. Adapted from Wang, et al . ,  2014. 
Both the knockdown of TbKAP6 and its overexpression alter the normal kDNA 
organization and segregation, triggering kDNA loss. Therefore, TbKAP6 is essential for 
kDNA replication and maintenance (Wang, et al., 2014). 
1 .7.3  Current Treatment 
Five drugs are currently approved for the treatment of HAT, depending on the causative 
trypanosome subspecies and on the disease stage (see Table 1-4 and Figure 1-28; 
Nagle et al., 2014). Drugs for the treatment of late (CNS) stage trypanosomiasis are 
those that are able to cross the blood-brain barrier (BBB) to kill the parasites in the 
cerebrospinal fluid and brain parenchyma (Fèvre et al., 2006). They include melarsoprol, 
effective against both T. b. rhodesiense and T. b. gambiense; and eflornithine only 
useful against T. b. gambiense. Pentamidine and suramin are limited by their 
effectiveness only to the early stage of gambiense and rhodesiense HAT, respectively 
(Babokhov et al., 2013). Nifurtimox has been used in the past for patients suffering 
from eflornithine- or melarsoprol-resistant trypanosomiasis (Fairlamb, 2003) but was 
never licensed as monotherapy for HAT due to the severity of its side-effects. In fact, 
the action of the mentioned clinically-approved drugs for HAT is marred by a range of 




An important advance in HAT chemotherapy occurred in 2009 with the introduction of 
nifurtimox-eflornithine combination treatment (NECT). NECT was compared in 
efficiency to eflornithine monotherapy in the treatment of second-stage T. gambiense 
infection (Priotto et al., 2009). In addition, it was found to be safer since it proved to 
be half as toxic as the standard eflornithine monotherapy, being able to cure HAT in a 
shorter period of administration than the monotherapy, and showing lower propensity 
for resistance by trypanosomes (Priotto et al., 2009). Despite this positive progress, the 
necessity of intravenous treatment, together with the high costs of distribution, place 
NECT far from being optimal chemotherapy for treating HAT.  
Table 1-4. Approval drugs for treating HAT.  








1 (Early) Pentamidine 1941 IM or IV No oral formulation 
  
Eflornithine 1981 IV 
Expensive  
Every 6 h dosing 
  




2 (Late) NECT a 2009 IV + PO 




1 (Early) Suramin 1922 IV No oral formulation 
 
2 (Late) Melarsoprol 1949 IV 
Arsenical (toxic 
encephalopathy) 
aNECT: nufurtimox-eflornithine combination therapy. IV: intravenous; IM: intramuscular; PO: oral 
administration. From Nagle et al., 2014. 
Due to the limits of currently used HAT therapies, greater emphasis should be placed 
on the research and development of the ideal HAT drug. This should be effective for 
both early and late disease, orally administered over relatively short periods, economic 
and the most important characteristic, it should be safe for all patients (Nagle et al., 
2014).  
Recent discoveries had suggested fexinidazole and oxaborole SCXY-7158 as drug 
candidates for HAT. Both cure the acute and the chronic mouse models of HAT 
infections, have oral bioavailability in mice (41% and 55% respectively), and 
progressed to the phase II/III studies in 2012 (Nagle et al., 2014). Furthermore, a wide 
variety of minor groove binding drugs, in particular amidines and imidazolines, have 




been synthesized, and have been strong and extensively evaluated against 
trypanosomiasis (Scott et al., 2016).  
 
 
F igure 1-28. Chemical structures of the establ ished drugs used in chemotherapy of 
HAT. Pentamidine and suramin are effective at early stage,  while melarsoprol ,  
nifurt imox and eflornithine are used as at late stage of HAT. 
1 .7.4  Dicationic MGBD as Antitrypanosomal Agents 
Diamidine-like derivatives are potent trypanocides. These dicationic aromatic 
compounds are DNA minor groove binders that have been used clinically against 
trypanosomes since the 1930s, starting with the diamidines pentamidine and 
diminazene (Scott et al., 2016). For years, scientists have synthesized and extensively 
screened in vitro and in vivo series of diamidines patterned after pentamidine, in 
order to improve their selectivity and properties such as bioavailability, efficiency, 
therapeutic index, and ability to cross the blood-brain barrier (BBB) (Paine et al., 2010; 
Mathis et al., 2006). The latter is of outmost importance to cure the late-stage of 
sleeping sickness when the parasites have invaded the central nervous system (CNS). 
It has been previously described that these dicationic compounds are selectively 




transport mechanism that aids in the accumulation of drug into parasites at levels 
∼1000-fold higher than in mammalian cells (Nagle et al., 2014).  
The effectiveness of diamidine-like derivatives including bisguanidines and bis(2-
aminoimidazolines) in recognizing the minor groove of AT-rich sequences of DNA has 
guided to design of novel potential antiparasitic agents (Tidwell & Boykin, 2003; 
Wilson et al., 2008; Soeiro et al., 2013; Dardonville & Nué Martínez, 2017). The 
compounds usually show a preference for binding to AT sequences of at least four 
consecutive AT base pairs in the binding site (Wilson et al., 2008). This selectivity is 
particularly relevant for the Kinetoplastid protozoa, like Trypananosma brucei, whose 
mitochondrial genome contains a high proportion of AT-containing DNA sequences 
(Ríos Martínez et al., 2014, Ríos Martínez et al., 2015a; Ríos Martínez et al., 2015b). 
The mechanism of antiparasitic action of dicationic compounds is surprisingly unclear 
notwithstanding many years of study by a number of laboratories. Both the 
mitochondrial and nuclear DNA are well established as targets of the diamidines. The 
strongest evidence indicates that DNA functional destruction is related to their 
antiparasitic activity (Soeiro et al., 2013; Scott et al., 2016). 
The necessity of new, more effective antiparasitic drugs with the lowest possible side 
effects has inspired Dr. Christophe Dardonville’s group to design and develop dicationic 
compounds like the bis(2-aminoimidazoline) derivatives over the last decade 
(Dardonville & Brun, 2004; Dardonville et al., 2006; Ríos Martínez et al., 2014; Ríos 
Martínez et al., 2015a; Ríos Martínez et al., 2015b). 
Bis(2-aminoimidazoline) derivatives display excellent antiprotozoal activity against T. 
brucei and P. falciparum and are generally safer than their bisguanidine counterparts 
(Rodríguez et al., 2008). These bis(2-aminoimidazoline) derivatives are excellent minor 
groove binders of AT rich DNA (Dardonville et al., 2006; Ríos Martínez et al., 2015a). 
This has prompted the study of the sequence affinity and selectivity with motifs like 
AATT, TTAA and ATAT (Nagle et al., 2010; Nagle et al., 2012; Glass et al., 2009; Ríos 
Martínez et al., 2015a). 




A good example is the bis(2-aminoimidazoline) derivative 4,4'-bis(imidazolinylamino) 
diphenylamine (CD27) (see Figure 1-18b) that is a potent inhibitor of Trypanosma 
brucei rhodesiense growth in vitro and in vivo (Dardonville & Brun, 2004; Dardonville 
et al., 2006). This compound shows curative activity in a mouse model of early stage 
HAT but results inactive against the late stage of the disease (Dardonville et al., 2006). 
The dicationic compound FR60 [4-((4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((4,5-
dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide dihydrochloride] is a very 
promising compound that has demonstrated submicromolar to nanomolar trypanocidal 
activity in vitro against Trypanosoma brucei brucei s427-WT and T. b. rhodesiense 
(Rodríguez et al., 2008; Ríos Martínez et al., 2015b). It exhibits no major cross-
resistance with the pentamidine-resistant cell line of Trypanosoma brucei brucei B48, 
and relatively low cytotoxicity (CC50>200 µM) for human embryonic kidney cells (HEK). 
As a result, FR60 shows a high selectivity for the parasite (SI>240), where 
SI=[CC50/EC50(s427)] (Ríos Martínez et al., 2015b). In addition, FR60 is 100% curative 
in vivo in the STIB900 mouse model of acute rhodesiense trypanosomiasis (i.e. early 
stage HAT) (Rodríguez et al., 2008; Ríos Martínez et al., 2015a). However, this 
compound proved to be inactive in the mouse model of late (CNS) stage disease (Ríos 
Martínez et al., 2015a). This could be due to the high polarity shown by this dibasic 
compound that holds two cationic charges at physiological pH, which possibly 
decreases its BBB penetration (Ríos Martínez et al., 2015b).  
A successful attempt to reduce the pKa of this compound was carried out through the 
incorporation of a fluorine, chlorine, or nitrogen atom in the structure of the lead drug 
FR60. In this approach, the electronegative halogen atoms decrease the electron 
density of the adjacent 2-iminoimidazolidine groups, reducing their basicity and hence 
their charge at physiological pH. Such substitution also increased favorably the 
lipophilicity of the molecule, both effects being potentially favorable to increase the 
BBB permeability of the compound (Ríos Martínez et al., 2015b).  
Ríos Martínez et al. measured in vitro the drug sensitivity of the FR60 derivative 




the trypanosomes compared with the fast killing cytotoxic drug phenylarsine oxide 
(PAO) used as reference in the assay (Ríos Martínez et al., 2015b). Nevertheless, the 
introduction of one halogen atom on the diphenyl scaffold led to an increase in 
antitrypanosomal activity for four compounds: JNI18, CRMV49, CRMV50 and CDMV65 
(half maximal effective concentration [EC50] < [EC50]FR60). JNI18 showed to be the 
drug that most modified the dynamics of action of the compounds, increasing the 
speed of trypanocidal action (see Table 1-5 and Table 2-9).  
None of the FR60 derivatives exhibit major cross-resistance with the pentamidine-
resistant cell line of T. b. brucei B48. Moreover, compounds 1-10 present relatively low 
cytotoxicity (CC50>200 µM) for human embryonic kidney cells (HEK).  
Table 1-5. In vitro activity of FR60 and derivatives against T.  brucei  s427 (wild type) 
and B48 (resistant) strains .   
Ref Compound T.  b .  brucei   
427WTa  
 EC50 (µM) ± SEM
b 
T.  b .  brucei   
AT1-B48 c  
EC50(µM) ± SEM 




1 FR60 0.83 ± 0.08 0.87 ± 0.20 1.1 >200 >240 
2 CRMV60 1.58 ± 0.31 2.16 ± 0.11 1.4 >200 >120 
3 JNI33 4.22 ± 0.14 4.35 ± 1.16 1.0 >200 >45 
4 CRMV65 0.58 ± 0.14 0.79 ± 0.21 1.4 >200 >340 
5 JNI18 0.220 ± 0.002 0.36 ± 0.02 1.7 >200 >900 
6 CRMV49 0.47 ± 0.05 0.65 ± 0.04 1.4 >200 >420 
7 JNI17 1.32 ± 0.03 2.44 ± 0.15 1.8 >200 >150 
8 CRMV50 0.53 ± 0.20 0.69 ± 0.07 1.3 >200 >370 
9 CRMV45 0.97 ± 0.01 0.83 ± 0.08 0.9 >200 >200 
10 JNI32 1.04 ± 0.02 3.23 ± 0.94 3.1 >200 >190 
 Pentamidine 0.00011 ± 0.0004 0.55 ± 0.003 3349   
 Diminazene 0.012 ± 0.002 0.78 ± 0.04 42   
 PAOh    0.32 ± 0.03  
aBloodstream form trypomastigotes of T. b. brucei s427 wild type. bStandard error of the mean.cT. b. 
brucei strain resistant to diminazene, pentamidine, and melaminophenyl arsenicals.dResistance factor 
compared to WT. eHuman embryonic kidney cells. fHalf maximal cytotoxic concentration gSelectivity 
index (SI) = CC50/EC50(s427).
hPhenylarsine oxide. Data taken from Ríos Martínez et al., 2015b.  
 
As FR60, compound CD27 is curative for early stage HAT. However, it also results 
inactive against late (CNS) stage sleeping sickness (Dardonville & Brun, 2004; 




Dardonville et al., 2006). To improve the BBB permeability of the CD27, Nieto Garrido 
et al. synthesized the 1-hydroxy analogue CDIV32 [4,4'-bis(1-hydroxyimidazolinyl 
amino)diphenylamine] (Table 2-9) (Nieto Garrido et al. 2011). CDIV32 was screened in 
vitro against Trypanosoma brucei rhodesiense and three other related parasites: 
Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum. CDIV32 
demonstrated submicromolar trypanocidal activity in vitro against T. b. rhodesiense 
and nanomolar trypanocidal activity against P. falciparum (Table 1-6).  
Table 1-6. In vitro  antiprotozoal activity of CDIV32. 
Cel l  EC50 (µM) 
T. b. rhodesiensea (SI)b 0.37 (236) 
T. cruzi c (SI) >204 
L. donovani d (SI) 58 
P. falciparume (SI) 0.055 (1673) 
Cytotox L6-cellsf 92 
aT. brucei rhodesiense STIB900 strain. Control: melarsoprol, EC50=12.6 nM. 
bSelectivity 
index=[EC50(L6-cells)/EC50(parasite)]. 
cAmastigotes of T. cruzi Tulahuen C4 strain. Control: 
benznidazole, EC50=1.64 µM. 
dL. donovani strain MHOM/ET/67/L82 axenically grown amastigotes. 
Control: miltefosine, EC50=0.275 µM. 
eP. falciparum K1 erythrocytic stages. Control: chloroquine, 
EC50=0.169 µM. 
fRat skeletal myoblast L-6 cells. Data taken from Nieto Garrido et al. 2011. 
Nieto Garrido et al. 2011 also proved that CDIV32 is active in vivo in the STIB900 
mouse model after intraperitoneal (IP) administration and it showed significant higher 
permeability than compound CD27 (nearly 3-fold). These results show that N-
substitution of the imidazolylamino group with OH enhances the in vitro BBB 
permeability of the CD27. 
Nevertheless, the drug target and mechanism of action of these bis(2-
aminoimidazolinium) compounds into the parasites’ cells is still not clear. 
Therefore, a functional and structural analysis of this bis(2-aminoimidazoline) series of 
FR60 derivatives, and a CD27-derivative compound, CDIV32, is presented here, in order 
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1 .8  Objective of the Work  
The present research work has two main objectives:  
v To contribute to the study of the structural and binding analysis of AT-rich DNA-
ligand complexes, specifically with HMG proteins (HMGA1a and HMGB1) and 
minor groove binding drugs bis(2-aminoimidazoline) derivatives.  
v To perform the in vitro study of the effect of bis(2-aminoimidazolines) derivatives 
on Trypanosoma brucei, in order to identify the mode of action of novel 
antitrypanosomal drug candidates. 
To achieve the first objective several different approaches were followed: 
§ Expression and purification of the recombinant HMG protein: HMGA1a(∆50-91), 
HMGB1(∆93-165) and HMGB1(∆8-165). 
§ Crystallographic assays with the HMG proteins and several different AT-rich 
oligonucleotide sequences. 
§ Crystallographic assays with different AT-rich oligonucleotide sequences and a 
series of diphenyl-based bis(2-iminoimidazolidine) compounds. 
§ X-ray diffraction of the crystals obtained from these complexes, analysis of the 
diffraction data and structural resolution of the molecules by computational 
methods. 
§ Binding and kinetic analysis of the HMG proteins and the bisimidazolinium 
compounds to AT-rich DNA by surface plasmon resonance (SPR) experiments. 
§ Study of the ability of the bisimidazolinium compounds to displace the HMG 
proteins from their DNA binding site by SPR experiments. 
§ Studies of the effect on the DNA topology induced by the HMGA1a protein in 
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Likewise, to accomplish the second objective different approaches were also followed: 
§ In vitro study of drug sensitivity in different cell lines of bloodstream form 
Trypanosoma brucei. 
§ Determination of the effect of the bis(2-iminoimidazolidine) compounds on T. 
brucei growth rate. 
§ Study of the cell cycle progression of T. brucei exposed to the bis(2-
iminoimidazolidine) compounds by flow cytometry. 
§ Determination of the DNA content of drug-exposed T. brucei by fluorescence 
microscopy. 
§ Study of the mitochondrial membrane potential of treated T. brucei by flow 
cytometry.  
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2 .1  Production and Purif ication of Recombinant 
HMG Proteins in E. coli  
For X-ray crystallography and surface plasmon resonance (SPR) assays protein samples 
with the maximum level of purity achievable are required. During the research work, 
the proteins HMGA1a(∆50-91), HMGB1(∆93-165) and HMGB1(∆8-165) have been 
expressed and purified. Table 2-2 lists the sequence, molecular mass and other 
characteristics of these proteins. 





coeff ic ient (ε)  
Amino 
acids 




7.99 a mL·mg-1·cm-1  
(at 220 nm) a 
42 
EVPTPKRPRG RPKGSKNKGA AKTRKTTTTP 
GRKPRGRPKK LE 




(at 280 nm) 
73 +2b 
GSNAPKRPPS AFFLFCSEYR PKIKGEHPGL 
SIGDVAKKLG EMWNNTAADD KQPYEKKAAK 
LKEKYEKDIA AYRAK  




(at 280 nm) 
158 +2b 
GSKPRGKMSS YAFFVQTCRE EHKKKHPDAS 
VNFSEFSKKC SERWKTMSAK EKGKFEDMAK 
ADKARYEREM KTYIPPKGET KKKFKDPNAP 
KRPPSAFFLF CSEYRPKIKG EHPGLSIGDV 
AKKLGEMWNN TAADDKQPYE KKAAKLKEKY 
EKDIAAYRAK  
HMGB1 extinction coefficients have been calculated using Peptide Calculator, Northwestern 
University. aData from Reeves & Nissen, 1999.bThe two additional N-terminal residues highlighted are 
derived from the cloning process.  
Obtaining HMG proteins directly from human cells has many limitations. Thus, the 
proteins of interest have expressed in the bacterium Escherichia coli, using different 
strains and expression vectors (plasmids) in each case. The plasmid pET-3a containing 
the human HMGA1a(∆50-91) was kindly provided by Dr. R. Reeves (Washington State 
University, USA) and the two plasmids pGEX-2T containing the genes encoding each of 
the HMGB1 mutant proteins were provided by Dr. M. E. A. Churchill (Department of 
Pharmacology at the University of Colorado).  
A multi-stage purification strategy adapted to each protein has been followed. Table 




summarizes the techniques followed during each purification step (capture phase, 
intermediate purification and polishing). 
The capture phase reduces the amount of unwanted proteins and concentrates the 
target protein. Intermediate purification removes most contaminant closely related to 
the target protein. Polishing removes specific contaminant and unwanted forms of the 
target protein that may have formed during isolation and purification. 
Table 2-2. HMG proteins production main stages.   
Protein Expression Purif ication Steps 
 




































2 .1.1  Expression of HMGA1a(∆50-91) 
The research work has studied the HMGA1a protein fragment from the amino acid 50 
to the 91, containing two of the three DNA binding domains: the II and the III AT-hook 
(Figure 2-1). This fraction does not include the acidic C-terminal tail to facilitate its 
crystallization. 
 
Figure 2-1. Scheme of HMGA1a(∆50-91) compared to the ful l- length protein 
HMGA1a. The AT-hook DNA-binding domains are shown in green. 
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E. coli Rosetta (DE3) pLysS strain (Novagen) has been transformed with the plasmid 
pET-3a containing the human HMGA1a(∆50-91) gene (Figure 2-2). This plasmid also 
contains a gene that confers resistance to the antibiotic ampicillin (ampR), in order for 
bacteria carrying the plasmids can be selected. 
Through the T7 promoter system present in the pET vectors, the expression of the 
recombinant protein is much more specific and can be induced by isopropyl β-d-1-
thiogalactopyranoside (IPTG) (see Appendix A). Induction will be done at the 
exponential growth phase of the cells to optimize the expression of the desired protein. 
 
Figure 2-2. Scheme of the plasmid used to expressed HMGA1a(∆50-91).  F igure 
created by Savvy SVG plasmid map generating program 
[http://www.bioinformatics .org/savvy/] .  
The protocols followed for the transformation, transformed cell selection, induction 
and expression of HMGA1a(∆50-91) are described next. In order to prevent 
contamination, all steps of the process were carried out under sterile conditions. 
Appendix B describes the protocol for preparing the culture media and buffers used for 
this process.  
Transformation 
0.5 µL of the pET-3a plasmid DNA solution (approximately 100 ng/µL) were added to 
~100 µL of competent cells of Escherichia coli Rosetta (DE3) pLysS strain. A negative 
control with only competent cells was also prepared. Cells were placed on ice for 15 




to ice immediately for 2 min. This heat shock facilitates the entry of plasmid DNA into 
the competent cells. The cells were then added to 1 mL of LB medium and incubated 
for 1 hour at 37°C in a water bath, followed by centrifugation at 4,000 rpm for 3 min 
(microfuge). About 1 mL of supernatant was removed. The pellet was resuspended and 
plated directly onto LB agar plates containing the appropriate antibiotics: ampicillin 
(50 µg/mL) and chloramphenicol (25 µg/mL). Plates were incubated overnight at 37°C.  
On the next day, some colonies must be observed on the transformed cells plate, 
whereas no colonies should appear in the control plate as the untransformed cells are 
not resistant to the ampicillin. 
Growing transformed E. coli in liquid media 
One single colony was picked from the transformed cells plate using a sterilized loop 
and inoculated into 3 mL LB medium containing 50 µg/mL ampicillin. Culture was 
grown for about 6 hours at 37°C with shaking at 250 rpm until medium turned turbid. 
Then, the culture was poured into 50 mL LB with 50 µg/mL ampicillin and incubated 
overnight at 37°C with shaking at 250 rpm.  
HMGA1a(50-91) protein induction 
The required volume of the overnight culture to reach a OD600 = 0.1-0.2 was diluted 
with 1 L of LB containing 50 µg/mL ampicillin. The culture was incubated at 37°C with 
shaking at 250 rpm until the OD600 of 0.6 to 0.7 was achieved. 1 mL of 1 M IPTG was 
added to the culture, followed by incubation at 37°C with shaking at 250 rpm for 3 
hours. Culture was centrifuged at 4,000 rpm for 10 min at 4°C (SLA 3000 rotor) and 
the supernatant was removed. The pellet (bacteria) was stored at -80°C until needed.  
Un-induced and induced samples (induction time: 0, 1.5 h and 3 h) were analyzed by 
measuring the absorbance and by SDS-PAGE to check protein expression levels. An 
aliquot of 125 µL was taken every time point and centrifuged at 4,000 rpm for 5 min 
(microfuge). The pellet was resuspended in 30 µL of 1× SDS sample buffer. 1 mL of 
culture was taken every time point to measure its absorbance. Samples were stored at 
-20°C until the electrophoresis was performed (see section 2.2.1). 
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Pellet preparation  
As the recombinant HMGA1a(∆50-91) protein is expressed intracellularly in E. coli, cell 
disruption is necessary. Preparation of the bacterial lysate is a critical step. Optimal 
conditions maximize the fraction of the recombinant protein extracted. The protocol 
followed is detailed next (adapted from Reeves & Nissen, 1999). 
For bacterial pellet obtained from 1 L of starting culture, 100 mL of 5% HClO4/0.5% 
Triton X-100 (cold) were used to resuspend the pellet by pipetting continuously to 
obtain a good dispersion of cells. Samples were incubated on ice for at least 15 min 
with occasional shaking. Cells were centrifuged at 10,000 rpm for 10 min at 4°C (GSA 
rotor, Sorvall) and the supernatant were collected. Recombinant HMGA1a(∆50-91) 
protein was precipitated from the supernatant by adding trichloroacetic acid (TCA) to a 
25% final concentration (add 33.3 mL). Samples were placed on ice for 1 h or more 
with occasional agitation. At this point, samples could be stored at 4°C overnight.  
Samples were centrifuged at 10,000 rpm for 20 min at 4°C (GSA rotor, Sorvall) and the 
supernatant was discarded very carefully. The protein pellet often appears to be "oily" 
and fluid, thus care should be taken not to lose it while decanting the supernatant. 
Pellet was resuspended in 60 mL H2O. 20 mL of TCA were added to get a final 
concentration of 25%. Samples were placed on ice with occasional shaking, followed 
by centrifugation at 10,000 rpm for 10 min at 4°C (GSA rotor, Sorvall). Supernatant 
was discarded carefully and the pellet was washed with 60 mL of acetone with 10 mM 
cold HCl (-20ºC). Samples were centrifuged at 10,000 rpm for 10 min at 4°C (GSA rotor, 
Sorvall), the supernatant was discarded carefully right after centrifugation and the 
pellet was washed with 60 mL of cold acetone (-20°C). This step was repeated twice. 
The pellet was dried under vacuum and stored at -20ºC. 




2 .1.2  Purif ication of HMGA1a(∆50-91) 
In order to achieve the required level of purity of the HMGA1a(∆50-91), the 
chromatographic techniques described below have been performed. 
Cation-exchange chromatography 
Chromatography is one of the most widely used methods of protein purification. 
Proteins can be purified based on characteristics such as size and shape, charge, 
hydrophobic groups present on the surface, and binding capacity with the stationary 
phase. 
Ion-exchange chromatography is based on electrostatic interactions between charged 
protein groups, and a solid support material called matrix. Matrix has an ion load 
opposite to that of the protein to be separated, and the affinity of the protein to the 
column is achieved with ionic bonds.  
Proteins are separated from the column either by changing pH, concentration of ion 
salts or ionic strength of the buffer solution. Positively charged ion exchange matrices 
are called anion-exchange matrices, and adsorb negatively charged proteins, while 
matrices bound with negatively charged groups are known as cation-exchange 
matrices, and adsorb positively charged proteins. The latter have been used as the first 
purification step for the HMGA1a(∆50-91) protein due to the net positive charge this 
protein has.  
Cation-exchange chromatography consists of three phases: 
§ Equilibration. At this stage the matrix is adjusted to the initial saline and pH 
conditions required for the experiment by contacting the stationary phase 
with the counterion. 
§ Application of protein sample. The sample, in the same buffer used to 
equilibrate, is applied to the stationary phase. It is necessary to centrifuge 
the sample before loading it in the column to eliminate possible insoluble 
residues. Proteins carrying a charge opposite to the stationary phase displace 
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the counterion and bind to the matrix of the column. Proteins with the same 
charge as the matrix or no charge do not bind and are washed out during this 
stage. 
§ Elution. By changing the buffer conditions (in this case the counterion 
concentration) to proteins that have bound to the stationary phase, ions 
replace the bound protein. Proteins with weaker ion interactions are released 
at lower counterion concentrations, whereas proteins with stronger charges 
have a higher affinity for the stationary phase and remain bound to the 
column longer. The matrix needs to re-equilibrate after elution with at least 
10 column volumes of equilibration buffer to reuse it. 
For HMGA1a(∆50-91) protein purification, a matrix (stationary phase) of 
carboxymethyl cellulose (CM52, Whatman) has been used, with sodium as counterion. 
Equilibration buffer solution was 50 mM NaCl, 25 mM Tris-HCl, pH 7 and elution was 
achieved by gradually increasing NaCl concentration from 50 mM to 600 mM, in 25 
mM Tris-HCl, pH 7. 
Eluted fractions were collected and their absorbance at 220 nm was measured. 
Selected fractions were analyzed by electrophoresis (see section 2.2). Fractions 
containing the HMGA1a(∆50-91) are then submitted to the next purification step or 
can be conserved at -20ºC until processing. 
Size-exclusion chromatography 
Also known as gel-filtration chromatography, the size-exclusion chromatography has 
been used for the final "polishing" step of HMGA1a(∆50-91) protein purification. In 
this chromatographic method, molecules in solution are separated by their size. 
The column matrix or stationary phase is a gel composed of a large number of 
microscopic porous spherical beads. These spheres are constituted of highly hydrophilic 
polymers linked together by chemical bonds to form a three-dimensional network. 
Separation occurs when molecules of different sizes are included or excluded from the 




pores and their flow through the column is retarded according to their size, while large 
molecules cannot enter the pores and are eluted in the column’s void volume. 
Therefore, molecules are separated based on their size as they pass through the column 
and are eluted in order of decreasing molecular weight. The entire separation process 
takes place as one total column volume (equivalent to the volume of the packed bed) 
of buffer passes through the gel filtration medium.  
In this case, unlike the ion-exchange columns, proteins do not bind to the matrix and 
therefore the buffer composition does not directly affect the resolution. The factors 
that indeed affect the resolution and thus good separation between the target protein 
and the impurities are mainly the sample volume, the particle and pore size, column 
dimensions, column packing, flow rate and sample viscosity.  
To address fast and efficient HMGA1a(∆50-91) protein polishing the ÄKTA Purifier 10 
system (GE Healthcare) has been used. The separating column was the Superdex™ 
Peptide 10/300 GL (GE Healthcare), with an optimum molecular weight range (Mr) 
from 100 to 7,000. Column matrix is composed of spherical composite of cross-linked 
agarose and dextran within a column volume of 24 mL. Protein samples were 
concentrated prior to loading onto the column by ultrafiltration using a Vivaspin® (GE 
Healthcare). 
The buffer used for both column equilibration and elution was 25 mM Tris-HCl, pH 7.5 
containing 100 mM NaCl. The flow rate was 0.5 mL/min, equilibration of the column 
was done with at least 2 column volumes and elution with 1.5 column volumes. 
The ÄKTA purifier 10 automatically collects fractions during elution and measures their 
absorbance at 220, 260 and 280 nm. Fractions absorbing at 220 were collected, and 
HMGA1a(∆50-91) purity verification was achieved by electrophoretic analysis (section 
2.2). The absorbance at 260 and 280 nm is monitored to evidence possible 
contamination of DNA or proteins containing aromatic residues, respectively.  
For crystallography assays, pure samples were concentrated to at least 10 mg/mL by 
ultrafiltration using a Vivaspin® (GE Healthcare). 
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2 .1.3  Expression of HMGB1 proteins 
In this work two deletion mutants of the HMGB1 protein have been studied, one from 
the amino acid 8 to the 165, containing both HMG boxes, and the second from amino 
acid 93 to 165, containing only the second DNA binding domain, the HMG box B 
(Figure 2-3). Both lack the acidic C-terminal tail to facilitate crystallization. 
As with HMGA1a(50-91), HMGB1 proteins production was performed in bacterial 
cultures. Plasmids pGEX2T containing GST-tagged rat HMGB1 proteins Boxes A+B and 
Box B were expressed in E. coli Rosetta (DE3) pLysS strain (Novagen). HMGB1 proteins 
were obtained by the Glutathione S-transferase (GST) Gene Fusion System, which is a 
versatile system for the expression, purification, and detection of GST-tagged proteins 
produced in Escherichia coli. 
This technique involves expressing the protein of interest fused to the known protein 
glutathione S-transferase (GST) to facilitate its purification by affinity chromatography. 
The pGEX2T vectors are designed for inducible, high-level intracellular expression of 
genes or gene fragments as fusions with Schistosoma japonicum GST. Expression in E. 
coli yields tagged proteins with the GST moiety at the amino terminus and the protein 
of interest at the carboxyl terminus. Once purified, cleavage of the protein from GST is 
done to obtain pure sample of the target protein.  
Figure 2-3 shows the scheme of the plasmid used to express the two fragments of the 
protein HMGB1. This expression vector also contains the genes Ptac promoter (Ptac), 
lacI repressor (lac Iq) and ampicillin resistance (ampR). Recombinant HMGB1 protein 
expression can be induced by adding IPTG (Appendix A).  
The protocols followed for the transformation, induction and expression of the 
HMGB1s are described next. In order to prevent possible contamination, all stages of 
the work were carried out under sterile conditions. Appendix B describes the protocol 






Figure 2-3. Scheme of the plasmid pGEX-2T encoding the GST-fusion protein 
HMGB1 ( left) .  F igure created by Savvy SVG plasmid map generating program 
[http://www.bioinformatics .org/savvy/] .  Schematic representation of the HMGB1 
proteins studied (r ight):  Box AB and Box B. 
Transformation 
0.5 µL of the pGEX-2T plasmid DNA solution (typically 1-20 ng/mL) were added to 
~100 µL of competent cells of Escherichia coli Rosetta (DE3) pLysS strain. A negative 
control with only competent cells was also prepared. Cells were placed on ice for 10-
20 min. They were heat shocked in a 37°C water bath for 5 min then transferred 
to ice immediately for 2 min. The cells were then added to 1 mL of room temperature 
LB medium and incubated for 1 hour at 37°C in a water bath, followed by 
centrifugation at 4,000 rpm for 2 min at 4°C (microfuge). About 1 mL of supernatant 
was removed and the pellet was resuspended and plated directly onto LB agar plates 
containing the appropriate antibiotics: ampicillin (50 µg/mL) and chloramphenicol (34 
µg/mL). Plates were incubated overnight at 37°C.  
Growing transformed E. coli in liquid media 
One single colony was picked from the transformed cells plate using a sterilized loop 
and inoculated into 3 mL LB containing 50 µg/mL ampicillin and 34 µg/mL 
chloramphenicol. Culture was grown for about 6 hours at 37°C with shaking at 250 
rpm until medium turned turbid. The culture was then diluted with 150 mL LB 
containing 50 µg/mL ampicillin and 34 µg/mL chloramphenicol and incubated 
overnight at 37°C with shaking at 250 rpm. 
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HMGB1 proteins induction 
The required volume of culture to reach a OD600 = 0.1 (usually about 60 mL) was 
inoculated into 1 L of LB with 50 µg/mL ampicillin and 34 µg/mL chloramphenicol. 
Culture was incubated at 37°C with vigorous shaking at 250 rpm until OD600 of 0.8 was 
achieved. HMGB1 protein induction was then performed by adding 0.5 mM IPTG. The 
culture was incubated at 37°C with shaking at 250 rpm for 3 hours, followed by 
centrifugation at 5,000 rpm for 10 min at 4°C (SLA 3000 rotor). The supernatant was 
removed and the pellet (bacteria) was flash-frozen in liquid nitrogen and store at -
80°C until needed.  
As in the HMGA1a(∆50-91) protein expression, aliquots were taken during induction at 
time 0, 1.5 and 3 h to measure the absorbance and to make electrophoretic controls of 
the process on SDS-PAGE gels (section 2.2.1).  
50 µL aliquot was taken every time point and centrifuged at 4,000 rpm for 5 min 
(microfuge). The pellet was resuspended in 15 µL of 1× SDS sample buffer. Additionally, 
1 mL of culture was taken every time point to measure its absorbance. Samples were 
stored at -20°C until the electrophoresis was performed. 
Pellet preparation  
HMGB1 protein fractions are expressed intracellularly in recombinant E. coli. Thus, cell 
disruption is necessary to extract the recombinant protein. Cell lysis is produced by 
sonication. 
In a falcon siliconized tube, the bacterial pellet obtained from 1 L of starting culture 
was resuspended in 25 mL of affinity column equilibration buffer (0.5 M NaCl, 10 mM 
EDTA, 1 mM DTT, 10% glycerol, 20 mM Tris-HCl, pH 7.9) with protease inhibitors (1/2 
cOmplete Protease Inhibitor Cocktail tablet, Roche) and a spatula tip of DNase by 
pipetting continuously to obtain a good dispersion of cells. Cell lysis was performed by 
sonication on Bandelin SONOPULS Ultrasonic Homogenizer HD 2200 twice for 2 min 
with 50% of output. It is very important to keep the samples cool (on ice) during 




at 4°C (GSA rotor, Sorvall) and the supernatant was decanted into a clean 50 mL 
centrifuge tube. Supernatant was ready for loading onto the affinity column. 
2 .1.4  Purif ication of the HMGB1 proteins 
At this point, the recombinant protein mixed with bacterial proteins and other 
impurities is available. In order to achieve the required level of purity, a multi-step 
chromatographic strategy for optimizing purification of the HMGB proteins is carried 
out. The purification process begins with an affinity chromatography (also called 
affinity purification), which makes use of the specific binding interactions between the 
tails of the GST fusion protein. Subsequently, a cation-exchange chromatography and 
size-exclusion chromatography are performed. 
Affinity chromatography 
Purification of proteins can be easier and simpler if the protein of interest is tagged 
with a known sequence commonly referred to as a tag. Here, GST affinity tag to aid in 
the purification of the HMGB1 recombinant proteins was used. 
The clarified lysate is incubated with Glutathione Sepharose™ 4B matrix (GE 
Healthcare). Hence, the GST moiety binds with high affinity to the glutathione coupled 
to the Sepharose beads. This binding is reversible and the protein can be eluted by the 
addition of reduced glutathione to the elution buffer. A specific protease site 
engineered between the GST moiety and the protein of interest allows removal of the 
GST moiety from the target recombinant protein. In our case, the pGEX-2T plasmid 
contains a protease cleavage site for thrombin, which cuts specifically the amino acid 
sequence LVPR/ /GS, between the GST moiety and the HMGB1 protein fragment, which 
is collected during the elution step. Finally, the glutathione Sepharose beads are 
regenerated by exposing to guanidine chloride, which denaturates the GST tag that 
remains bound to the column. 
The matrix used is packed in a glass Bio-Rad column but unlike the chromatography 
system previously described (section 2.1.2), this is a semi-batch chromatography, 
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where the sample is incubated for a certain time with the column matrix and eluted by 
gravity flow. The protocol detailed for a clarified lysate obtained from 1 L of starting 
culture is presented next.  
The Glutathione Sepharose™ 4B matrix (about 2.5 mL resin per 1 L of culture) was 
thoroughly equilibrated by passing 3 times 10 bed volumes of equilibration buffer: 0.5 
M NaCl, 10 mM EDTA, 1 mM DTT, 10% glycerol, 20 mM Tris-HCl, pH 7.9. Then, the 
clarified lysate (supernatant from sonication) was loaded on the matrix and incubated 
by rotating gently for 2 h at 4°C. The flow through (FT) was eluted. 5 column volumes 
(one at a time) were washed with wash buffer: 1 M NaCl, 10 mM EDTA, 1 mM DTT, 20 
mM Tris-HCl, pH 7.9. The eluent (W) was collected. 3 column volumes of thrombin 
buffer: 100 mM NaCl, 2,5 mM CaCl2, 1 mM DTT, 20 mM Tris-HCl, pH 7.9 was passed 
through the column, eluted and collected (ThW). 200 U of thrombin (Fisher Bioreagents) 
in 1 mL of thrombin buffer was added to the column to remove the GST tag and 
incubated by rotating overnight at 4°C. To inactivate the enzyme, enough 0.5 mM 
EDTA was added to get to a final concentration of 10 mM. The flow through (FTc) was 
eluted and collected. The elution of the HMGB1 protein was performed using 3 
volumes of elution buffer: 100 mM NaCl, 10 mM EDTA, 1 mM DTT, 10 mM Tris-HCl, pH 
7.9. Each elution was collected separately (E1, E2, E3). Column matrix regeneration was 
achieved by passing 3 volumes of water, 3 volumes of 6 M guanidine chloride and rinse 
with 3 volumes of water. Column can be stored in ethanol to prevent any microbial 
growth once 3 volumes of ethanol have passed through it.  
All samples eluted by SDS-PAGE were analyzed to verify the resolution of the 
purification process (section 2.2). The fractions eluted after the GST tag removal (FTc 
E1, E2, E3) are pooled in one sample ready to load into the cation exchange column as 
described below. 
Cation-exchange chromatography 
The protein was further purified using a 5 mL HiTrap SP FF cation-exchange column 
(GE Healthcare) to separate the enzyme thrombin and other minor impurities from the 




particles, with sulphopropyl (SP) strong cation exchange groups. Cation-exchange 
chromatography technique has been described in section 2.1.2. The chromatography 
was performed in an ÄKTA purifier 10 system. Equilibration buffer solution was 100 
mM NaCl, 1 mM EDTA, 1 mM DTT, 10 mM Tris-HCl, pH 7.9 and the protein was eluted 
with a linear gradient to a final concentration of 1 M NaCl in the same buffer. The 
flow rate used is 2 mL/min, equilibration of the column is done with 10 column 
volumes. 
Absorbance of each collected fraction was measured at 220, 260 and 280 nm. 
Fractions absorbing at 280 nm were separated (unlike the HMGA, HMGB protein does 
present aromatic residues), and their protein purity was verified by SDS-PAGE (section 
2.2). The most pure fractions were pooled and concentrated for final purification via 
size-exclusion chromatography. 
Size-exclusion chromatography 
Size-exclusion chromatography technique is described in section 2.1.2. For HMGB1 
protein polishing, a HiLoad Superdex™ 75 (GE Healthcare) column was used, with an 
optimum molecular weight range (Mr) from 3,000 to 70,000 Da.  
The buffer used for both column equilibration and elution was 150 mM NaCl, 1 mM 
DTT, 50 mM HEPES, pH 7.4. The flow rate used was 0.5 mL/min, equilibration of the 
column was done with at least 2 column volumes and the elution with 1 column 
volumes. Pure fractions, based on analysis by SDS–PAGE (section 2.2), were pooled and 
dialyzed to decrease the salt concentration in buffer containing in 50 mM NaCl, 1 mM 
DTT in 25 mM HEPES, pH 7.4 at 4ºC. Finally, pure samples were concentrated to at 
least 10 mg/mL for crystallography assays using a Vivaspin® (GE Healthcare) ultra-
concentration device. Samples were submitted to flash-freezing in liquid nitrogen and 
stored at -80ºC. 
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2 .2  Electrophoretic Techniques 
Gel electrophoresis is a technique widely used to separate biological macromolecules 
(basically proteins or nucleic acids) according to their length, conformation and charge. 
Using an electric field, molecules can be made to move through a gel. This electric field 
consists of a negatively charged cathode and a positively charged anode at each end of 
the gel, which drive the molecules through the gel according the their charge. The gel 
is placed in an electrophoresis buffer-filled chamber, which is connected to a power 
source. Samples being sorted are dispensed individually into wells in the gel. Applying 
the electric field, molecules move through the gel at different rates and then, they 
migrate different distances, which form distinct bands on the gel, one band per 
component. 
The gel (matrix) is a polymer whose composition and porosity is chosen based on the 
specific weight and composition of the macromolecule to be analyzed. It is usually 
composed of different concentrations of acrylamide and a cross-linker or agarose, 
producing different sized mesh networks of polyacrylamide or agarose. Polyacrylamide 
gel matrix is formed through a free radical driven chemical reaction. On the other hand, 
agarose is composed of long unbranched chains of uncharged carbohydrate without 
cross-links, resulting in a gel with large pores allowing separation of superior 
macromolecules and macromolecular complexes.  
2 .2.1  SDS Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method for 
separating molecules based on the difference of their molecular weight. The SDS-PAGE 
protocol followed in the present work is based on the discontinuous buffer system 
devised by Laemmli (Laemmli, 1970), which is the most popular electrophoresis system.  
During sample preparation for SDS-PAGE, proteins are boiled in SDS-PAGE sample 




and the detergent 2% (w/v) SDS (Sigma-Aldrich)	 (Table 2-3). This formulation 
simultaneously breaks disulfide bonds and disrupts the tertiary structure of proteins. 
SDS binds to linear proteins (polypeptide subunits) in a range of 1.4 g of SDS per g of 
polypeptide. SDS also coats the protein with a uniform negative charge, which masks 
the intrinsic charges on the R-groups of the amino acids. One of the most significant 
properties of this anionic detergent is that when it binds to polypeptides, all assume 
the same hydrodynamic shape, which means that their electrophoretic mobilities are 
nearly identical. Then, proteins separate by sieving on basis of size (molecular weight) 
through migrating towards the anode. The glycerol (Sigma-Aldrich) present in the 
sample buffer provides density for applying the sample on the gel, and bromophenol 
blue (Thermo Fisher Scientific) is used as a color marker to monitor the progression of 
the gel electrophoresis. 
The gel is divided into two portions, a smaller upper "stacking" gel of lower percentage 
of acrylamide and pH 6.8, and a resolving gel with highest percentage of acrylamide, 
higher pH (8.8) with a different ionic content (Table 2-3). This allows the proteins in a 
loaded sample to be concentrated into one tight layer during the first few minutes of 
electrophoresis before entering the resolving portion of a gel.  
Electrophoresis gels are formulated in buffers that enable electric field to flow through 
the matrix. The prepared solution is poured into the thin space (usually 0.75 mm or 1.5 
mm) between two glass plates that form a "cassette". This process is referred to as 
“casting a gel”. First, resolving portion is dispensed, then, prior to polymerization, a 
small layer of isopropanol is added on top of the gel to straighten the level of the gel. 
After the resolving gel is polymerized, isopropanol is removed and stacking gel solution 
is poured. Immediately after, a gel comb (a well-former template) is inserted. Once the 
gel polymerizes, the cassette is mounted (typically vertically) into the electrophoresis 
chamber so that the top and bottom edges are placed in contact with the running 
buffer, and the comb is removed.  
The running buffer contains ions that conduct the current through the gel. SDS is also 
present in the gel and in the running buffer to make sure that once the proteins are 
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linearized and their charges are masked, they stay that way throughout the run. The 
compositions of the SDS-PAGE gel and buffers are listed in Table 2-3. 
Table 2-3. SDS-PAGE gel and buffers composit ion.  
SDS-PAGE GEL (10 cm ×  15 cm ×  1 .5 mm thick) 
Reagent 
Resolving (10 mL) 
(15% acrylamide, 0,4% bisacrylamide, 
0.375 M Tris, 0.1% SDS) 
Stacking (3 mL) 
(6% acrylamide, 0.16% bisacrylamide, 
0.125 M Tris, 0.1% SDS) 
30% acrylamide, 
0.8% bisacrylamide 
5 mL 0.6 mL 
1.5 M Tris-HCl, pH 
8.8 
2.5 mL - 
10% SDS 100 µL 30 µL 
0.5 M Tris-HCl, pH 
6.8 
- 0.75 µL 
H20 2.3 mL 1.59 mL 
TEMED a 4.5 µL 3 µL 
10% APS b 75 µL 30 µL 
 
SDS-PAGE RUNNING BUFFER 
Reagent 5× (1 L) [1×] 
Tris Base 30 g 0,01 M 
Glycine 144 g 0,075 M 
SDS 5 g 0,02 % 
 
SDS-PAGE SAMPLE BUFFER 
Reagent 4× (10 mL) [1×] 
2 M Tris, pH 6.8 1.25 mL 62 mM 
Glycerol 4 mL 10 % 
SDS 0.8 g 2% 
β-mercaptoethanol 2 mL 5 % 
Bromophenol blue  Spatula tip - 
aN,N,N',N-Tetramethylethylenediamine (Sigma-Aldrich). bAmmonium persulfate (Bio-Rad). 
SDS-PAGE gel preparation 
Glass plates, combs, and spacers required were cleaned and dried. The gel cassette was 
assembled and the resolving gel was prepared following Table 2-3 and poured into the 
cassette. To avoid polymerization, TEMED was added when solution was well mixed. 
Immediately, a small layer of isopropanol was added to the top of the gel prior to 




stacking gel (Table 2-3) was started (TEMED was not added yet). Isopropanol layer was 
removed and the top layer of the gel was rinsed with ddH2O and dried off as much of 
the water as possible by carefully using filter paper. TEMED was added to the stacking 
gel solution, mixed and quickly transferred the gel solution into the cassette until full, 
and then the appropriate comb was inserted.  
Sample preparation 
4x SDS-PAGE sample buffer was prepared following the Table 2-3. The required volume 
of 4x sample buffer (or 2x) was added to each protein sample and mixed. Samples were 
boiled for 3-6 min. Samples were spun and loaded onto the gel using a Hamilton. 
Syringe must be thoroughly rinsed with ddH2O between applications to avoid cross 
contamination of different samples. 
Protein samples (containing sample buffer) can be stored at -20°C and reboiled for 5 
min when used the following time. 
Electrophoresis 
The gel cassette in the electrophoresis chamber containing 1× SDS-PAGE running 
buffer (Table 2-3) was placed on the bottom chamber. Air bubbles attached to the 
bottom ends of the glass plates were removed. The comb was removed carefully and 
the upper chamber was filled with running buffer until completely covering the wells. 
Protein samples were loaded in consecutive wells. The electrophoresis tank was 
connected to the power supply and the gel was run at constant voltage (100-130 V) 
for 45-60 min until the tracking dye (bromophenol blue) was about 1 cm from the 
bottom of the plates. 
Protein detection with Coomassie® blue 
To visualize the proteins sorted in the gel, they need to be stained. For that purpose, 
Coomassie® blue G-250 dye dissolved in isopropanol and acetic acid was used (see 
Table 2-4). This solution not only dyes but also fixes the proteins in the gel matrix.  
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After the electrophoresis is complete, the power supply was turned off and 
disconnected. The gel cassette was taken out from the chamber and the glass plates 
were removed carefully. The gel was placed in a container and enough staining 
solution was added to completely cover the gel. It was gently agitated during 60 min 
at room temperature on an orbital shaker. 
Table 2-4. SDS-PAGE staining and unstaining solutions.   
SDS-PAGE COOMASSIE® STAINING SOLUTION 
Reagent Volume (2 L) Concentration 
Isopropanol 500 mL 25% 
Acetic Acid 200 mL 10 % 
Coomassie® Blue G-250 Dye 5 g 0.25 % 
1.  
SDS-PAGE DESTAINING SOLUTION 
Reagent Volume (2 L) Concentration 
Isopropanol 200 mL 10% 
Acetic Acid 200 mL 10 % 
 
After staining, a destaining step is needed to wash away excess unbound dye from the 
gel matrix background.  
The gel was immersed into the destaining solution (Table 2-4) and left it shaking 
overnight. Next day, a clear gel with blue bands of protein was obtained. The gel can 
be then photographed and dried to maintain a permanent record.  
Protein detection with silver staining 
Alternatively, detection of proteins in gels has been performed using SilverQuest™ 
Silver Staining Kit (Invitrogen™) following the manufacturer’s instructions. This is a 
rapid and easy method that allows detection of most proteins since it is 30-fold more 
sensitive than staining with Coomassie® G-250 dye. The basis of the staining relies on 
the chemical reduction of silver ions (Ag+) to metallic silver (Ag0) on a protein band 




For optimal results, it is recommended to use ultrapure water, to always use gloves to 
avoid fingerprint contamination and rinse them with deionized water previous to 
handling gels, to avoid applying pressure on gels, to use freshly made solutions and to 
use clean glass containers designated for silver staining purposes only. 
2 .2.2  Acetic Acid-Urea Polyacrylamide Gel 
Electrophoresis (AU-PAGE) 
Panyim and Chalkley developed in 1969 a continuous acetic acid-urea polyacrylamide 
gel system that separates very similar basic proteins based on differences in size and 
effective charge (Panyim & Chalkley, 1969). The original method has been modified by 
replacing ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) with 
thiourea and H2O2 (Hurley, 1977).  
At the highly acidic pH of AU- PAGE system (around pH 3.5) and deprived of SDS 
detergent, the positively charged proteins of similar size are still subject to the sieving 
effect of the gel matrix, but their charges would vary according to their amino acid 
content. Subsequently, they can be also resolved from each other according to their 
charges, and not only by their size. The presence of urea, which is an efficient agent for 
breaking non-covalent protein interactions, improves the protein solubility and 
facilitates electrophoretic migration.  
The compositions of the AU-PAGE gel and sample buffer are listed in Table 2-5. AU-
PAGE running buffer is 5% acetic acid.  
AU-PAGE gel casting and electrophoresis assembly are performed as already described 
in section 2.2.1 but gels are composed of only one phase (resolving gel) in this case. 




                                                                                                                            
MATERIALS AND METHODS 
  
 91 91 
Table 2-5. AU-PAGE gel and sample buffer composit ion.  
AU-PAGE GEL (10 cm ×  15 cm ×  1 .5 mm thick) 
Reagent 
Resolving (12 mL) 
(15% acrylamide, 0.1% bisacrylamida, 2.5 M Urea, 
5.37% acetic acid) 
30% acrylamide, 1% bisacrylamide 6 mL 
20% acrylamide, 1% bisacrylamide - 
Acetic acid 1.5 mL 
10 M Urea 3.32 mL 
Thiourea 10.5 mg 
H2O2 67.5 µL 
H20  Up to 12 mL 
 
SDS-PAGE SAMPLE BUFFER 
Reagent 2x (10 mL) [1×] 
Urea 4.8 g 4 M 
Acetic Acid 0.5 mL 2.5 % 
β-mercaptoethanol 14 µL 10 mM 
Methyl green Spatula tip - 
 
Sample preparation 
In some instances, in order to remove the high concentration of salt in the protein 
samples that could affect the resolution of the electrophoresis, the trichloroacetic acid 
(TCA)/acetone precipitation method was used. The samples were treated according to 
the protocol described next. 
Trichloroacetic acid (TCA) was added to the samples up to a final concentration of 25%. 
Samples were placed on ice for 15 min and then centrifuged at 13,000 rpm for 5 min 
at 4°C (microfuge). The supernatant was carefully discarded and the sediment was 
washed with 1 mL of acetone and mixed (vortex). Samples were centrifuged at 13,000 
rpm for 5 min at 4°C (microfuge), the supernatant was carefully discarded and samples 
were dried. Samples were resuspended in H2O milliQ®. 2x AU-PAGE sample buffer 
(Table 2-5) was added to each protein sample and mixed. Each sample was loaded 
using a Hamilton syringe. Syringe must be thoroughly rinsed with ddH2O between 




Table 2-6. AU-PAGE staining and destaining solutions.   
AU-PAGE COOMASSIE® STAINING SOLUTION 
Reagent Volume (2 L) Concentration 
Methanol 1 L 50% 
Acetic Acid 200 mL 10 % 
Coomassie® Blue R-250 Dye 5 g 0.25 % 
1.  
AU-PAGE DESTAINING SOLUTION 
Reagent Volume (2 L) Concentration 
Methanol 1 L 50% 
Acetic Acid 200 mL 10 % 
 
Gel staining and destaining protocol is described in section 2.2.1. 
2 .2.3  Electrophoretic Mobil ity Shift Assay (EMSA) 
The gel electrophoresis mobility shift assay (EMSA) is used to detect protein complexes 
with nucleic acids. The principle of EMSA is that DNA with a bound protein migrates 
through a polyacrylamide gel more slowly than the corresponding free unbound DNA. 
This technique is simple to perform. Solutions of protein and nucleic acid are combined 
and incubated for a period of time. The resulting mixture is subjected to 
electrophoresis under native conditions through polyacrylamide gel. If the protein is 
capable of binding to a given DNA sequence, the complex is formed. The speed at 
which the molecules (and combinations thereof) move through the gel is determined 
by their size and charge. Consequently, after electrophoresis, DNA-protein complexes 
migrate less than the corresponding free nucleic acid. 
Under appropriate conditions, EMSA can provide quantitative data for the 
determination of binding stoichiometries, affinities and kinetics. The complex 
stoichiometry varies according to the DNA sequence and the protein nature. Then, a 
range of DNA:protein ratios are tested in order to find conditions that best stabilize 
the DNA- protein complex. A negative control lane (DNA probe without protein 
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present), which is observed as a single band corresponding to the unbound DNA 
oligonucleotide, is also loaded in the gel.  
Sample preparation 
EMSA sample buffer does not include tracking dye to prevent any interference in the 
formation of complexes. 
A set of samples containing different DNA-protein ratios were prepared and mixed 
softly in 0.3x TBE containing 3% glycerol. The mixtures were incubated at least 30 min 
at 4°C to allow the complex formation. 
Table 2-7. EMSA Gel composit ion.  
EMSA GEL (10 cm ×  15 cm ×  1 .5 mm thick) 
Reagent 
Resolving (12 mL) 
(8% acrylamide, 0.2% bisacrylamida) 
30% acrylamide, 0.8% bisacrylamide 3.2 mL 
5× TBE 
54 g Tris Base, 27.5 boric acid, 20 mL 0.5 M 
EDTA, pH 8 
0.8 mL 
H20 7.83 mL 
10 M Urea 3.32 mL 
10% APS 60 µL 
TEMED 12 µL 
 
Electrophoresis 
EMSA gel recipe is listed in Table 2-7. The electrophoresis assembly and gel casting are 
described in section 2.2.1. EMSA running buffer is 1× TBE pH 8 (see buffer composition 
in Appendix B). 
EMSA gels are native gels (as opposed to SDS- and AU-PAGE); any factor that can 
disturb the integrity of labile DNA-protein complexes is not allowed. Thus, a 
prerunning step is needed to remove all traces of ammonium persulfate, to 
distribute/equilibrate any special stabilizing factors or ions from the running buffer, 




temperature-sensitive, EMSA has to be performed at 4°C in a cold room and 
electrophoresis assembly is placed on ice.  
The gel was pre-run at a constant voltage (75 V) for at least 60 min on ice in a cold 
room. After the prerunning step, samples were loaded gently and quickly using a 
Hamilton syringe and the voltage was re-applied. Electrophoresis was performed at 
125 V constant voltage for 45-60 minutes, depending on the size of the DNA and 
complexes.  
DNA detection 
SYBR® Gold nucleic acid gel stain (Invitrogen™) is a sensitive fluorescent stain that 
allows the detection of DNA in electrophoretic gels using standard ultraviolet 
transilluminators. SYBR® Gold stain is not only less mutagenic than ethidium bromide 
(the DNA-intercalator compound commonly used to detect DNA), but also has a 
detection sensitivity comparable to that of ethidium bromide. Therefore, SYBR® Gold 
nucleic acid gel stain for DNA detection in EMSA gels was used. 
Gel was immerse in a staining solution containing 50 mL 0.3x TBE containing 5 µL 
SYBR® Gold. The container was covered with aluminum foil or placed in the dark to 
protect the staining solution from light. Then, it was gently agitated for 20 min at 
room temperature on an orbital shaker. Stained gels were visualized and imaged in a 
UV transilluminator using a Gel Doc XR System (Bio-Rad). 
2 .2.4  Agarose Gel Electrophoresis  
Agarose gel electrophoresis is the most effective electrophoresis method for separating 
DNA fragments of varying sizes (for visualization and/or purification). The matrix is 
comprised of agarose, one of the two main components of agar. Molecular sieving is 
determined by the size of pores generated by the bundles of agarose in the gel matrix, 
then the higher the concentration of agarose, the smaller the pore size.  
Electrophoresis uses an electrical field to move the negatively charged DNA through an 
agarose gel matrix toward a positive electrode. Longer DNA fragments migrate through 
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the gel more slowly than shorter ones. An estimation of the DNA oligonucleotides 
lengths can be determined if a DNA ladder marker (a collection of DNA fragments of 
known lengths) is also loaded on the gel. 
1% Agarose gel preparation 
1g agarose was mixed with 100 mL 1× TAE (see buffer composition in Appendix B) in a 
microwavable flask and microwaved for 1-3 min until the agarose was completely 
dissolved. The solution was cooled down to about 50°C (e.g. until you can comfortably 
keep your hand on the flask) and 5 µL SYBR™ Safe DNA Gel Stain (Invitrogen™) were 
added for visualization of DNA (1 µL per 20 mL of buffer).  
Both ends of the gel tray were sealed with tape and the dissolved agarose was poured 
slowly into a gel tray (cast) with the corresponding comb in place. Bubbles formation 
that will disrupt the gel should be avoided. When necessary, bubbles were pushed 
away from the gel with a pipette tip. 
Electrophoresis 
There are many types of electrophoresis units, but the horizontal electrophoresis unit is 
the most commonly used unit for separating DNA molecules on agarose gels. The 
horizontal electrophoresis apparatus is basically a rectangular-shaped box with 
electrodes at each end where the gel is completely submerged in buffer during 
electrophoresis. 
Once the gel solidifies in the casting tray, the tape and comb were removed and the 
gel was placed in the electrophoresis chamber. Enough running buffer (1× TAE) was 
added to completely cover the gel. Samples were loaded in consecutive wells using a 
micropipete. The safety cover was attached, leads were connected to power source and 
the gel was run at constant voltage (90-100 V) for 45-60 min until the tracking dye is 




2 .2.5  DNA Supercoil ing Assays 
DNA topological changes such as bending, compaction and negative supercoiling can 
be induced by chromatin proteins and are related to crucial biological processes 
(Gilbert & Allan, 2014).  
The supercoiling ability of the HMGA1a(∆50-91) protein was evaluated by measuring 
the degree of circular DNA supercoiling, which indicates whether the DNA-bending 
activity of this protein is important enough to cause a topological stress.  
First, the HMGA protein is incubated with previously relaxed circular DNA. Alterations 
in the DNA conformation due to the presence of the protein, may force a change in the 
DNA torsion or twisting, forming supercoils. Topoisomerase I is added, which dissipate 
the topological stress by unwinding the helix. Finally, the HMG protein is removed as 
well as the topoisomerase I, thus the twisting caused by the protein is removed but the 
changes caused by the topoisomerase remain. Thereby, DNA is rewound and there will 
be compensatory negative supercoils if the protein, in first instance, caused the 
topological change.  
The resulting samples are analyzed by electrophoresis in an agarose to visualize the 
change in the degree of supercoiling of a circular DNA induced by the incubation of 
different concentrations of HMG protein (see Figure 2-4). 
 
Figure 2-4. Scheme of a supercoi l ing assay.   
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Supercoiling Assay Protocol 
The reaction buffer, water, supercoiled circular DNA (see Table 2-8) and 0.5 µL 
topoisomerase I were mixed and incubated 1 h at 37°C in a water bath in order to 
relax the plasmid. Once incubation was performed, the corresponding concentration of 
protein was added to each sample as well as 0.5 µL topoisomerase I. The mixture was 
incubated 1 h at 37°C in a water bath. 1 µL 10% SDS and 0.5 µL 10 mg/mL proteinase 
K were added to the sample. The mixture was incubated 30 min at 37°C in a water 
bath. 4.3 µL 6x TPE (see Appendix B) was added to the samples (4 µL to the SC control). 
The electrophoresis was performed in a 1% agarose gel using 1× TPE as running buffer 
for around 2 h at constant voltage of 90 V. DNA staining was carried out with 1× TPE 
containing SYBR® Gold (Invitrogen™) for 30 min with shaking. Then, the gel was 
visualized with a UV transilluminator and photographed. 
Table 2-8. Reaction samples for a supercoi l ing assay.  
DNA/Protein Ratio [M] SC a 1:0 1:300  1:1000  1:3000 
0.8 µg/µL DNA [µL] 3.75 3.75 3.75 3.75 3.75 
50 µM protein [µL] - - 0.6 2 6 
10x Reaction buffer [µL] 2 2 2 2 2 
H2O 14.25 13.25 12.65 11.25 7.25 
Final Volume [µL] 20 19 19 19 19 
Different 10x Reaction buffers were used containing 50 mM MgCl2 and 350 mM Tris-HCl pH 7.5 
varying the ionic strength with different concentrations of NaCl (0.8-1.9 M). a SC, a control sample of 
supercoiled circular DNA without adding topoisomerase I, SDS nor proteinase K. 
2 .3  N-phenylbenzamide Bis(2-aminoimidazoline) 
Derivatives 
The antiparasitic minor groove binding drugs (MGBD) evaluated within this research 
work are a series of eleven diphenyl-based bis(2-aminoimidazolinium) compounds 
(Table 2-9): the lead compound FR60 (Ref 1), nine chloro, fluoro, and pyridinyl 
derivatives (Refs 2-10), and one CD27 N-hydroxy derivative called CDIV32 (Ref 11). The 




Table 2-9. Chemical structure of the bis(2-aminoimidazoline) compounds studied in 
this work.  
REF Compound Structure Salt  MW 
1 FR60 
 
2 HCl 436.3 
2 CRMV60 
 
2 HCl 454.3 
3 JNI33 
 
2 TFA 625.9 
4 CRMV65 
 
2 HCl 454.3 
5 JNI18 
 
2 TFA 625.9 
6 CRMV49 
 
2 HCl 454.3 
7 JNI17 
 
2 HCl 470.8 
8 CRMV50 
 
2 TFA 609.5 
9 CRMV45 
 
2 TFA 625.9 
10 JNI32 
 
2 TFA 560.1 
11 CDIV32 
 
2 HCl 440.3 
The compounds were prepared as dihydrochloride salts (2 HCl) or ditrifluoroacetates (2 TFA = 
CF3CO2H).  
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These promising antiprotozoal agents were synthetized by Dr. Dardonville’s group at 
the Institute of Medicinal Chemistry, CSIC, Madrid. The synthesis of the lead FR60 (1) 
was performed following a procedure described previously in Rodríguez et al., 2008. 
The FR60 derivatives (compounds 2-10) were synthesized as described in Ríos Martínez 
et al., 2015b. Compound CDIV32 (11) was synthesized as described Nieto Garrido et al. 
2011. 
The samples are dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich) by stirring 
vigorously with a vortex at atmospheric pressure and room temperature until 
completely homogeneous. 10 mM stock solutions in DMSO are stored at -20°C. 
Dilutions from the stock solution are performed by dilution with the corresponding 
buffer or media according to the experiment to be performed, to obtain a final amount 
of DMSO in the dissolved solution >5%. 
2.4  DNA Oligonucleotides  
Due to the high flexibility and polymorphism of AT-rich DNA, short oligonucleotides 
with maximum 23 bp were used (Table 2-10). Longer oligonucleotides induce disorder 
and complicate the aim of obtaining high quality ordered crystals. The length of the 
oligonucleotide, together with the sequence and oligonucleotide stacking interactions 
can influence periodicity and packing in the crystal by changing the length of the 
helical repeat unit. Due to this fact a considerable portion of structures in the PDB are 
decamers and dodecamers. 
DNA samples for crystallography must comply high purity standards. Any impurity (as 
contaminant particles or degradation) could influence the crystallization process and 
disrupt the internal periodicity in the crystal. The oligonucleotides used for 
crystallographic essays must be in the range of 95 to 98% purity.  
All the oligonucleotides used were synthesized at the Genomic Platform of the Pasteur 
Institute as the ammonium salt on an automatic synthesizer by the phosphoramidite 




DNA powder samples were disolved in 25 mM sodium cacodylate pH 6.5, as it prevents 
the degradation of the sample due to its antimicrobial effect. Concentration of the 
oligonucleotide sample is verified by spectrophotometric quantification using the 
Lambert-Beer law (Equation 2-1). 
! =  ! ! !  
Equation 2-1. Lambert-Beer Law. 
where A is absorbance at a given wavelength, C is the concentration in [M], l is the 
path length, which is usually 1 cm for typical cuvettes and ε is the extinction 
coefficient in [cm-1M-1] calculated based on the nearest-neighbor model (Cantor et al, 
1970). In our case there are no contributions from DNA modifications and ε can be 
obtained with Equation 2-2. The data for ε are given at neutral pH, 25°C and 260 nm 
in Table 2-10. 







Equation 2-2. Extinction coeff icient equation by Cantor et al .  (1970).  
Table 2-10. Extinction coeff ic ient (ε) at 260 nm, neutral  pH and 25°C. 
DNA  ε [L ·mmol -1cm -1]   DNA  ε [L ·mmol -1cm -1]   
pdA  15,4  dCpdG  9,0  
pdC  7,4  dCpdT  7,6  
pdG  11,5  dGpdA  12,6  
pdT  8,7  dGpdC  8,8  
dApdA  13,7  dGpdG  10,8  
dApdC  10,6  dGpdT  10,0  
dApdG  12,5  dTpdA  11,7  
dApdT  11,4  dTpdC  8,1  
dCpdA  10,6  dTpdG  9,5  
Values from Cantor et al. (1970). 
Absorbance is read in the range approximately of 210 nm to 310 nm in a 
spectrophotometer to verify maximum absorbance wavelength, which typically is 
                                                                                                                            
MATERIALS AND METHODS 
  
 101 101 
around 260 nm for DNA, corresponding to the aromatic rings of the nucleobases. This 
is used to calculate the concentration of the oligonucleotide, but can be also used to 
confirm the absence of other molecules and proteins as contaminant, which contribute 
with local maximums at different wavelengths. 
For the UV-Vis spectrophotometry analysis a Carry 100 system from Agilent was used. 
The cuvette used for these measurements requires a relative large volume (0.5 mL), 
which is not typically available. Thus the original sample is diluted 1:1000 (in H2O 
milliQ®) in order to make an easy measurement and calculate the concentration. The 
value obtained is then divided by two in order to obtain the double-stranded DNA 
concentration, which is the final concentration of the oligonucleotide used in the 
experiment calculations. 
Table 2-11. Extinction coeff ic ients (ε)  and concentration and specif ications of 
ol igonucleotides used in this work.  











  1. CCAATAATCGCGATTATTGG 20 196.5 30 7.32 12232.2 
  2. ATTATTAATAAT 12 129.3 20 4.36 7285 
  3. AATATATATATT 12 131.3 10 3.38 7285 
  4. AAATATATTT 10 107.2 50 3.05 6050.2 
  5. CGAATTAATTCG 12 119.5 25 4.44 7289 
  6. ATTAATTAAT 10 107.2 50 5.28 6050.2 
  7. AATAAATTTATT 12 127.3 50 4.52 7285 
  8. ATATGCATAT  10 104.6  30 3.35 6052.2 
  9. ATATCGATAT  10 106.2  40 7.47 6052.2 
10. AATAATCGCGATTATT 16 163.1 80 1.56 9758.6 
11. AATTTAAATT 10 105.2 50 3.79 6050.2 
12. ATTTATAAAT 10 107.2 10 5.61 6050.2 
13. GGGAAATTTCCC 12 114.9 10 3.3 7290.8 
14 AATAAATTTATTT 13 135.4 50 3.66 7902.4 
15. AAATTT  6 63  40 2.6  3580.6 
16. AATAATTATT 10 107.2 20 5.22 6050.2 
17. CATATATATG 10 105.2 50 2.72 6050.2 
18. AATTATAATT 10 107.2 40 5.03 6050.2 
19. ATAATATTAT 10 109.2 40 2.515 6050.2 




The values of extinction coefficients and concentrations calculated for the 
oligonucleotides stocks prepared during this work are listed in Table 2-11. 
2 .5  Crystall ization of Macromolecules 
Crystallization of macromolecular complexes represents a crucial step for the analysis 
by X-ray crystallography, as it requires well-ordered single crystals of adequate size. 
Obtaining crystals does not necessarily imply that they are well ordered and have the 
appropriate atomic periodical arrangement for structure resolution by X-ray 
crystallography. This can result in poor diffraction patterns with low resolution. In 
particular, for AT-rich DNA, getting the right crystallization conditions to obtain 
diffraction-quality crystals is not an easy task.  
 
Figure 2-5. General scheme for DNA- l igand crystal l ization  
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The successful crystallization of macromolecules relies on several factors such as the 
physicochemical properties of the oligonucleotide, the purity of the samples, 
concentration, pH, temperature, ionic force, precipitants and additives, control of mass 
transfer (diffusion, convection) and pressure, and presence of electric and magnetic 
fields, among others. 
The determination of the 3D structure by X-ray crystallography includes basically the 
following steps: (1) obtaining the target macromolecule (design and synthesis or 
expression, and purification), (2) search of initial crystallization conditions, (3) 
optimization of crystal quality, (4) diffraction data collection, (5) data analysis and 
processing, (6) structure determination, (7) refinement of the 3D model and (8) 
validation. Figure 2-5 represents a general scheme of the process for DNA-ligand 
crystallography. 
2 .5.1  Crystall ization Fundaments and Parameters 
The crystallization of macromolecules is a multi-parametric process involving three 
main steps: 
1. Nucleation: the most difficult problem to address since it occurs when a 
specific number of macromolecules associate to form a critical mass that 
breaks the energetic barrier of a first-order phase transition and precipitates 
to the solid state as a nucleus. This step takes place when the solution is 
supersaturated, in a meta-equilibrium called labile zone to avoid amorphous 
precipitation (Figure 2-6). 
2. Crystal growth: once a nucleus has formed, it serves as a scaffold center for 
incorporation of the macromolecules in a crystal network, usually from a 
monomeric state. This step takes place in a supersaturated state in meta-
equilibrium, near the phase boundary called metastable zone (Figure 2-6). A 
solution reaches this state after nucleation, a consequence of the 




nucleus. The metastable phase favors diffusion conditions for ordered 
incorporation of molecules as layer addition over crystallographic faces. 
3. Halt in growth (or cessation of growth): after consumption of excess 
macromolecules during crystal growth, concentration decreases, reaching 
equilibrium when thermodynamic energetics are not enough for solute to 
pass to solid state, resulting in the stop of crystal growth.  
 
F igure 2-6. Schematic representation of a 2D phase diagram for the crystal l ization 
of macromolecules showing the compound solubil ity as function of precipitant.  
Labi le and metastable zones,  where nucleation and crystal  growth respectively 
occur ,  are indicated.  
The whole crystallization process can be suitably visualized in a two-dimensional phase 
diagram (Figure 2-6), representing the stable states as a function of two crystallization 
variables: macromolecule concentration and precipitant concentration. When the 
concentration of a protein solution is brought above its solubility limit, the solution 
becomes supersaturated. Depending on the level of supersaturation this zone of the 
diagram can be divided into three regions: very high supersaturation (precipitation), 
where molecules form amorphous aggregates; intermediate supersaturation (labile), 
where nucleation occur; and lower supersaturation (metastable), where only crystal 
growth is accomplished.  
Supersaturation is the variable that drives the crystallization and determines their 
occurrence and extent as well as the kinetics that govern them. The best crystallization 
strategy is to induce nucleation at the lowest level of supersaturation, just within the 
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labile region. Regardless the variable condition manipulated to reach to this point, this 
should be done slowly in order to obtain well-ordered crystals. If this process takes the 
system excessively fast to supersaturation, protein aggregates having short-range 
order or disordered amorphous precipitate not suitable for X-ray diffraction may 
appear. On the other hand, if the system never reaches supersaturation, it will not 
crystallize. 
The evolution of the three crystallization steps during the process usually generates 
diffusion from concentration gradients of precipitant, water and other components 
present in the crystallization solution. This process slowly brings the solution to the 
supersaturated state for nucleation, while crystal growth compensates for solute lost, 
extending the residence time in the metastable phase for better crystal growth. 
Changing the temperature, pressure or both can also change the thermodynamic state. 
The temperature control and variation is performed carefully according to the 
evolution of the crystallization process.  
For the here presented work, the crystallization system is constantly modified as the 
process evolves by changing the concentrations in the equilibrium solution, in 
particular for the precipitant. The relationship between macromolecule solubility and 
precipitant concentration is a function of the type of precipitant, but usually, 
macromolecules solubility decreases proportionally as the precipitant concentration 
increases (Benvenuti & Mangani, 2007).  
The crystallization of biomacromolecules is an exceptionally complex process. Some 
variables that influence crystallization of macromolecules are the concentration of 
components in the solution (e.g macromolecule concentrations and ratio, precipitants, 
additives), pH, temperature, ionic strength, pressure, electric fields, magnetic fields, 
properties that affect mass transfer (e.g. density, viscosity, volume, geometry, diffusion, 
convection), sample integrity and purity (i.e. heterogeneity of sequence and length, and 
presence of other molecules), contaminant, biochemical and biophysical properties of 
the macromolecule (eg. hydrophobicity, electrostatic interactions, conformational 




are experimental contributions and external factors that perturb the system (e.g. 
vibrations) and influence crystallization. Therefore, this multi-variable process is largely 
empirical in nature, and demands patience, perseverance and intuition. 
The large number of variables involved in crystallization makes this process particularly 
hard to control and specific for the crystallization of each macromolecule. Then, the 
number of possible screening conditions turns almost infinite when defining rationally 
the set of parameters to crystallize a given macromolecule. For this reason, commercial 
kits based on previous successful conditions described in literature have been 
developed. One of such kits is the Hampton Natrix HR2-116 (Scott et al., 1995), which 
can be used for the initial test. In any case, crystallization is commonly an iterative 
process where crystallization conditions are modified based on results of tested 
conditions. 
The main parameters that are controlled during crystallization are: 
§ Oligonucleotide concentration; we have worked with oligonucleotide 
concentrations between 0.1 mM and 0.4 mM. A high concentration of 
oligonucleotide will reach supersaturation easily with little precipitant, 
whereas low oligonucleotide concentration will require more precipitant. 
§ HMG protein concentration; high protein concentration is normally used for 
crystallization in a range of 3 to 10 µg/µL. To carry it out samples were 
concentrated by ultrafiltration. 
§ Sample purity and homogeneity; very high macromolecule purity is required 
for crystallization. Impurities or heterogeneities can prevent crystallization or 
introduce irregularities limiting the quality of the obtained crystal. In the 
case of proteins, purity and homogeneity is determined by electrophoretic 
methods (see section 2.2). For DNA oligonucleotides, samples from the 
Pasteur Institute guarantee purity level of 98-99%. DNA stocks are conserved 
in sodium cacodylate to prevent bacteria or fungi contamination. 
§ pH; the role of pH in macromolecule crystallization is very important. A 
change of pH can modify solubility of the macromolecule, and more 
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dramatically when the pH is close to its pKa. More importantly, pH affects the 
conformation and stability of the macromolecule, and plays a key role in the 
binding specificity, molecular hydration and in the interactions with small 
molecules and ions by modifying the intramolecular interactions in the 
crystal. Defining the right pH depends on which are the most beneficial 
configuration of conformation and intermolecular interactions for the 
crystallization of the desired complex, which vary from macromolecule to 
macromolecule. In particular for DNA, a starting point would be a range of 
pH from 6 to 7.5, which ensures base pairing, and has demonstrated good 
crystallographic results also for proteins. 
§ Ionic strength; the ionic concentration not only helps to stabilize the helical 
structure of DNA and the tertiary structure of proteins, but also stabilizes 
intermolecular interactions generated by packing in the crystal. Different ions 
have different affinities for specific groups of nucleobases and amino acid R-
groups. Thus, defining the right ions for crystallization depends on the 
physicochemical properties of the oligonucleotide and/or protein, and the 
intermolecular and intramolecular interactions generated during 
crystallization, which are not easy to predict. Besides, the ionic strength 
modifies the solubility of the macromolecules. 
§ Drugs; DNA binding drugs are crystallized in complex with DNA in order to 
determine the specific interactions and structural features that confer a 
specific function. The presence of certain ligands can influence crystallization; 
they can stabilize specific configurations beneficial for the crystal packing, 
but can also prevent crystallization by the formation of unspecific 
interactions or steric hindrance. Drug samples must be perfectly dissolved 
and present high purity (see section 2.3). 
§ Temperature; it affects the solubility of the macromolecule, but more 
importantly, it also affects its stability and secondary structure. In the case of 
DNA, the temperature must be below the melting temperature to avoid 
denaturation. Some AT-rich oligonucleotides have melting temperatures 




temperatures for crystallization, usually between 4°C and 21°C when 
crystallizing DNA-drug complexes. For HGM proteins, we always work at low 
temperature (4°C) to ensure their stability. 
§ Precipitants; they change the solubility of the macromolecules to reach 
supersaturation and produce nuclei that later could grow as crystals. For DNA 
and protein crystallization, the most common precipitants are 2-methyl-2,4-
pentanediol (MPD or Hexylene glycol) and polyethylene glycol (PEG), which 
work also as cryo-protectants. Additionally co-precipitants, such as isopropyl 
alcohol, can be used to force the system to reach supersaturation and later 
keep it in the metastable zone. Spermine is commonly used as a co-
precipitant for DNA. It is a symmetric lineal polyamine that has its amino 
groups positively charged at pH 6-7.5 and contributes to neutralize the 
negative charges of the phosphate backbone and stabilize the helical 
structure. 
During this research work, crystallization conditions were based on previous successful 
assays and are described next. 
The droplets were prepared to a final volume of 3-5 µL. The pH screening values were 
6.0, 6.5, 7.0, and 7.5, using buffers such as sodium cacodylate, potassium cacodylate, 
HEPES and Tris-HCl. For DNA-drug complexes, the typical starting point was pH 6.5 
using sodium cacodylate above 25 mM.  
The oligonucleotide is dissolved in the buffer containing determined ions needed for 
annealing process, ensuring correct base pairing and conformational homogeneity. The 
divalent ions used for crystallization were magnesium (Mg2+), manganese (Mn2+) and 
calcium (Ca2+) and ammonium (NH4+). The anions used were chloride (Cl2-) and acetate 
(CH3-COO-). Ion concentrations between 5 to 20 mM were used, since higher 
concentrations may lead to precipitation or denaturation. 
Temperatures used for DNA-drug crystallization were: 4°C, 8°C, 11°C and 16°C. 
Temperature was modified depending on the first screening result, usually starting at 
11°C. When droplets showed numerous crystalline nuclei, increasing the temperature 
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was beneficial to obtain fewer nuclei that lead to the growth of the adequate size 
crystals. Temperature changes were always made, in steps, transferring to the next 
lower temperature and left until equilibrium before transferring to the next 
temperature if required. DNA-protein crystallization was performed at 4°C. 
Precipitants used were MPD and PEG 3350. A common practice is to set the initial 
precipitant concentration relatively low (typically at 20%) and wait until the system 
reaches equilibrium. Then, increments of 2 or 3% are performed until equilibrium is 
reached again, repeating this process until nucleation. When crystals are growing, 
precipitant concentration can be incremented in steps of 0.5-1% to promote crystal 
growth. 
For crystallization of DNA, spermine as co-precipitant is occasionally added, in a molar 
ratio between 2:1 (DNA/spermine) to stabilize the helical structure while contributing 
to reach supersaturation. Other compounds used as co-precipitants are isopropyl 
alcohol in 3-10% concentration. 
Commercial crystallization conditions were used mainly for the crystallization of the 
DNA-protein complex. The tested conditions were: Hampton Natrix HR2-116 (Scott et 
al., 1995): 7, 10, 15, 16, 22, 25, 31, 34, 42, 43, 46, and 48. 
For the crystallization of the DNA-drug complex, the drug and the DNA were usually 
preincubated in buffer to promote interaction for 1-2 hours, while DNA-protein 
complex was preincubated from 1 hour to overnight periods. 
In order to verify the DNA-protein complex formation, electrophoretic mobility shift 
assay (EMSA) was performed (see section 2.2.3), not only to detect the DNA-binding 
protein activity but also to evaluate the binding stoichiometries, which provide 
information of conditions that best stabilize the DNA-protein complex. For the 
crystallization of DNA-HMG protein complexes, DNA/Protein molar ratio of 1:1, 1:2, 




2 .5.2  Crystall ization Method: Vapor Diffusion 
Technique 
To obtain high quality single crystals is the basis of X-ray structure determination and 
also its limiting step. For this reason, multiple different macromolecular crystallization 
methods have been described, which use different approaches to control mass transfer 
and concentration of all components of the system to reach supersaturation for 
crystallization. The selection of the method employed depends on the particular 
requirements and the available amount of macromolecule(s) for each case. The most 
used macromolecular crystallization methods are vapor diffusion, microbatch, 
evaporation, microdialysis and free-interface diffusion. For the purpose of this research 
work, crystallization assays were performed using the technique of vapor diffusion, 
which is the most widely used method for macromolecular crystallization. 
In this technique, a droplet of the solution of macromolecule, precipitants and 
additives in a non-supersaturated state is equilibrated by vapor diffusion against a 
reservoir with precipitant and additives at high concentration, the whole in a hermetic 
system. This process gradually changes concentration of all components, taking the 
system gently to a supersaturated state to obtain well-ordered crystals.  
The two typical vapor diffusion set-ups are hanging-drop, where a droplet is placed on 
an inverted cover slip, and sitting-drop, where the droplet is placed on a pedestal 
(Figure 2-7). Modern crystallization robots use micro-fluidics technologies with the 
sitting-drop technique to generate large screens of crystallization conditions using low 
volume samples. Frequently, when favorable conditions are found with robots, they 
have to be replicated by hand in a larger volume to obtain suitable crystal for X-ray 
diffraction. Both set-ups, hanging-drop and sitting-drop, were performed in two 
different arrangements, either using a MRC Maxi 48-Well Crystallization Plate (Swissci) 
or individual capsules were used for crystallization of DNA-drug and DNA-protein, 
(Figure 2-7). 
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Figure 2-7. Schematic representation of the vapor diffusion crystal l ization set-ups 
used: hanging-drop and sitt ing-drop. This technique has two l iquid phases: (1) the 
droplet ,  containing a crystal l ization solution with the macromolecule and (2) the 
reservoir ,  which contains the precipitant solution. A third gaseous phase is  used to 
carry out vapor diffusion. 
For the DNA-HMG protein complex study, screens of crystallization conditions were 
carried out using 48-well plates with 3 µL droplets, containing different defined 
concentrations of oligonucleotide and protein, buffer, ions, precipitant and other 
additives. The reservoir is filled with 200 µL of the precipitant solution at high 
concentration, and then a silylated coverslip is placed on top and sealed to promote 
vapor diffusion and reach the equilibrium that will drive the system to the 
supersaturated state required for crystallization. In this set-up, the conditions in the 
reservoir are not changed during the experiment. 
Generally, DNA-protein and DNA-drug complexes crystallization studies were screened 
using individual capsules. This method has the advantage that parameters (such as 
temperature) can be modified individually for each condition. Another advantage of 
this set-up is that once the equilibrium is achieved, if the system has not reached 
supersaturation or produced crystals, the conditions in the reservoir can be changed to 
generate new equilibrium conditions. As evaporation affects directly the kinetics of 
supersaturation (Wilson et al., 1991), the idea of this process is the control of 




nuclei and extend the time in the metastable zone to promote crystal growth. Typically, 
a waiting time of 3 to 5 days prior to increasing the precipitant concentration was 
adopted. For MPD, it is normal to start at 20% precipitant and carefully increase 
concentration stepwise. In particular cases, once crystals appear, precipitant 
concentration can be increased to promote crystal growth. 
The iterative process of obtaining diffraction-quality crystals can be divided into two 
main phases: coarse screening to identify initial crystallization conditions, followed by 
optimization of these conditions. There are several parameters and considerations to 
take into account during the optimization process of macromolecular crystallization.  
During this work, the employed optimization strategies were grid screen and seeding 
technique. The first one was carried out starting on a positive condition in which 
obtained crystals were not presenting enough quality for X-ray diffraction. The 
screening is prepared using closely related experimental conditions to the ones 
performed before varying only two factors. If the results are negative, the procedure 
continues with a second choice of factors and so on until success is achieved. The 
other method employed includes two categories of the seeding technique: 
macroseeding and microseeding. Macroseeding consists in the transfer of one crystal 
(usually 5-10 µm in size) from a solution in which nucleation and initial growth have 
occurred to a less supersaturated solution to slowly continue the growth. In 
microseeding method, very small nuclei are transferred to solutions with metastable 
supersaturation.  
2 .5.3  Crystal Selection and Cryo-Crystal lography 
The crystals obtained are continuously evaluated and scored to monitor their evolution. 
The best crystals are selected initially based on a visual inspection that evaluates the 
size, the shape, and perceivable defects. A second inspection is carried out under 
polarized light to evaluate the birefringence of the crystal, which is an indicator of the 
internal order of the crystal. It can be used additionally to identify a twinned crystal 
(macle) by the presence of two polarizing domains. 
                                                                                                                            
MATERIALS AND METHODS 
  
 113 13 
Cryo-crystallography is a common and indispensable technique for macromolecular 
crystallography (Pflugrath, 2004) that is routinely used for single-crystal X-ray 
diffraction (section 2.6.3). It allows preserving the best crystals cryo-cooled at 100 K 
until diffraction to reduce radiation damage and disorder from thermal motion (Debye-
Waller effect). Selected crystals are fished from the droplet using a cryo-loop that 
catches the crystal in a thin layer of liquid by surface tension (see Figure 2-8). A cryo-
protectant, such as glycerol, MPD, ethylenglycol or PEG, may also be added by soaking 
the crystal in a solution that contains the cryo-protectant. During this research work, 
the crystallization conditions already contained either MPD or PEG, which work as 
cryo-protectants, and the crystals were directly transferred from the cryo-loop to a 
Dewar with liquid nitrogen for flash freezing immediately after fishing. Fished crystals 
are stored and transported at liquid nitrogen temperature until X-ray diffraction.  
 
Figure 2-8. Diagram of a cryo-crystal lography system ( left)  and a cryo- loop with a 
crystal  mounted (r ight) 
2 .6  X-Ray Crystal lography 
The elucidation of the three-dimensional structure of biological macromolecules has 
contributed enormously to the current understanding of many basic mechanisms 
involved in life processes. X-ray diffraction from high quality crystals remains the most 
reliable approach to obtain accurate structural details at atomic resolution. It provides 
powerful insight into the molecular mechanisms in which macromolecules interact 
with each other to form complex supramolecular assemblies capable of performing 




sites at atomic detail allows a rational drug design, which is essential for searching of 
novel drugs. For this reason, X-ray crystallography has been the main technique used 
for DNA-ligand structure determination. 
2 .6.1  Crystall ine Structure  
X-ray diffraction by crystals is a reflection of the periodicity of crystal architecture. 
Crystals represent the most highly ordered state of matter, where molecules are 
organized in a three-dimensional network with a periodical motif based on a 
geometrical simple unit. The main elements that define this crystal network are the 
unit cell, the asymmetric unit and the space group. 
The unit cell depicts the simplest portion of the crystalline structure that can be 
repeated by translation to reproduce the full crystal. In other words, it is defined as the 
smallest parallelepiped containing all the symmetry operations of the space group. It 
describes the distribution of atoms in the lattice from a simple motif and it comprises 
three vectors that are independent from the coordinate system. These vectors are 
described by six lattice parameters (Figure 2-9), the lengths of the cell or vectors 
modulus (a, b, c) and the angles between them (α, β, γ). Atomic positions are defined 
on this reference frame with the set of atomic position (xi, yi, zi).  
 
 
Figure 2-9. The unit cel l  is  the simplest repeating unit in a crystal .  It  is  determined 
by three vectors ,  which are described by s ix parameters:  the lengths of the cel l  (a ,  b ,  
c)  and the angles between them (α,  β,  γ) .  
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The minimum group of atoms that after applying a set of symmetry operations 
reproduce the content of the unit cell is called the asymmetric unit (Figure 2-10). The 
asymmetric unit does not necessarily correspond to one molecule in the crystal; it can 
be defined as fractions of the molecule or multiple molecules, including other atoms 
like ions and water. In spite of the fact that the asymmetric unit is a subset contained 
within the cell, this does not imply that the entirety of the asymmetric unit must lie 
within the boundaries of the unit cell. However, its distribution may be constrained by 
the Bravais lattice. 
 
Figure 2-10. Schematic representation of the asymmetric unit as a group of atoms. 
After applying a set of symmetry operations the unit cel l  is  obtained; when this cel l  
is  regularly repeated, the crystal  is  generated. 
Bravais lattices, also referred to as space lattices, are a mathematical concept of an 
infinite distribution of discrete points with invariable structure under a certain group 
of translations. When the discrete lattice points correspond to atoms, molecules or 
ensembles of both, the Bravais lattice defines the crystalline arrangement. For a three 
dimensional space, there are seven crystalline systems with fourteen Bravais lattices 
(Table 2-12) geometrically defined by the parameters of the unit cell (a,b,c, α, β, γ). 
Distribution of the lattice points in the unit cell defines the lattice type as Primitive (P) 
with nodes in the corners; Body-Centered (I) with nodes in the corners and the cell 
center; Face-Centered (F) with nodes in the corners and the center of faces; Base-
Centered (A, B, or C) with nodes in the corners and one in the center of the 
corresponding face; Rhombohedral (R) with nodes in the corners with a = b = c and α 




Table 2-12. Bravais latt ices .  
Latt ice System  Latt ice Type Distances Axial  Angles  
Cubic  P, I, F a = b = c α = β = γ = 90° 
Tetragonal  P, I  a = b ≠ c α = β = γ = 90° 
Orthorhombic P, I, F, C a ≠ b ≠ c α = β = γ = 90° 
Hexagonal P a = b ≠ c α = β = 90°, γ = 120° 
Rhombohedral R or P a = b = c α = β = γ ≠ 90° 
Monoclinic P, C a ≠ b ≠ c α = β = 90°, γ ≠ 90° 
Triclinic P a ≠ b ≠ c α ≠ β ≠ γ ≠ 90° 
 
Moreover, the symmetry operations (reflection, rotation, inversion and improper 
rotation) comprise 32 possible point groups or crystal classes. In addition to the point 
group, configuration of the atoms in space, which comprises additional symmetry 
operations (pure translation, screw axes and glide planes), originate 230 different 
space groups, from which only 65 are possible for chiral organic molecules. 
Crystallographic vectors and planes in a Bravais lattice are described by the Miller 
index notation: h; k; l. The set (hkl) defines a point in reciprocal space; in real space 
they denote a plane that intercepts the three points a/h, b/k, c/l. Then, the Miller 
indices are proportional to the inverses of the intercepts of the plane with the unit cell. 
Any point in the reciprocal lattice can be expressed as a vector (q), which is the sum of 
integer multiples of the reciprocal axes (defined as a*, b*, c*). 
The Miller indices are very useful to work between the real and reciprocal space, and to 
identify the crystal planes that contribute to diffraction.  
2 .6.2  Fundamentals of X-Ray Crystal lography  
The purpose of macromolecular X-ray crystallography is to determine the three-
dimensional structure of a macromolecule through the reconstruction of the electronic 
density of its atoms, which generate the diffraction pattern when the incident 
radiation interacts with the crystal. The electron density distribution of the 
macromolecular crystal is the Fourier transform of the waves diffracted by the crystal.  
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The Fourier transform can be expressed as a complex number with a magnitude and a 
phase. From the X-ray diffraction data, the information for the amplitude can be 
obtained because the intensity of reflections is proportional to the square of the 
structure factors amplitude.  
For an ideal crystal, the Fourier transform has zero value except for the Bragg peaks, 
where the three dimensional vector corresponds to the nodes of the reciprocal lattice, 
known as Miller indices (hkl; described before). Therefore, the electronic density 
function can be expressed as the sum of structure factors amplitudes and phases as 
presented in Equation 2-3,  





Equation 2-3. Function defining the electron density in a point of the unit cel l  
given by the coordinates (x ,  y ,  z) .  
where ρ(xyz) represents the electronic density at a three dimensional vectorial position 
(x,y,z) in the crystal; |F(hkl)| represents the resultant of the structure factors 
amplitudes of all atoms contained in the unit cell; h,k,l the Miller indices; and ϕ(hkl) 
the phases of the structure factors. 
The diffraction data give all the information for the amplitude of the structure factors, 
but the information for the phases is still missing, lost during diffraction experiments. 
This is known in crystallography as “the phase problem”. To complete this phase 
information, different mathematical methods have been developed, such as Ab initio 
phasing or direct methods (used for relatively small molecules) and anomalous X-ray 
scattering (Multi-wavelength Anomalous Diffraction (MAD) and Single-wavelength 
Anomalous Diffraction (SAD)), Multiple Isomorphous Replacement (MIR), and 
Molecular Replacement (MR), commonly used for macromolecules. The latter is used 






The Bragg's Law (Bragg and Bragg, 1913) defines the condition for diffraction in terms 
of the scattering at a given wavelength. 
When X-rays hit an atom, the electromagnetic wave interacts exciting the external 
electrons, which emit back the incident electromagnetic radiation in all directions with 
the same frequency. In practice, an elastic scattering process dominates the re-emitted 
radiation, but it can be slightly affected by various effects (Rayleigh scattering). 
In a crystal, the molecules and their atoms are periodically distributed in the crystalline 
network. This can be conceptualized as a set of discrete scatterers distributed in 
parallel planes separated by a constant distance d (Figure 2-11). If the scattered 
radiation from different planes interferes constructively, it would produce a Bragg peak 
or X-ray diffraction. The Bragg condition establishes that an interference is 
constructive when the phase shift among the emitted radiation by different atoms is a 
multiple of 2π. This leads to Bragg's law, described in Equation 2-4: 
2! sin θ = !λ 
Equation 2-4. Bragg’s Law. 
where the path difference for two interfering waves is given by 2dsinθ, and the waves 
remain in phase only when this path difference produces a phase shift proportional to 
2π; θ is the angle between the incident rays and the diffraction planes, 2θ is the 
scattering angle, n is an integer, λ is the wavelength of the x-ray radiation and d 
corresponds to the interplanar distance. Consequently, a diffraction pattern is 
produced by the cumulative effect of constructive and destructive interference from 
reflections in consecutive crystallographic planes. 
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Figure 2-11. Bragg's law determines the angles for coherent scattering. Angle 2θ is  
the scattering angle,  λ is  the wavelength and d  is  the interplanar distance. The 
lower beam travels an extra path 2dsinθ for which constructive interference occurs 
if  the path is  a multiple of the wavelength (nλ)   
Two common problems that enormously complicate the structure resolution are the 
presence of pseudo-translation and twinning. In particular, oligonucleotides with 
hexagonal packing have a high tendency to suffer pseudo symmetry and merohedral 
twinning (Abrescia & Subirana, 2002). 
Pseudo-translation corresponds to two molecules or motifs with similar orientation 
that are related by non crystallographic symmetry (NCS). This can be usually identified 
in the Patterson map as an off origin peak with high intensity. The position of this peak 
can be used to identify its relative displacement and define the pseudo-translation 
vector to reproduce the molecule or motif from a known orientation. 
In some cases, a special approach can be used to solve the structure by reindexing the 
data in a smaller cell (pseudo-cell) based on the translational vector. Here the density 
of the two related molecules is added and only one position needs to be identified. This 
position may give a clue of molecular packing, which later can be translated into the 
original cell. Some modern molecular replacement software like Molrep (Vagin & 
Teplyakov, 2010) and Phaser (McCoy et al., 2007) automatically detect any pseudo-
translation peak and use it during MR. 
Twinning, on the other hand, occurs when a multiple domain reorientation follows a 
transformation related to the crystal lattice but not of the symmetry of the point 




The presence of twinning adds more symmetry to the crystal, which can lead to define 
the crystal in an apparent space group of higher symmetry than the real one. The twin 
lattice is formed by the overlap of lattices, which correspond to the different regions of 
the crystal. These regions are related by geometrical operations called twin operations, 
which include reflection that generates a twin plane, rotation that generates a twin 
axis and inversion that generates a twin center. The twin law is the set of twin 
operations used to map two regions of a twin.  
Polarized light can be used to detect twinned crystals, which never reach, complete 
extinction by rotation (crystallization setup can interfere with this detection). In 
addition, a visual inspection is useful for the identification of potential twinned 
crystals that share a common growth center. Nevertheless, most of the twinned 
crystals are not detected until analysis of the diffraction data. Programs such as 
SFCHECK (Vaguine et al., 1999), Scala-Pointless (Evans, 2006) and Xtriange (Zwart et 
al., 2005) use these methods to detect twinning. Molecular replacement can be 
affected by the presence of twinning that adds noise to the rotation and translation. 
For the refinement of the model, programs such as SHELX (Herbst-Irmer and Sheldrick, 
1998), REFMAC5 (Murshudov et al., 2011) and phenix.refine (Afonine et al., 2005) 
already include procedures for twinning treatment. 
2.6.2.2 Ewald	Sphere	
A crystal can be defined as a lattice of nodes (reflections) of equal symmetry. The 
requirement for constructive interference in a diffraction experiment means that in 
momentum (or reciprocal space) the values of momentum transfer where constructive 
interference occurs also form a lattice (the reciprocal lattice). The Ewald’s sphere is a 
geometrical construction in that reciprocal space (Figure 2-12) that allow to determine 
which planes of the crystalline network will result in a diffracted signal for an incident 
radiation at a given wavelength λ.  
For an incident wave vector Si, if considering no energy is gained or lost in the 
diffraction (elastic process), the diffracted wave vector So has the same length as Si. 
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The scattering vector ΔS is defined as ΔS = So - Si, a condition satisfied for diffraction 
when reciprocal lattice nodes lie on the sphere of radius 1/λ. This sphere is called the 
Ewald’s sphere.  
 
Figure 2-12. Ewald's Sphere of radius 1/λ.  In reciprocal space,  the latt ice nodes that 
l ie on the sphere satisfy that the diffraction vector ΔS is  the difference between 
the incident wave vector Si and the diffracted vector S0.  This establ ishes the 
relationship between the wavelength of the incident radiation (wave vector)  with 
the reciprocal latt ice of the crystal  and the diffraction angle 2θ 
The reciprocal lattice nodes are the values of momentum transfer where the Bragg 
diffraction condition is satisfied (see section 2.6.2.1). For diffraction to occur, the 
scattering vector must be equal to a reciprocal lattice vector.  
2 .6.3  Single-Crystal X-Ray Diffraction  
For single-crystal X-ray diffraction, a beam of X-rays is focused on a single-crystal of 
the macromolecule to produce a diffraction pattern. There are various diffraction 
methods to obtain a diffraction pattern such as the Laue method, the Weisenberg 
method, the precession method and the oscillation method. The latter is the method 
employed during this work. 
The oscillation method is the most widely used, especially for macromolecules. In this 
method, a single wavelength is used and the crystal is rotated an angle (ϕ) that defines 
multiple regions of reciprocal space that intersect the Ewald's sphere to produce 
diffraction. Modern detector efficiency allows operating with small angles (ϕ) for each 




For this work, the angle of rotation (ϕ) and resolution (2sinθ max/λ) or detector distance 
are defined after performing a preliminary diffraction test. For crystals with low 
resolution and few diffractions spots, the angle ϕ is between 8 and 12°. For high 
resolution cases ϕ is between 0.5 and 1°. When the orientation of the crystal is not 
optimal (e.g. the axial helical axis is perpendicular to the X-rays during all the 
collection), the angle (ϕ) can be modified to reorient the crystal. 
When a monochromatic X-ray beam is passed through a single crystal, the radiation 
interacts with the electrons in the atoms, resulting in scattering of the radiation to 
produce a unique image pattern. Multiple images are recorded with an area X-ray 
detector as the crystal is rotated in the X-ray beam. The diffraction patterns obtained 
have a symmetry center described by the Friedel's law. Friedel's pairs have the same 
amplitude due to the symmetry of the Fourier transform (Equation 2-5), where a 
complex number and its conjugate correspond to the same real part. 
|! ℎ!" |! =  |! ℎ!! |! 
Equation 2-5. Fr iedel ’s  Law. 
From this, collecting an angle of 180° will provide the complete data for 360°. 
Furthermore, the symmetry of the space group may reduce the angle of collection 
required for a complete dataset. 
X-rays can be produced by conventional generators, synchrotrons and by plasma 
sources. Conventional X-ray sources are sealed anode or rotating anode, which are 
commonly used in home source equipment.  
A synchrotron radiation source is a very intense, tunable source of radiation that 
generates a bright X-ray beam from the velocity change of electrons accelerated nearly 
to the speed of light in an electron storage ring.  
The single-crystal X-ray diffraction studies were performed using synchrotron radiation 
(ESFR - BM16 and ALBA - Xaloc bl13). Relevant specifications of these synchrotron 
lines can be found in Appendix C. 
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In a synchrotron, the X-ray beam passes through a monochromator to filter all non-
desired wavelengths. Then, mirrors redirect and concentrate the beam in a focusing 
step and finally the beam passes through a collimator. All these processes aim to 
obtain a narrow coherent X-ray beam that can be focused in the single-crystal to 
generate the best diffraction patterns with high resolution and less possible noise. 
The diffracted light is collected using electronic detectors such as point detectors or 
area detectors. Area detector was used for this work, which has the advantage of 
recording simultaneously multiple diffraction spots, which are essential for 
macromolecular crystallography. 
The crystal is mounted in a goniometer using a cryo-loop, which should remain all the 
time under a stream of liquid nitrogen (at 100 K) to preserve the crystal and to reduce 
radiation damage. 
The parameters controlled during X-ray diffraction are: 
§ The wavelength and size of the beam 
§ The centering of the crystal within the X-ray beam on rotation 
§ The angle of rotation defines the number of diffraction spots per frame. If the 
direct cell is big, then a small angle should be used to avoid spots overlapping 
(usually between 0.5 and 1°) 
§ The collection angle, which is usually 180°. For more redundancy, 360° can be 
used 
§ The exposition time, which should be used the longest exposition before 
saturating the detector. The time varies considerably with crystal size 
§ The distance to the detector, which defines the maximum resolution for the 
collected diffractions (small distances for high resolution and large distances 
for low resolution) 
The recorded set of two-dimensional diffraction patterns corresponding to a different 
crystal orientation are collected during single crystal X-ray diffraction and taken to the 




2 .7  Structure Determination 
The steps of the structure resolution process are: the determination of the unit cell 
parameters and the space group, assignation of the Miller indices to all diffractions in 
each frame, integration of diffractions, merge of diffractions and scaling of intensities, 
conversion of intensities to amplitudes, initial phase assignation, model building, 
model refinement and finally validation. To perform all these steps, computer packages 
that include specific software to perform each task are available. A comprehensive list 
of software for crystallography can be found in www.iucr.org/resources/other-
directories/software. The software’s packages employed in this work are CCP4 (Winn et 
al., 2011) and Phenix (Adams et al., 2010).  
2 .7.1  Data Processing 
Once X-ray diffraction has been performed on the selected crystals and the data has 
been collected, a mathematical analysis has to be done with the diffraction patterns. 
The main purpose of analysis and interpretation of diffraction data is to solve the 
density function ρ(xyz) in order to solve the structure of the macromolecule(s) studied. 
The dimensions of the unit cell, the space group symmetry and the amplitude term 
|F(hkl)| for all diffraction directions are information that can be extracted from the 
diffraction patterns. The phase ϕ(hkl) of the diffractions cannot be directly determined. 
Data analysis is done in two stages: (1) data reduction, which involves indexing, 
parameter refinement and integration; and (2) merge and scaling.  
Data processing begins with “indexing” the reflections, i.e. to identify the dimensions 
of the unit cell and which image peak corresponds to which position in reciprocal 
space. To perform indexing and integration the programs iMOSFLM (Battye et al., 2011) 
and XDS (Kabsch, 2010) were used.  
Each diffraction pattern corresponds to a segment of the reciprocal space and each 
spot corresponds to a different type of variation in the electron density. Then, it is 
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necessary to define which variation corresponds to which spot. When indexing, a 
reconstruction of peaks in the reciprocal space allows estimating the crystal lattice, 
dimensions of the unit cell (a, b, c, α, β, γ) and the orientation of the crystal from a 
subset of the data collection. The parameters obtained are refined together with the 
rotation matrix, center of the beam, masked regions (e.g. beam stop, ice rings), 
mosaicity (i.e. spread of crystal plane orientations), beam divergence, y-scale, twist, tilt 
and distance to detector. With the optimized parameters the diffraction spots are 
integrated, summarized as full or partial reflections and stored in a single file 
containing the unit cell dimensions, space group and for each reflection the Miller 
indices, position, intensity and its associated error. 
To verify the space group, the integrated reflections must follow the diffraction 
conditions of the selected space group, for which the program Pointless (Evans, 2006) 
was used. This software confirms conditions for the Laue group, point group and space 
group systematically, giving a probability for all possible space groups, with the 
additional possibility to reindex the dataset in a new best space group.  
To converge multiple observations of reflections and produce a file that contains 
averaged (equivalent) intensities for each reflection, the data obtained is then merged 
and scaled into a set of unique reflections with the proper intensity value. The 
programs used in this part of the process are Scala or Aimless (Evans, 2006). 
An indicator used to assess the quality of the dataset is Rmerge defined by Equation 2-6:  
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Equation 2-6. Rmerge equation. 
However, due to its dependence on redundancy, Rmerge may be substituted for an 












Equation 2-7. Rmeas equation. 
Common criteria for resolution cut-off are the average ratio of signal to noise the 
highest resolution shell <I> / σ (<I>) ≈ 2, completeness in all shells > 90% and Rmerge < 
0.25 in the highest resolution shell. However, recent approaches recommend to not to 
cut resolution, but use all available data and only define the effective resolution (Evans 
& Murshudov, 2013; Diederichs & Karplus, 2013). 
Finally, using the program TRUNCATE (French and Wilson, 1978) from the CCP4 
package (Winn et al., 2011) intensities are converted to amplitudes and placed on an 
approximate absolute scale using a scale factor obtained from a Wilson plot, as 
presented in Equation 2-8. 
!!!" = ! ∙ ! ∙ ! ∙ ! ||! ℎ!" |! 
Equation 2-8. Relation between the structure factors and the intensity .  
where K is a scale factor (K = C-½); A the absorption factor; L the Lorentz factor; and p 
is the polarization factor. 
2 .7.2  Phasing: Molecular Replacement Method 
To address the phase problem in the case of macromolecular structure determination, 
initial phase estimates can be obtained with different methods: multiple isomorphous 
replacement (MIR), anomalous X-ray scattering (MAD or SAD phasing) and molecular 
replacement (MR).  
The MIR method is based on the Patterson method (Patterson, 1934). It uses the 
presence of heavy atoms in the crystal by soaking or co-crystallization. These atoms 
should not interfere with crystallization or change unit cell dimensions, as the crystal 
should be isomorphic with the native form. The heavy atoms act as large scatters that 
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can be identified with the Patterson function. The difference in the scattering 
amplitudes from the heavy and the native structures are used to calculate initial 
phases. 
Anomalous X-ray scattering (MAD or SAD phasing) is based also on the changes in the 
intensity produced by the introduction of heavy atoms, but in this case using radiation 
at different energies (i.e. different wavelengths). When the frequency of the X-ray 
radiation is close to the natural vibration frequency of the electrons in a given atom, 
the atom behaves as an anomalous scatterer and the atomic scattering factor is 
modified. By analyzing the differences between diffraction data, it is possible to 
calculate initial phases. 
By taking advantage of the homology between macromolecules, the MR method was 
used in this research work. This technique uses a related known structure as a search 
model to find the orientation and position of the molecules within the unit cell. The 
initial phases are assigned using the phases from the replaced homologous structure. 
For proteins, sequence identity with more than 40% is used to select possible 
candidate models for MR. For DNA, it is more common to use an ideal model of the 
double helix with information inferred from the diffraction data, such as the rise, 
rotation and possible packing. The molecular symmetry of the double helix structure 
and the similarity between base pairs containing different nucleobases makes it 
difficult to rely only on the sequence, and even more if MR is done with a truncated 
resolution. 
When the MR is performed, the unknown molecule orientation is obtained first with 
the rotation function, and then, a translation defined by the interatomic cross vectors 
between molecules is applied to place the molecule in the right position within the 
unit cell. The main purpose of the MR method is to find these two operators: the 
rotation and the translation functions. 
The programs used for MR are Molrep (Vagin and Teplyakov, 2010) and Phaser (McCoy 




Phaser uses a different approach by computing the likelihood of the solution. These 
programs also provide the R and the C parameters, which provide the suitability of 
positioning solutions regarding the data, as shown in Equation 2-9 and Equation 2-10. 
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Equation 2-9. R parameter calculation. 
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Equation 2-10.  C parameter calculation. 
where F obs and F calc are the observed and calculated structure factor amplitudes; R is 
the reliability index or R factor, which represents the error between the model and 
diffraction data; and C is the correlation coefficient between the adequacy of the 
model and the observed data. 
Besides, for MR of oligonucleotides, not only an existing known structure can be used, 
but it is also common to generate a theoretical structure with programs like Turbo-
Frodo (Roussel et al., 1998) or 3DNA (Lu & Olson, 2003). The particular anisotropy of 
nucleic acids, together with the typical crystal arrangement of pseudo-continuous 
helices and the similarity between base pairs, may turn the process of MR especially 
difficult. 
For MR of DNA-protein complexes, a strategy that has previously shown its relevance 
within the hosting research group was used: perform the MR first with a B-DNA model 
theoretically generated, and once this molecule is positioned, the MR of an existing 
known structure can be used to find the protein. 
In general, if the model replaced is similar, model building can be performed using the 
program Coot (Emsley et al., 2010) to fix the model. Computer software like Pymol 
(Schrödinger, LLC, 2015) and CCP4mg from the CCP4 package (McNicholas et al. 2011) 
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are molecular visualization programs used to view and manipulate the molecular 
model obtained. 
2 .7.3  Structure Refinement 
The aim of structure refinement is to maximize the consistency between the electronic 
density (X-ray diffraction data) and the atomic model. Several specialized optimization 
methods have been developed to refine macromolecules, such as the least squares 
method, conjugate gradient minimization, maximum-likelihood refinement and 
dynamics-based simulated annealing. 
The program used for structure refinement is REFMAC5 (Murshudov et al., 2011), 
which uses maximum-likelihood restrained refinement. The target function (Equation 
2-11) for optimization (ftotal) is defined using Bayesian methods (Equation 2-12), in 
terms of a prior knowledge that depends on the geometry of the model (fgeom) and a 
likelihood function (fxray) that define the link between the model parameters and the 
experimental data. The idea that unifies these two parameter realms is a common 
means for assessing the correctness of the model. 
!!"!#$ =  !!"#$ + ! !!"#$ 
Equation 2-11. Maximum- l ikel ihood restrained refinement function. 




Equation 2-12. Bayesian function. 
Geometrical parameters include chemical information of the molecule and its residues, 
internal consistency and structural knowledge such as known interatomic distances 
and secondary structure. The restrains commonly used for refinement include bond 
distances, bond angles, torsion angles, chiral centres, planar groups, van der Waals 
repulsions, van der Waals interactions, torsion, H-bond, chain bond B values, long-
range B values and NCS. The latter is very useful if the model is close to correct. NCS 




conformation, but are not related by the crystal symmetry. An alternative to 
secondary-structure restraints are the Ramachandran restraints, performed in 
phenix.refine to restrain the protein backbone, two different target functions are 
implemented based on the (ϕ,) distributions. 
If necessary, REFMAC5 can perform twin refinement. Rigid body refinement is usually 
done during MR, but it can also be used for further optimization of the orientation and 
the position of the macromolecule in the cell. TLS refinement is used for modeling 
anisotropic displacements, a set of rigid body domains are defined in the molecule and 
its rigid-body motion is described by translation (T), libration (L) and screw (S) tensors. 
TLS should not be used until the latest stages of refinement, since in early stages it 
could induce bias and set the system in a local minimum. Real space refinement is 
performed using the program Coot (Emsley et al., 2010), where residues can be 
optimized or refined to follow an electron density map or difference map.  
The correlation between the X-ray data and the model quality equation (Equation 2-9) 
is measured, among other factors, by the improvement of two refinement statistics: 
Rwork and Rfree. Rfree, is used to assess possible overmodeling (overfitting) of the data. It 
is calculated according to the Equation 2-9, but on a subset of data that usually 
corresponds to 5% of the total diffractions. This set of diffractions is not used for 
refinement. Rwork uses the set of refined diffractions.  
During each cycle of refinement the R-factors are reduced and atom positions (x,y,z), 
phases ϕ(hkl) and B factors are optimized. Optimum values of R depend on the 
resolution, but usually should be below 0.30, and the difference between Rwork and 
Rfree should not exceed 0.05. B-factor should be on the order of 100 Å2 for resolutions 
around 3 Å and 40 Å2 for resolutions around 2 Å. If after extensive refinement Rwork 
and Rfree cannot reach that value, potential reasons could be errors in MR, wrong space 
group, twinning or pseudo-translation. 
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2 .7.4  Structure Validation 
The final step in macromolecular structure resolution is the validation. In other words, 
it is the process of evaluating reliability for the three-dimensional atomic model. 
To validate the structure is to locate incongruities, such as bond lengths, bond angles, 
dihedral angles, chirality, planarity, short atom contacts, electron density correlation, 
B-factors, and conformations. 
Common programs used for this purpose are SFCHECK (Vaguine et al., 1999) and 
MolProbity (Chen et al., 2010). Using the graphical viewer Coot (Emsley et al., 2010) is 
possible to assess and fix geometry parameters, real space correlation, conformations 
(i.e. Ramachandran plot) and other parameters. The program 3DNA (Lu and Olson, 2008) 
is used additionally for oligonucleotides, to analyze and validate base pairing, sugar 
puckering, type of DNA, bending, local base pair parameters, local base pair helical 
parameters and local base pair step parameters; all described in Figure 1-4. In this 
thesis, the atomic model figures were prepared either with Pymol (Schrödinger, LLC, 
2015), Coot (Emsley et al., 2010) or CCP4mg (McNicholas et al. 2011).  
Once the molecular structure is analyzed and validated, the final model is deposited in 
a crystallographic database providing the atomic coordinates, the related experimental 
data and the structure resolution details. The most popular database for 
macromolecules is the Protein Data Bank (PDB). Once the PDB validation is complete, 
an identification code of the macromolecule or complex is assigned and the atomic 
coordinates of this new structure become freely accessible to the scientific community. 
2 .8  SPR-Biosensor Assays 
Surface plasmon resonance (SPR) binding analysis methodology is an optical technique 
used for detecting molecular interactions. It allows the real-time detection and 
monitoring of biomolecular binding events of two different molecules in which one is 




Biacore® technology have been employed in this work to perform the SPR binding 
analysis. Biacore® is a widely used technique due to its high sensitivity, great precision, 
fast assay development and because of the wide range of interactions that this system 
supports for analysis. This technology provides high-quality qualitative and 
quantitative data in a range of fields such as immunogenicity studies, vaccine 
development, biological research, biotherapeutics and small-molecule drug discovery 
and development. 
In our case, SPR binding analysis is performed to aid in understanding the molecular 
interaction between the bis(2-aminoimidazoline) compounds or HMG proteins with 
AT-rich oligonucleotides, and to analyze and compare the selectivity, affinity and 
kinetics of these DNA-binding molecules.  
SPR is a phenomenon that occurs in thin conducting films at an interface between 
media of different refractive index. In the case of this work, the media are the glass of 
the sensor chip and the sample solution, and the conducting film is a thin layer of gold 
on the sensor chip surface. In an SPR experiment, the ligand (interacting molecule) is 
bound to the biosensor surface while the analyte is delivered to the surface in a 
continuous flow through a microfluidic system (Figure 2-13). When polarized light is 
applied to the surface of the sensor chip and is reflected, the intensity of the reflected 
light is reduced at a certain incident angle, the SPR angle. The interacting molecules at 
the surface of the sensor chip increase the refractive index, which alters the SPR angle 
(see Figure 2-13). The detector reveals position changes of the intensity dips in the 
wedge of the reflected light corresponding to the SPR angle. Consequently, the binding 
of biomolecules to the sensor surface will cause a shift in the SPR angle, which is 
directly proportional to the increased mass. The response (signals) generated is 
measured in resonance units (RU).  
All SPR experiments were performed at the Institute of Medicinal Chemistry, CSIC, 
Madrid, using a Biacore® X-100 apparatus (Biacore GE). The sensor chip employed was 
Sensor Chip SA from Biacore® due to its suitability to work with nucleic acid ligands. 
Sensor Chip SA consists in a dextran matrix to which streptavidin has been covalently 
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attached. Streptavidin is a protein with a high affinity for biotin. Therefore, the surface 
of the chip is able to capture biotinylated ligands (Figure 2-15). This binding is 
equivalent in stability to covalent immobilization of the ligand. 
 
Figure 2-13. The principle of surface plasmon resonance (SPR) .  
The duplex immobilization can be formed through hybridization of an unlabeled DNA 
strand that is complementary to a biotin labeled previously immobilized strand. 
However, it is possible that some of the non-immobilized complementary strands may 
be lost through dissociation. For that reason, DNA hairpins have been employed, where 
the two single-strands of the duplex are connected through a loop of nucleotides (see 
Figure 2-14).  
 
Figure 2-14. Scheme of a streptavidin-biotin immobil ization of a DNA hairpin used 
during SPR experiments .  
Once the ligand is immobilized, a set of solutions containing different concentrations 




handling facilities of the Biacore® X-100. At the end of each injection, sample is 
replaced by a flow of running buffer and bound analyte is dissociated from the surface 
in a process called regeneration. The aim of regeneration step is to remove all non-
covalently bound molecules from the surface without affecting the activity of the 
ligand. The three process steps (surface preparation, analysis and regeneration) are 
monitored in a sensorgram (Figure 2-15), which records changes in terms of molecular 
concentration at the sensor surface with time. Binding is monitored in real time as the 
sample passes over the surface.  
 
Figure 2-15. Schematic i l lustration of a SPR sensorgram. The bars below the 
sensorgram curve indicate the solutions that pass over the sensor surface.   
In addition to binding assays, competitive experiments were performed using SPR 
technique. For this purpose, the set of analyte solutions used was composed of a fix 
concentration of an HMG protein and increasing concentrations of the diamidine 
compound. The goal was to detect the destabilization and disruption of the complex 
DNA-HMG by the dicationic compound. 
The 5’-biotin labeled DNA hairpins studied by SPR were purchased from Sigma-Aldrich 
with reverse-phase HPLC purification. The DNA hairpin sequences are included in Table 
2-13.  
The oligonucleotides were dissolved in 150 mM NaCl, 10 mM HEPES pH 7.4. The DNA 
hairpins were immobilized on the Sensor Chip SA by injection of a 25 nM hairpin DNA 
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solution with a flow rate of 1 µL/min until 400 RU were reached. Flow cell 1 was used 
as reference while flow cell 2 was immobilized with the hairpins in different chips. 
Table 2-13. DNA hairpin sequences studied by SPR. 









The latter sequence was selected as a control.  
SPR binding and competitive experiments were performed at 25°C. Running buffer 
used (designated as HEPES 1) contained 10 mM HEPES, 3 mM EDTA, 200 mM NaCl, 
and surfactant P-20 at 0.05% (v/v) pH 7.4. Proteins and diamidines compounds 
samples were also diluted in HEPES 1 buffer.  
Direct binding of the HMGA1a[∆50-91] and HMGB1 Box AB proteins was measured by 
injection of increasing the protein concentration over the immobilized DNA surfaces at 
a flow rate of 50 µL/min for a period of 60 s followed by a dissociation period of 120 s. 
Regeneration of the surface was made with 200 mM NaCl/10 mM NaOH using a flow 
rate of 10 µL/min during 30 s. The binding affinity was determined by fitting the 
results to a two-site binding model according to the Equation 2-13: 
! =  !!!! + 2!!!!!!
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Equation 2-13. Two-site binding model .  
where r is the moles of bound compound per mole of DNA hairpin duplex, Cf is the free 
concentration at the equilibrium, and K1 and K2 the microscopic binding constants. 
Direct binding analysis of the bis(2-aminoimidazolinium) compounds was measured by 
injection of increasing drug concentrations over the immobilized DNA surfaces at a 
flow rate of 18 µL/min for a period of 300 s followed by a dissociation period of 300 s. 




rate of 10 µL/min during 60 s. The binding affinity was determined by fitting the 
results to a two-site binding model according to the Equation 2-13. 
The competition experiments were prepared with samples containing a fixed 
concentration of HMGA1a and HMGB1 proteins (2 µM) and a series of concentrations 
of the bis(2-aminoimidazolinium) compounds ranging from 0.05 to 200 µM (for 
HMGA1a) or 400 µM (for HMGB1) in HEPES 1 buffer. The samples were injected to the 
immobilized DNA surfaces at a flow rate of 50 µL/min for a period of 60 s followed by 
a dissociation period of 150 s. The regeneration conditions were similar to the binding 
experiments described above. The binding responses (RU) at steady state were averaged 
and normalized by setting the RU with the proteins HMGA1a and HMGB1 alone as 
100% binding to DNA and the RU with saturation by the inhibitor as 0%. IC50 values 
were determined by fitting the inhibition data with a model according to a 
competition system with 1:1 binding stoichiometry for HMGA1a and HMGB1 and two- 
site binding for competitor (Equation 2-14) 
% proteins binding to DNA = 100 /  1 + !(1 + !!!!)!"!"(1 + !!!!"!")
 
Equation 2-14. Two-site binding for competitor .  
where Kc2 is a macroscopic binding constant for inhibitor binding to DNA, IC50 is the 
concentration of the inhibitor that causes 50% inhibition of HMGA1a and HMGB1 
binding to DNA, and C is the concentration of inhibitor (Miao et al., 2008). 
2 .9  Effect of Bisimidazolinium Diphenyl Compounds 
on Trypanosoma brucei 
The antitrypanosomal activity and mechanism of action of the bis(2-
aminoimidazolinium) compounds listed in Table 2-9 were evaluated in vitro against the 
parasite Tryanosoma brucei during two 4-month research stays with Dr. Harry de 
Koning at the Institute of Infection, Immunity & Inflammation, University of Glasgow, 
United Kingdom. 
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2 .9.1  Strains and Cultures 
Three parasite cultures of Trypanosoma brucei brucei bloodstream forms (BF) were 
analyzed: (1) the strain Lister 427/MiTat1.2 (wild-type, Tb427WT); (2) TbAT1-B48, 
which is derived from the Tb427WT strain by the deletion of both alleles coding for the 
TbAT1/P2 transporter (this s427-WT derivative strain is also called TbAT1-KO) (Matovu 
et al., 2003) and also by selection through exposure to increasing concentrations of 
pentamidine until the cells also lost the high-affinity to pentamidine transporter, 
HAPT1 (Bridges et al., 2007), leading to high resistance to diminazene, pentamidine 
and melaminophenyl arsenicals; and (3) ISMR1, which is a clonal, Tb427WT-derived 
dyskinetoplastid cell line, adapted to in vitro growth in 1 µM of isometamidium (ISM) 
by stepwise increases in the medium concentration of the drug (Eze et al., 2016). 
All T. b. brucei strains were cultured under standard conditions (37°C under a 
humidified 5% CO2 atmosphere) in HMI-9 medium (Gibco) (Hirumi & Hirumi, 1989) 
supplemented with 2 mM β-mercaptoethanol (Sigma-Aldrich) and 10% fetal bovine 
serum (FBS; Gibco) at pH 7.4 (see Appendix B). Passage was done three times per week 
in vented flasks. 
Additionally, three Trypanosoma congolense BF cell lines were studied in this project. 
The wild type strain IL300 and two diminazene-resistant cell lines (growing at a 
concentration of 800 nM of diminazine) called 6C3 and 4C2. T. congolense strains 
were cultured in TcBSF-3 medium (see Appendix B) in log-phase culture at 34°C, 5% 
CO2 by changing the medium every 3 days. 
All medium was sterilized inside a flow cabinet by filtration through 0,22 µm Millipore 




2 .9.2  Drug Sensitivity Assays 
2.9.2.1 Alamar	Blue	Assay	in	BF	T.	brucei	
Fifty percent effective concentrations (EC50) were determined using the fluorescence 
viability indicator dye Alamar Blue (resazurin sodium salt, Sigma-Aldrich) as described 
(Gould et al., 2008), with small modifications. Resazurin is metabolized by live cells to 
resorufin and the fluorescent signal generated is thus proportionate to the number of 
live cells (Gould et al., 2008) (Figure 2-16).  
 
Figure 2-16. Conversion of resazurin to resorufin by viable cel ls  results in a 
f luorescent product.  The f luorescence produced is  proportional to the number of 
viable cel ls .  
Drug stock solutions (see section 2.2.5) were diluted to 400 µM with HMI-9 medium 
with 10% FBS. 200 µL of these test compound dilutions were added to the first well of 
rows A, C, E and G of a white-bottomed 96-well microplate (Greiner - Bio-One) (Figure 
2-17). A volume of 100 µL of HMI-9 medium with 10% FBS was loaded into all 
remaining wells. Up to four drugs could be tested in one plate. Doubling dilutions of 
test compounds were prepared, leaving the last well drug-free as a control, before the 
addition of an equal volume of cell suspension to each well, to get a final cell density 
of 1 × 104 cells/mL. The plates were incubated at 37°C/5% CO2 for 72 h after which 20 
µL of resazurin solution (125 µg/mL in phosphate-buffered saline, pH 7.4) were added 
followed by another incubation for 24 h.  
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Figure 2-17. 96-well  microplate diagram. Arrow explains the way the drugs are 
doubly di luted down two rows across the plate.  DF; drug free,  negative control .  
Pentamidine and isometamidium were used as positive controls throughout the study. 
Viable cells reduce the dark blue dye to a pink colour. The change in fluorescence was 
determined using a FLUOstar Optima plate reader (BMG Labtech), at excitation and 
emission wavelengths of 530 and 590 nm, respectively. Data were analyzed and 
plotted to a sigmoid curve with variable slope using Prism 5.0 (GraphPad). Each 
experiment was performed at least on three independent occasions. 
2.9.2.2 Alamar	Blue	Assay	in	BS	T.	congolense	
Alamar blue end point assays were also used to estimate the drug sensitivity in 
Trypanosoma congolense cell lines as described in the previous section. Stock solutions 
of drugs were diluted to 200 µM with TcBSF-3 medium. Cell density was adjusted to 
reach a final density of 2.5 × 105 cells/mL. Diminazene was used as positive control 
throughout this study. The plates were incubated at 34 °C + 5% CO2 for 48 h after 
which 20 µL of sterile resazurin solution (125 µg/mL in phosphate-buffered saline, pH 
7.4) was added to every well, followed by a further incubation of 24 h in the same 
conditions. Each experiment was performed at least on three independent occasions. 
2 .9.3  Drug Sensitivity Assay using Cell  Count 
The effects of the bis(2-aminoimidazolinium) compounds on growth of BF 




under standard conditions (HMI-9/10% FBS; 37°C, 5% CO2) in the presence or absence 
of 0.5, 1, 2.5 and 5 times their EC50 values for up to 48 h. Cells were seeded at a 
density of 2 × 104 cells/mL using a haemocytometer. Cells were counted in triplicate at 
the following times (h) after initiation of the experiment: 0, 4, 8, 24, 36 and 48.  
2 .9.4  Assessment of Cell  Cycle Progression in T.  brucei  
2.9.4.1 Fluorescence	Microscopy	
Nuclei and kinetoplasts were visualized by using the fluorescent dye 4’,6-diamidino-2-
phenylindole (DAPI) on BF trypanosomes after fixation. 50 µL of cells at 2 × 106 
cells/mL were spread onto a glass microscope slide, left to dry in a fume hood and 
fixed in 4% paraformaldehyde in fresh PBS for 10 min at room temperature. The slides 
were washed with 1× PBS. The PBS was gently removed by inclining the slide on a soft 
tissue and a drop of Vectashield® mounting medium with DAPI (Vector Laboratories) 
was placed on the slide before covering with a cover slip. The slide was then viewed 
under UV light on a Zeiss Axioskop 2 fluorescent microscope (Carl Zeiss Microscopy). 
500 cells were recorded for each sample, and scored for DNA configuration following 
these groups: 1N1K, 1N2K, 2N2K(Early) and 2N2K(Late) (N, nucleus; K, kinetoplast; 
Early, early stage of division; Late, late stage of division;) (see Figure 1-22). The effect 
of test compounds on DNA configuration was determined at 0, 8 and 24 h. Untreated 
cultures served as control. 
2.9.4.2 Flow	Cytometry	
DNA content of BF trypanosomes was measured by flow cytometry using the 
fluorescent dye propidium iodide (PI), as described (Ibrahim et al., 2011; Hammarton et 
al., 2003) with minor modifications. Cell density was adjusted to 2 × 106 cells/mL. Five 
milliliters of sample were transferred at each time point into microfuge tubes and 
centrifuged at 1620 g for 10 min at 4 °C, washed once in 1× PBS with 5 mM of EDTA 
and re-suspended and fixed in 1 mL of 70% methanol and 30% PBS with 5 mM EDTA 
(first re-suspend in 300 µL of PBS with 5mM EDTA and then add, drop-wise while 
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vortexing gently, the 700 µL of methanol). The tube containing the cells was covered in 
foil paper and leave at 4 °C overnight. After storage, the samples were washed once 
with 1 mL of 1× PBS with 5 mM EDTA and subsequently re-suspended in 1 mL 1× PBS 
with 5 mM EDTA containing 10 µg/mL RNase A and 10 µg/mL propidium iodide and 
incubated at 37 °C for 45 min while protected from light. 
Samples were analyzed using a BD FACSCalibur™ system (BD Biosciences). Data were 
acquired from the FSC, SSC, FL2- W and FL2-A detectors using BD CellQuest™ software 
(BD Biosciences), and further analyzed and graphically represented using the ©FlowJo® 
10.2 software. 
2 .9.5  Mitochondrial Membrane Potential Assay 
The mitochondrial membrane potential of treated and untreated cells was assessed by 
using tetramethylrhodamine ethyl ester (TMRE) following a protocol previously 
described (Ibrahim et al., 2011). TMRE is a cell permeant, positively-charged, red-
orange dye that accumulates in active mitochondria due to their relative negative 
charge. Depolarized or inactive mitochondria have decreased membrane potential and 
fail to sequester TMRE.  
Cell density was adjusted to 2 × 106 cells/mL and the drugs were added to make a 
concentration corresponding to their EC50 and 5 times their EC50 values; a negative 
control (drug free sample) was also prepared. One milliliter of sample was transferred 
at each time point into a microfuge tube and centrifuged at 1,500 g for 10 min at 4°C. 
The pellet was washed once with 1× PBS and re-suspended in 1 mL PBS containing 25 
nM of TMRE. Then, cells were incubated at 37°C for 30 min and subsequently placed 
on ice for at least 30 min.  
Samples were analyzed using a BD FACSCalibur™ system (BD Biosciences). Data were 
acquired from the FL2-height detector using BD CellQuest™ software (BD Biosciences), 
and further analyzed and graphically represented using the ©FlowJo software, version 
10.2. Valinomycin (100 nM) and troglitazone (10 µM) were employed as depolarization 




membrane potential was determined at 0, 3, 6 and 12 h. The detector was calibrated so 
that the peak of control cells (Tb427WT not exposed to any test compound) was set at 
100 arbitrary units, i.e. with 50% of cells at >100 A.U. and 50% at <100 A.U. The data 
are presented as percent of the cell population with a fluorescence >100 A.U. 
2 .9.6  Cellular Localization of Compounds in BF T.  
brucei  
The localization and distribution of the fluorescent compounds in the BF trypanosomes 
was studied by fluorescence microscopy. After measuring the fluorescence of all the 
compounds studied in this project, only the compound JNI18 was found fluorescent in 
DMSO. The fluorescence emission spectral peak of JNI18 in solution was determined in 
the region of 450 nm (Table 2-14), which is exactly the emission wavelength of DAPI.  
Table 2-14. Fluorescence parameters of the compound JNI18 in DMSO. 
Emission (nm)  450 
Molar extinction coefficient 23708 
Quantum yield 0.42 
Fluorescence intensity 9957 
Parameters obtained at the Instituto de Química Médica IMQ-CSIC, in Madrid. 
Therefore, in order to visualize both nuclei and kinetoplast DNA of the parasites, 
instead of DAPI, the green-fluorescent counterstain SYTOX® Green nuclei acid stain 
was used, which emits fluorescence at 523 nm. Thus, the fluorescence due to our 
compound JNI18 and to the stained DNA can be differentiated. The red-fluorescent 
(λem= 599 nm) dye MitoTracker® Red CMXRos, which stains mitochondria in live cells, 
was also used.  
Trypanosome cultures were grown in HMI-9/FCS media, cell density was adjusted to 2 
× 106 cells/mL and the compound JNI18 was added to make a concentration of 5 µM; 
a negative control (drug free sample) was also prepared. 1 mL of sample was taken 
every time point and transferred into an empty tube, and 1 µL of 100 µM solution of 
MitoTracker® Red CMXRos (Thermo Fisher Scientific) in DMSO was added to make a 
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final concentration of 100 nM. Samples were incubated at 37°C and 5% CO2 for 5 min. 
Subsequently, samples were washed with filter-sterilized 1× PBS and spun at 1,500 × 
g. Pellets were re-suspended in 50 µL of PBS and spread into a glass microscope slide. 
The cells were dried in a fume hood and fixed in 4% formaldehyde/PBS fresh for 10 
min at room temperature. Cells were permeabilized with cooled methanol for 5 to 10 
min at -20°C, washed once or twice with 1× PBS and then washed twice with Hanks' 
Balanced Salt Solution (HBSS) (see Appendix B). Enough solution 1:30,000 (167 nM) of 
green-fluorescent counterstain SYTOX® Green nuclei acid stain (Thermo Fisher 
Scientific) in HBSS to cover all the cells was added to the slides and incubated for 15 
to 30 min protected from light.  
Finally, cells were washed twice with HBSS and the slides were covered with a cover 
slip. The location of the test compound was determined at 0, 3, 6 and 24 h. The slide 
was then viewed under DeltaVision Core microscope (Image Solutions - Applied 
Precision, United Kingdom) under several fluorochromes (blue for JNI18, green for the 
SYTOX® and red for the Mitotracker®), as well as under UV light. Image acquisition was 
controlled using Zen software (Zeiss) and SoftWorx was used for further image 
processing. 
2 .9.7  Transmission Electron Microscopy Analysis 
Transmission electron microscopy was used to assess the action of the compounds on T. 
brucei ultrastructure. Cells were harvested and the density was adjusted to 2 × 106 
cells/mL. The samples incubated 3 and 24 h with 5 µM of the compound, as well as 
untreated cells for control were centrifuged at 610 × g for 10 min at room 
temperature and the pellet was washed once with 1× PBS and re-suspended in 1 mL of 
the fixative solution containing 2.5% of glutaraldehyde and 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.4) and left at 4°C overnight. Then, samples were 
centrifuged at 4,000 rpm for 8 min and pellet was washed three times with 0.1 M 
phosphate buffer (pH 7.4). Cells were post-fixed in a solution of 1% osmium tetroxide 
for one hour on ice, and washed with the phosphate buffer to remove excess of 




washed three times with distilled water and dehydrated by using a series of increasing 
concentrations of acetone (30, 50, 70, 90 and 100%). Next, cell infiltration was 
performed using an epoxy resin. Thin sections (50-60 nm) were observed in a Tecnai 
T20 (FEI) at 200 kV.  
2 .9.8  PCR Amplif ication of Kinetoplast DNA Markers 
Polymerase chain reaction (PCR) of kinetoplastid and nuclear markers was used to 
verify the presence of kinetoplast in Tb427WT treated 0, 3, 6, 9, 12, 24 and 32 h with 
the bisimidazolinium diphenyl compounds.  
Trypanosome cultures were grown under standard conditions (HMI-9/10% FBS; 37°C, 
5% CO2), cell density was adjusted to 2 × 106 cells/mL and the compound JNI18 was 
added to make a concentration of 5 µM; 1 mL of cells were transferred into a tube and 
processed each time point. Full genomic DNA (nuclear and kinetoplast) from T. b. 
brucei was obtained using the NucleoSpin® tissue kit (Machery-Nagel, Düren, Germany) 
according to the manufacturer’s instructions, quantified using a NanoDrop ND1000 
spectrophotometer, and stored at -20 °C. PCR master mix 1× in a total volume of 19 
µL (11.8 µL nuclease free water, 4 µL Green GoTaq reaction buffer, 1 µL of 10 mM 
dNTPs, 1 µL forward primer and 1 µL reverse primer along with 0.2 µL GoTaq DNA 
polymerase) was prepared for each primer pair and DNA sample. One milliliter of 
extracted DNA was added in the relevant tubes. Primer sequences specific for 
maxicircle and minicircle kinetoplast (kDNA) are listed in Table 2-15.  
Cycle conditions for maxicircle sequences were 95 °C for 5 min and 30 cycles of 95 °C 
for 1 min, 54 °C for 1 min, and 72 °C for 30 s followed by a final elongation step at 72 
°C for 8 min. On the other hand, cycle conditions for minicircle sequences were 94 °C 
for 5 min and 35 cycles of 94 °C for 40 s, 59.4 °C for 1 min, and 72 °C for 90 s 
followed by a final elongation step at 72 °C for 10 min. All samples were run on 1% 
(w/v) agarose gels and visualized using SYBR™ Safe DNA Gel Stain (Invitrogen™) as 
described in section 2.2.4. 
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Table 2-15. Ol igonucleotide primer sequences used in this study.  

































A6, ND4, ND5, ND7: fragments of 4 genes known to be encoded only by the kinetoplast maxicircles 
from Tb427WT. Actin: Tb427WT nuclearly encoded gene. Minicircles Type A, Type A-like: 
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3 .1  Obtaining HMG proteins 
The proteins of interest were expressed in E. coli and purified following the protocol 
described in section 2.1.  
3 .1.1  Expression and Purif ication of HMGA1a(∆50-91) 
HMGA1a(∆50-91) protein was expressed several times to obtain enough amount to 
perform crystallographic and binding assays. Each expression batch was obtained from 
1 L of starting culture as described section 2.1.1.  
The recombinant pET-3a plasmid containing the human HMGA1a(∆50-91) gene (Figure 
2-2) was transformed into E. coli Rosetta (DE3) pLysS strain. A transformed colony 
was used to obtain a saturated liquid culture from which 1 L of culture was inoculated 
into LB medium containing ampicillin at 37°C. Protein expression was induced when 
the culture featured an OD600 of about 0.6-0.7 by adding 1 mM IPTG (see 2.1.1). The 
culture was incubated for 3 h to allow the bacteria to synthesize the recombinant 
protein and then the cells were recovered by centrifugation. The bacterial pellet was 
processed using 5% HClO4/0.5% Triton X-100 as described section 2.1.1. The 
recombinant protein was extracted and precipitated from the supernatant using 25% 
TCA to obtain a pellet enriched in HMGA1a(∆50-91). Figure 3-1 shows the AU-PAGE 
gel of the induction process (0 h, 1.5 h and 3 h) and the enriched extract after the 
pellet preparation.  
 




The pellet enriched in HMGA1a(∆50-91) was admitted to a multi-stage purification 
process described in section 2.1.2. 
The purification process started with a cation-exchange chromatography based on the 
conditions described by Reeves & Nissen (1999) with small modifications. A 
carboxymethyl cellulose (CM52, Whatman) column of 20 cm in length, 1.5 cm internal 
diameter and 25 mL column volume was used. Equilibration buffer was 50 mM NaCl, 
25 mM Tris-HCl, pH 7 and protein elution was achieved by increasing the 
concentrations of NaCl from 50 mM (buffer A) to 600 mM (buffer B). Flow rate was 1 
mL/min and 4 mL samples were collected. 
Figure 3-2a shows a chromatogram obtained from the cation-exchange 
chromatography. Peaks of absorbance at 220 nm were collected and analyzed by 
AU-PAGE (Figure 3-2b). As expected, HMGA1a(∆50-91) protein was identified in the 
fractions forming the major peak of the chromatogram. Secondary peaks, from which 
samples 5 and 57 were analyzed, were not containing our target protein.  
 
F igure 3-2. (a)  Cation-exchange chromatogram and (b)  AU-PAGE analysis  of 
HMGA1a(∆50-91) protein.  Sample P corresponds to the pel let obtained in a 
previous-to- load centrifugation of S ,  which is  the protein sample loaded into the 
column. B,  buffer containing 600 mM NaCl ,  25 mM Tris-HCl,  ph7. 
                                                                                                                            
RESULTS AND DISCUSSION: HMG PROTEINS 
  
 153 153 
Fractions 65 to 70, which corresponded to the most pure samples, were concentrated 
to proceed with the second purification step. Sample concentration was carried out 
using the ultra-concentration device Vivaspin® 20 mL MWCO 3000 following the 
manufacturer's instructions until the sample volume was around 1 mL.  
 
Figure 3-3. AU-PAGE of HMGA1a(∆50-91) concentrated samples after cation-
exchange chromatography.  
The electrophoretic analysis of the concentrated samples of HMGA1a(∆50-91) protein 
(Figure 3-3) shows that most of the unwanted proteins were eliminated during the 
cation-exchange chromatography. Nevertheless, it also confirmed the necessity to 
continue with the purification of HMGA1a(∆50-91) since it contained (in different 
proportion) a few impurities (Figure 3-3). 
For that purpose, the HMGA1a(∆50-91) samples were submitted to a last “polishing” 
purification step by size-exclusion chromatography following the protocol described in 
section 2.1.2. An ÄKTA Purifier 10 system (GE Healthcare) and a 24 mL column volume 
Superdex™ Peptide 10/300 GL (GE Healthcare) with Mr 100 - 7,000 were used.  
Samples A, B and C (see Figure 3-3) were loaded to the column in two/three 
independent injections per sample. The equilibration and elution buffer used was 100 
mM NaCl, 25 mM Tris-HCl, pH 7.5, flow rate was 0.5 mL/min and elution was achieved 
with 1.5 column volumes. As an example, Figure 3-4 shows the chromatogram of the 
size-exclusion column for one run of sample A. Peaks of absorbance at 220 nm 





Figure 3-4. (a)  Size-exclusion chromatogram and (b)  AU-PAGE analysis  of the 
fractions from the main peak.  S corresponds to the HMGA1a(∆50-91) protein sample 
loaded into the column. 
The electrophoretic gel displayed in Figure 3-4 shows how the band above the 
HMGA1a(∆50-91) protein band (corresponding to a higher molecular weight protein) 
elute first.  
 
Figure 3-5. AU-PAGE of HMGA1a(∆50-91) f inal samples .   
Fractions containing the target protein from all the size-exclusion column runs were 
pooled according to their degree of purity, dialyzed and concentrated using the ultra-
concentration device Vivaspin® 6 mL MWCO 3000. Dialysis was carried out washing 
the sample twice with 6 mL final buffer (80 mM NaCl, 25 mM Tris-HCl, pH 7.5). 
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Samples were concentrated until the volume was around 100 µL. Final sample 
absorbance was measured and the concentration was calculated using Equation 2-1. 
Finally, samples were analyzed by AU-PAGE gel (Figure 3-5).  
The concentration and volume of HMGA1a(∆50-91) protein samples obtained are 
listed in Table 3-1. 






M1 75 8,7602 1,8321 
M2 108 19,9704 4,1765 
M3 100 1,6023 0,3351 
M4 80 4,8149 1,0070 
M5 102 7,1325 1,4917 
M6 113 0,3863 0,0808 
M7 100 28.5391 5.9685 
M8 100 23.1827 4.8483 
M9 50 8.1957 1.7140 
All samples were in 80 mM NaCl, 25 mM Tris-HCl, pH 7.5 buffer and stored at -20°C. 
Due to the high purity and suitable concentration of samples M2 and M8, they were 
used for crystallization assays. For SPR assays sample M5 was used. 
3 .1.2  Expression and Purif ication of HMGB1 Proteins 
HMGB1 Box B(∆93-165) and Box AB(∆8-165) proteins were expressed following the 
same methodology. Each protein expression batch was obtained from 1 L of starting 
culture as described section 2.1.3.  
The recombinant pGEX-2T plasmid containing GST-tagged rat HMGB1 proteins Box AB 
and Box B (Figure 2-3) was transformed into E. coli Rosetta (DE3) pLysS strain. A 
transformed colony was used to obtain a saturated liquid culture which was diluted in 
1 L LB medium containing ampicillin and chloramphenicol at 37°C. Protein expression 
was induced when the culture featured an OD600 of about 0.8 by adding 0.5 mM IPTG 




Figure 3-6 displays the SDS-PAGE gel of samples collected during induction of GST-
HMGB1 Box B and GST-HMGB1 Box AB fusion proteins expression. An increase in the 
amount of the corresponding GST-HMGB1 fusion protein can be observed as the 
induction progressed.  
 
Figure 3-6. SDS–PAGE of the induction of GST-fusion HMGB1 proteins expression.  
MW, molecular weight marker MW-SDS-6 Dalton Mark™ VI (Sigma).   
Cell disruption was performed as described in section 2.1.3, by sonication on a 
Bandelin SONOPULS Ultrasonic Homogenizer HD 2200. The clarified lysate 
(supernatant from sonication) was purified by a multi-stage purification process 
described in section 2.1.4. First, the sample was loaded and incubated for at least 2 h 
with gentle rotation in a column packed with 6.5 mL Glutathione Sepharose™ 4B 
matrix (GE Healthcare), where the GST moiety bound to the glutathione coupled to the 
Sepharose beads. After incubation, the flow through (FT) was collected and the column 
was rinsed with wash buffer (W). Thrombin buffer was added to the column and eluted 
(ThW), followed by incubation with 200 U thrombin diluted in 1 mL thrombin buffer at 
4°C overnight. Here, the GST tag was removed from the fusion protein. Next, thrombin 
was inactivated with EDTA and eluted (FTc) and finally the HMGB1 protein fragments 
were eluted with elution buffer and collected as E1, E2 and E3. Figure 3-7 shows all 
the fractions collected during the affinity chromatography as well as a small sample of 
resin (beads) that was used as control.  
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Bacterial proteins were discarded in the first fractions washed from the glutathione 
Sepharose column (FT, W) as shown in Figure 3-7. The fractions FTc E1, E2 and E3, 
eluted after the GST tag removal, contained the target protein (Figure 3-7). Those 
fractions were pooled together into a single sample and loaded into a cation-exchange 
column.  
 
Figure 3-7. SDS-PAGE gels of the fractions eluted from the aff inity column 
corresponding to (a)  the GST-HMGB1 Box B fusion protein and (b)  the GST-HMGB1 
Box AB fusion protein.  MW, molecular weight marker;  FT ,  f low through; W, column 
wash; THW, thrombin buffer wash; FTc,  f low through after tag cleavage; El ,  E2 and 
E3, eluted fractions; Beads,  sample from microparticles of the column matrix taken 
at the end of the elution as a control .  
As described in section 2.1.4, the ÄKTA Purifier 10 system and a 5 mL HiTrap SP FF 
column were used. The sample of about 24 mL was filtered through a 0.22 µm filter 
membrane and loaded into the column in three consecutive injections with a 10 mL 
loop. The chromatography was performed with a constant flow of 2 mL/min at 4°C and 
5 mL fractions were collected.  
The column was equilibrated with 10 bed volumes buffer A (100 mM NaCl, 1 mM EDTA, 
1 mM DTT, 10 mM Tris-HCl, pH 7.9) and a 45 min gradient (18 bed volumes) from 
buffer A to buffer B (1 M NaCl, 1 mM EDTA, 1 mM DTT, 10 mM Tris-HCl, pH 7 9) was 
applied.  
Figure 3-8 shows the HiTrap SP FF column chromatograms corresponding to the 
purification of the protein HMGB1 Box B and Box AB, and the SDS-PAGE gels for the 
fractions conforming the main absorption peak at 280 nm. For the HMGB1 Box B 




were also analyzed. HMGB1 Box B fractions 22 to 27 and HMGB1 Box AB protein 
fractions 28 to 34, containing the target protein were pooled and concentrated to 
proceed with the last purification step: size-exclusion chromatography.  
 
Figure 3-8. Cation-exchange chromatogram (left)  and SDS-PAGE analysis  of the 
fractions from the main peak (r ight) .  MW, molecular weight marker;  S ,  HMGB1 
protein sample loaded into the column. 
The concentration of protein sample was carried out using the ultra-concentration 
device Vivaspin® 20 mL MWCO 3,000 (for the HMGB1 Box B) and MWCO 5,000 (for 
the HMGB1 Box AB) following the manufacturer’s instructions until the sample volume 
was around 0.5 mL.  
Size-exclusion chromatography was performed as described section 2.1.4 using a 
HiLoad Superdex™ 75 (GE Healthcare) column, Mr 3,000 - 70,000 Da. The samples 
were filtered through a 0.22 µm filter membrane and loaded into the column in two 
independent injections with a 500 µL loop. The equilibration and elution were 
performed with 150 mM NaCl, 1 mM DTT, 50 mM HEPES, pH 7.4 with a constant flow 
of 0.5 mL/min at 4°C and 0.5 mL fractions were collected.  
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Figure 3-9 shows the chromatograms obtained during the polishing step of the 
HMGB1 proteins.  
Pure fractions were pooled together according to their degree of purity and 
concentrated/dialyzed in buffer containing in 50 mM NaCl, 1 mM DTT in 25 mM HEPES, 
pH 7.4 to a final volume of 100 µL using a Vivaspin® 6 mL MWCO 3,000 (for the 
HMGB1 Box B) and 4 mL MWCO 5,000 (for the HMGB1 Box AB). Final samples were 
analyzed by SDS-PAGE gel (Figure 3-10).  
 
Figure 3-9. Size-exclusion chromatogram of (a)  HMGB1 Box B protein sample and (b)  
HMGB1 Box AB protein sample.  
Finally, samples were flash-frozen in liquid nitrogen and stored at -80ºC. The 
concentration and volume of HMGB1 protein samples prepared during this research 






Figure 3-10. SDS-PAGE of HMGB1 protein (Box B and Box AB) concentrated samples 
after s ize-exclusion chromatography. MW, molecular weight marker  MW-SDS-6 
Dalton Mark™ VI (Sigma).  









M1 B 400 33.9528 4.02 
M2 B 1,700 1.23 0.1467 
M1 AB 300 48.5259 2.6253 
M2 AB 300 15.1387 0.8190 
M3 AB 200 6.7985 0.3678 
M4 AB 200 16.9630 0.9177 
M5 AB 275 9.1438 0.4947 
All samples were in 50 mM NaCl, 1 mM DTT, 25 mM HEPES, pH 7.4 buffer and stored at -20°C. 
Due to the high purity and suitable concentration, samples HMGB1 box B M1 and box 
AB M1 were used them for crystallization assays. For SPR assays, HMGB1 box AB 
sample M1 was used. 
3 .2  Interaction of HMGA1a(∆50-91) Protein with 
AT-r ich DNA 
In order to evaluate its activity, the most pure samples of HMGA1a(∆50-91) protein 
obtained (M2, M5 and M8; see Figure 3-5 and Table 3-1) were used for supercoiling 
assays, crystallography assays and SPR experiments. 
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3 .2.1  Supercoil ing Induced by HMGA1a Proteins  
Supercoiling is a non-covalent and elusive topological modification modulated by 
DNA- and chromatin-binding proteins (Gilbert & Allan, 2014). The functionality of the 
HMGA1a(∆50-91) protein was verified as regarding to its ability to induce supercoiling 
by measuring the degree of circular DNA supercoiling in presence of topoisomerase I. 
The protocol performed in this assay is described in section 2.2.5.  
The plasmid used during these experiments has been constructed by Dr. Joaquim Roca 
from the Molecular Biology Institute of Barcelona (IBMB), CSIC, Barcelona. This 4.6 kb 
pSTAT-CEN2-S2 plasmid contains two inserts [AT]11 in opposing sites. 
The induction of supercoiling in the circular plasmid by HMGA1a(∆50-91) has been 
measured using three different salt concentrations in the reaction buffer: 50 mM NaCl 
(low ionic strength), 100 mM (medium ionic strength) and 150 mM (high ionic 
strength) (Figure 3-11). Opposite to previous published studies with other HMG 
proteins (Štros et al., 1994; Teo et al., 1995), the most favorable ionic strength for the 
HMGA1a supercoiling assays proved to be at very high salt concentration (150 mM 
NaCl; (1) in Figure 3-11). 
 
Figure 3-11. Supercoi l ing activity of the HMGA1a(∆50-91) in the presence of 
different salt  concentrations: (1) 150 mM NaCl (high ionic strength) ,  (2) 100 mM 
NaCl (medium ionic strength) and (3) 50 mM NaCl ( low ionic strength) .  DNA/protein 
molar ratio is  specif ied for each sample.  SC, supercoi led DNA; OC, nicked form 




In addition, the supercoiling effect of the HMGA1a protein from amino acid 1 to 90, i.e. 
the fraction containing the three AT-hook domains, was analyzed in order to compare 
it with that caused by the (∆50-91) fraction (see Figure 2-1). The pure HMGA1a(∆1-90) 
sample tested in this experiment was provided by a member of MACROM research 
group. 
 
Figure 3-12. Supercoi l ing activit ies at high ionic strength of two fragments of the 
HMGA1a(∆50-91) and the complete protein lacking the acidic tai l  HMGA1a(∆1-90).  
DNA/protein molar ratio is  specif ied for each sample.  SC, supercoi led DNA; OC, 
nicked form (open circular DNA).   
At high ionic strength, a clear supercoiling effect is seen for both protein fragments 
HMGA1a(∆50-91) and HMGA1a(∆1-90) as shown in Figure 3-12. The degree of 
unwinding observed on nicked circular DNA depends on the DNA/protein molar ratio, 
but is very similar for both proteins. Therefore, the truncated HMGA1a protein (∆50-91) 
containing only two AT-hook domains seems to be as functional and active as the 
HMGA1a(∆1-90), which contains the three AT-hook motifs. 
The untwist provoked by the protein in the circular DNA previously relaxed is 
compensated with a positive supercoiling at other region of the plasmid. This positive 
supercoiling is dissipated by the topoisomerase I. But when both, the protein and the 
topoisomerase are excluded, topoisomeres are obtained with negative supercoiling. 
Then, the negative supercoiling introduced by two fractions of HMGA1a protein is 
correlated with its unwinding activity. 
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3 .2.2  HMGA1a(∆50-91) Crystal lography Assays 
The crystallography assays of the HMGA1a-DNA complexes were evaluated with a set 
of AT-rich oligonucleotides by the vapor diffusion crystallization technique using the 
two typical set-ups: hanging-drop and sitting-drop. The oligonucleotides used are 
shown in Table 3-3. 
Table 3-3.Oligonucleotide sequences used for crystal lographic assays with 
HMGA1a(∆50-91) 
DNA sequence  Length [bp] MW [mol ·g -1]  
1. CCAATAATCGCGATTATTGG 20 12232.2 
2. ATTATTAATAAT 12 7285 
3. AATATATATATT 12 7285 
4. AAATATATTT 10 6050.2 
5. CGAATTAATTCG 12 7289 
6. ATTAATTAAT 10 6050.2 
Molecular weight is given in terms of DNA duplex. 
The complexes formation was evaluated first by EMSA electrophoresis in order to 
determine the ability of the protein to form complexes with DNA following the 
protocol described in section 2.2.3. DNA-protein samples containing 3% glycerol in 
0.3x TBE were incubated for 1 h at 4°C to allow the complex formation. The EMSA gel 
was run around for 1 h after a 30 min pre-run, and stained with SYBR® Gold 
(Invitrogen™) for 20 min. Figure 3-13 shows the EMSA gels performed with 
HMGA1a(∆50-91) protein. For these assays, 1 µM oligonucleotide was incubated with 
increasing concentrations of protein (from 0.25 to 7 µM). Although a different amount 
of protein may be needed in each case, the formation of complex with all the tested 
oligonucleotides was confirmed.  
Crystallography assays were performed varying a series of parameters as DNA/protein 
ratio, buffer, salt, pH and MPD concentration. Hampton Natrix HR2-116 (Scott et al., 





Figure 3-13. EMSA assays of HMGA1a(∆50-91) in complex with AT-r ich 
ol igonucleotides: (1) d[CCAATAATCGCGATTATTGG]2,  (2) d[ATTATTAATAAT]2,  (3) 
d[AATATATATATT]2 and (4) d[AAATATATTT]2.   
3 .2.3  DNA-HMGA1a(∆50-91) Protein Binding Analysis 
by SPR 
AT-rich sites of DNA are typically recognized by the HMGA proteins through their AT-
hook binding domains. EMSA assays were a useful procedure for analyzing the binding 
of the protein HMGA1a(∆50-91) with DNA. However, in order to investigate 
quantitatively the affinity of this protein with AT-rich DNA, measurements of SPR 
using Biacore® technology were performed. Therefore, HMGA1a(∆50-91) protein 
binding affinity and kinetics were analyzed following the protocol described in section 
2.8. The DNA hairpin 5’-biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT-3’ 
[AATAAT_ATTATT] (see Table 2-13 and Figure 2-14) was immobilized in the SA sensor 
chip. Multiple sensorgrams for direct protein binding were collected, keeping the 
hairpin concentration constant at ~400 RU and varying the HMGA1a(∆50-91) protein 
concentration from 10 nM to 10 µM. The best sensorgrams were obtained in HEPES, 
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instead of MES or Phosphate buffer. Figure 3-14a shows the SPR sensorgrams of the 
HMGA1a(∆50-91) binding to DNA hairpin [AATAAT_ATTATT], obtained with running 
buffer HEPES 1 containing 10 mM HEPES, 3 mM EDTA, 200 mM NaCl, and surfactant 
P-20 at 0.05% (v/v) pH 7.4) at a flow rate of 50 µL/min for a period of 60 s followed 
by a dissociation period of 120 s. Results were fitted to a two-site binding model 
according to the Equation 2-13 in order to determine the binding affinity (Figure 
3-14b). 
 
Figure 3-14. (a)  SPR sensorgrams of HMGA1a (10 nM to 10 µM) binding to dsDNA 
biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT in HEPES 1  at 25°C. (b)  
Binding curve for interaction of HMGA1a(∆50-91) with target DNA and f itt ing curve 
for a two-site aff inity model .  Graphs were created with Prism 5.0  (GraphPad  
Software) .  
During the experiments, HMGA1a(∆50-91) protein showed a high affinity binding site 
to the AT sequences of the [AATAAT_ATTATT] oligonucleotide and a weaker secondary 
binding site that most likely accounts for nonspecific binding to the hairpin loop (K2/K1 
= 32). The KD values are K1= 0.35 × 10-6 M and K2= 11.3 × 10-6 M. 
3 .3  Interaction of HMGB1 Protein with AT-r ich DNA 
The analysis of the interactions of HMGB1 box B and box AB proteins with a series of 
AT-rich DNA sequences was studied by X-ray crystallography assisted with EMSA 
assays, and by SPR experiments. For this purpose, the most pure samples of the 
HMGB1 proteins (see section 3.1.2) were used, which were sample M1 of HMGB1a Box 




3 .3.1  DNA-HMGB1 Crystal lography Assays 
The main goal during this phase was to obtain high quality ordered crystals of DNA-
HMGB1 protein complexes for structure resolution by X-ray crystallography. For this, 
multiple crystallization conditions were screened (see Appendix E). The 
oligonucleotides used with HMGB1 box B and HMGB1 box AB proteins are listed in 
Table 3-4. See Table 2-11 for more details. 
Table 3-4. Ol igonucleotide sequences used for crystal lographic assays with HMGB1 
proteins .  









  1. CCAATAATCGCGATTATTGG 20 12232.2 ✓ ✓ 
  6. ATTAATTAAT 10 6050.2 ✓  
  7. AATAAATTTATT 12 7285 ✓  
  8. ATATGCATAT  10 6052.2 ✓  
  9. ATATCGATAT  10 6052.2 ✓ ✓ 
10. AATAATCGCGATTATT 16 9758.6 ✓ ✓ 
11. AATTTAAATT 10 6050.2  ✓ 
12. ATTTATAAAT 10 6050.2 ✓  
13. GGGAAATTTCCC 12 7290.8  ✓ 
14. AATAAATTTATTT 13 7902.4  ✓ 
Molecular weight is given in terms of DNA duplex. ✓  Oligonucleotide studied with the HMGB1 
fragment indicated.  
The formation of complexes with different oligonucleotide sequence was first 
evaluated by EMSA electrophoresis (see section 2.2.3). For these assays, a set of 
samples containing increasing concentrations of protein from 1 to 6 µM were 
incubated for 1 h at 4°C with 1 µM oligonucleotide (Figure 3-15).  
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Figure 3-15. EMSA assays of a HMGB1 protein fragments in complex with AT-r ich 
ol igonucleotides:  (1) d[CCAATAATCGCGATTATTGG]2,  (10) d[AATAATCGCGATTATT]2 and 
(14) d[AATAAATTTATTT]2.  HMGB1 box A, residues 7-80; box B,  residues 93-165; and 
box AB residues 1-165 of HMGB1 protein .  HMGB1a box A sample was provided by a 
member of MACROM research group.  
From the EMSA assays, the formation of complex was confirmed in each case. HMGB1 
box AB was able to start complex formation since 1:1 molar ratios, whereas HMGB1 
box B (and box A) complexes were not as stable as with the HMGB1 box AB, leading to 
association/dissociation of the complex, which resulted in fuzzy extended bands (see 
Figure 3-15).  
Initial crystallography assays were performed using Hampton Natrix HR2-116 numbers 
15 and 43, both of them containing MgCl2 (see Appendix D). Due to the lack of success, 
new crystallization conditions were tested by changing the composition of the salts 
and precipitant. Thus, CaCl2, NH4 acetate and Mg acetate, and PEG 3350 as precipitant 
were also tested. Detailed information of crystallization conditions used for DNA-





Crystallization assays with oligonucleotide (7) d[AATAAATTTATT]2 in complex with 
HMGB1 box B were performed by the vapor diffusion technique using the sitting-drop 
set-up into 48-well crystallization plates. Crystals appeared after a few days in wells 
containing buffer T6 (10 mM MgCl2, 1 mM DTT, 5% MPD, 25 mM Tris-HCl, pH 7.5) and 
C6 (10 mM MgCl2, 1 mM DTT, 5% MPD, 25 mM sodium cacodylate buffer pH 6). 
Therefore, it was decided that a new screening has to be done varying the MgCl2 
concentration. Crystals were obtained in droplets containing buffers C9 (12.5 mM 
MgCl2, 1 mM DTT, 5% MPD, 25 mM sodium cacodylate buffer pH 6), T9 (12.5 mM 
MgCl2, 1 mM DTT, 5% MPD, 25 mM Tris-HCl, pH 7.5) and C10 (7.5 mM MgCl2, 1 mM 
DTT, 5% MPD, 25 mM sodium cacodylate buffer pH 6).  
Using those buffers, crystallization assays were performed into individual capsules as 
an attempt to obtain better-sized crystals in a 4 µL droplet equilibrated against 800 µL 
reservoir containing initially 30% MPD. Precipitant concentration was gradually 
increased until 45% MPD. Eleven crystals were fished from droplets containing buffers 
T6 and T9 and diffracted as described in section 2.6.3. Figure 3-16 and Figure 3-17 
show the images and diffraction patterns of the best crystallization conditions found 
in droplets 4C4 and IG5, respectively.  
The diffraction patterns of crystal 4C4-2 (Figure 3-16) indicate a very large and 
complex unit cell, as shown by the rows of closely spaced spots. It is expected an 
arrangement of the oligonucleotides in two directions due to the cross lines formed in 
the patterns. Unfortunately the spots are diffused and the patterns could not be 
properly indexed.  
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Figure 3-16. Crystal  4C4-2 image and diffraction pattern of ol igonucleotide (7) 
d[AATAAATTTATT]2 with HMGB1 box B. Crystal l ization condit ions are detai led below 
the image. 
The diffraction patterns of the crystal IG5-6 (Figure 3-17) show fiber-like diffraction 
mixed with define spots at low resolution. In this case, the duplexes show a parallel 
orientation, as demonstrated by the parallel layer-line streaks (perpendicular to the 
duplexes axis). The low resolution indicates that the parallel duplexes are randomly 
displaced in the vertical direction. 
 
Figure 3-17. Image of the crystal  IG5-6 of ol igonucleotide (7) d[AATAAATTTATT]2 
with HMGB1 box B ( left) .  Its  diffraction pattern corresponds to a mixture of f iber-
l ike diffraction and defined spots at low resolution. Crystal l ization condit ions are 





The oligonucleotide (1) d[CCAATAATCGCGATTATTGG]2 was widely studied during this 
work. Different crystallization conditions were tested for oligonucleotide 1-HMGB1 
box B (see Appendix E). Crystallization screening was performed in individual capsules 
using magnesium as divalent ion and MPD as precipitant.  
The best crystallization conditions found were 0.4 mM DNA duplex, 0.8 mM HMGB1 
box B, buffer C9 (25 mM sodium cacodylate buffer pH 6, 25 mM MgCl2 and 5% MPD), 
and equilibrated against a 43% MPD reservoir. Figure 3-18 shows an image of the 
crystal NC5-1 and its diffraction patterns. 
 
Figure 3-18. Image of crystal  NC5-1 and diffraction pattern of ol igonucleotide (1) 
d[CCAATAATCGCGATTATTGG]2 with HMGB1 box B. Crystal l ization condit ions and an 
image of the crystal  in the loop taken at the moment of the diffraction are also 
shown. Arrows indicate the crystal  diffracted.  The patterns on the left show two 
orientations of diffraction that are at ∼90° to each other .  
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The diffraction patterns of the crystal NC5-1 show well-defined spots of two 
orientations of stacked columns of DNA helices that are at ∼90° to each other (see 
Figure 3-18 right panel). 
The diffraction patterns of the crystal NC5-1 was indexed using the program iMOSFLM 
(Battye et al., 2011) as orthorhombic with cell parameters a = 29.94 Å, b = 89.65 Å, c 
= 109.1 Å, α = β = γ = 90° in space group P22121. The cutoff resolution limit was set 
to 2.68 Å. The data were scaled using the program Scala (Evans, 2006). Rmerge and Rmeas 
values were 0.049 and 0.054. The search DNA model for molecular replacement (MR) 
was constructed using the program Turbo-Frodo (Roussel et al., 1998), taking the full 
length of the oligonucleotide on a first attempt. Due to the difficulties that finding the 
20 bp oligonucleotide presented, fragments of 6 and 10 bp, as DNA models, were 
created. Despite all the DNA models used for MR, it was not possible to find the 
molecule. Therefore, MR with numerous PDB structures was used to find the HMGB1 
box B protein including HMGD protein (PDB ID: 3NM9), TFAM protein (PDB ID: 4NNU 
and PDB ID: 3TQ6), transcription factor SOX-9 (PDB ID: 4EUW), among others. 
MR in this crystal structure faced a particular difficulty. When DNA models were 
replaced, they adopted an L-shape similar to the HMGB1 box B structure and the 
electron density map partially followed those replacements. Nevertheless, a good 
correlation within the electron density map and the oligonucleotide could not be 
obtained. On the other hand, the MR with HMG protein structure models positioned 
the HMG-box in the same place where the oligonucleotide was set when DNA models 
were used for MR. This probably happened due to the oligonucleotide configuration in 
the crystal. The HMGB1 box B protein, by its ability to recognize the DNA minor groove 
and provoke a dramatic distortion on it, may have bent 90° the linear DNA 
oligonucleotides. That whould explain the two orientations of diffraction obtained in 






In order to test the protein content in the obtained crystals, they were analyzed by 
SDS-PAGE once X-ray diffraction had been performed (see section 2.2.1).  
After diffraction, crystals were re-stored in liquid nitrogen to avoid degradation until 
their analysis by electrophoresis. Once the SDS-PAGE was ready to be performed, each 
crystal was dissolved in 4.5 µL H2O milliQ® (cold). 1.5 µL of 4x SDS sample buffer was 
added to the sample. Samples were boiled for 6 min and loaded into the SDS gel. Gel 
was run for 1 h at constant voltage of 100 V and stained with SilverQuest™ Silver 
Staining Kit (Invitrogen™) for 20 min. Figure 3-19 show the SDS-PAGE of crystals NC5-
1, 4C4-1, 4C4-2, 1G5-6 and 1G5-17. 
 
Figure 3-19. SDS-PAGE of crystals of HMGB1 box B with DNA. Sample of HMGB1 
box B were used as control (50 and 100 ng) .  
Intense bands corresponding to the crystals NC5-1, 4C4-1 and 4C4-2 clearly show the 
presence of the HMGB1 box B. On the other hand, crystals 1G5-6 and -17 show also 
the presence of the HMGB1 box B but with a poorer protein content.  
3 .3.2  DNA-HMGB1 Protein Binding Analysis 
In contrast to the HMGA proteins, HMGB1 binds more non-specifically to DNA. 
Measurements of SPR using a Biacore® X-100 apparatus were also performed for the 
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protein HMGB box AB to analyze the protein binding affinity and kinetics to an AT-rich 
DNA following the protocol described in section 2.8. 
To study the binding interactions between HMGB1 and the DNA hairpin 
[AATAAT_ATTATT] (see Table 2-13), a dilution series of HMGB1 box AB samples was 
prepared (from 10 nM to 10 µM) by dilution into HEPES 1 buffer. Multiple sensorgrams 
were collected, keeping the DNA concentration constant at ~400 RU, and injecting the 
series of protein samples over the immobilized DNA at a flow rate of 50 µL/min for a 
period of 60 s followed by a dissociation period of 120 s (Figure 3-20a). HEPES 1 was 
used as the running buffer. A solution containing 200 mM NaCl/10 mM NaOH was 
used to regenerate the free DNA surface after each injection using a flow rate of 10 
µL/min during 30 s. The binding affinity was determined by fitting the results to a two-
site binding model according to Equation 2-13 (Figure 3-20b). 
 
Figure 3-20. (a)  SPR sensorgrams of HMGB1 box AB (10 nM to 10 µM) binding to 
dsDNA biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT hairpin in HEPES 1  
at 25°C and (b)  Binding curve for interaction of HMGB1 box AB with target DNA 
and f itt ing curve for a two-site aff inity model .  Graphs were created with Prism 5.0  
(GraphPad  Software) .  
Similar to HMGA1a(∆50-91), HMGB1 box AB protein showed two KD values: a high 
affinity binding site to the AT sequences of the [AATAAT_ATTATT] oligonucleotide (K1= 
0.33 × 10-6 M), and a weaker secondary binding site (K2= 5.91 × 10-6 M; K2/K1 = 18) 
that most likely accounts for nonspecific binding to the hairpin loop. The higher 
affinity of HMGB1, compared to the HMGA1a(∆50-91) (K2= 11.3 × 10-6 M), to this 




non-specifically to DNA compared to the higher preference of HMGA proteins to bind 
AT-rich DNA.  
3 .4  GENERAL DISCUSSION 
Several goals were achieved in this chapter regarding the obtainment of the HMG 
proteins of interest and their characterization and analysis.  
First, the human HMGA1a(∆50-91) protein containing two AT-hook DNA binding 
domains has been expressed with the recombinant DNA technology in the bacterium E. 
coli (Rosetta (DE3) pLysS strain) using a pET vector. Pure protein samples were 
obtained by cation-exchange chromatograpy followed by size-exclusion 
chromatography. On the other hand, two fractions of the HMGB1 protein [the box B, 
HMGB1(∆93-165) and the two tandem boxes AB, HMGB1(∆1-165)] were also 
successfully expressed as GST-fusion proteins in the same E. coli strain transformed 
with a plasmid pGEX-2T. HMGB1 proteins were purified by a multi-stage purification 
strategy, which involved affinity chromatography, cation-exchange chromatography 
and size-exclusion chromatography. 
Using the high-purity samples, an analysis of DNA supercoiling induced by the 
HMGA1a(∆50-91) protein was performed. The verification of the functionality of the 
recombinant protein was achieved by demonstrating the capacity of this HMGA1a 
fragment to induce supercoiling in a DNA plasmid containing two alternating AT 
inserts. In addition, the activity of the protein was compared with a fragment 
containing the three AT-hook domains, HMGA1a(∆1-90), finding a similar behavior for 
both proteins. Then, it can be assumed that two-AT-hook DNA motifs could act 
comparably to the three-AT-hook fragment in terms of inducing changes in the DNA 
configuration.  
HMGA1a(∆50-91) and HMGB1 box AB showed high affinity binding to the AT region of 
the 39 bases (GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT) hairpin used for the 
SPR assays. They also presented a weaker secondary binding site due to nonspecific 
binding to the hairpin loop, weaker for the HMGA1a than for the HMGB1. This could 
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be probably due to the HMGA higher specificity for AT sites compared to the HMGB 
proteins.  
In the DNA-protein interaction analysis by EMSA, HMGA1a(∆50-91) showed good 
binding at 1:1 and 1:2 DNA/protein ratios with the oligonucleotides d[AAATATATTT]2, 
d[CCAATAATCGCGATTATTGG]2, d[ATTATTAATAAT]2 and d[AATATATATATT]2. On the other 
hand, DNA-HMGB1 box AB complex formation was achieved with 
d[CCAATAATCGCGATTATTGG]2, d[AATAATCGCGATTATT]2 and d[AATAAATTTATTT]2. DNA 
complexes with HMGB1 box B displayed fuzzy extended bands due probably to the 
formation of an instable complex. A similar behavior has been described for the 
HMGB1 box A (Sánchez-Giraldo et al., 2015). Nevertheless, DNA-HMGB1 box AB 
complexes were observed as a neat band at 1:1 molar ratios. 
Although the structure of a single AT-hook in complex with DNA has been previously 
solved for the first time in our reaserch group, all the attempts to crystalize the two-
AT-hook domains protein HMGA1a(∆50-91) have not succeed. HMGA1a is an 
intrinsically disordered protein and even though the crystallographic assays were 
performed in complex with DNA, no crystals with any of the oligonucleotides analyzed 
were obtained. However, the crystallization of the HMGB1 with several DNA sequences 
has been achieved.  
Crystals of macromolecular complexes containing HMGB1 box B-d[AATAAATTTATT]2 
and HMGB1 box B-d[CCAATAATCGCGATTATTGG]2 were diffracted at ALBA Syncrothron. 
Crystals containing the oligonucleotide d[AATAAATTTATT]2 showed fiber-like diffraction 
patterns at low resolution. On the other hand, a complex with the HMGB1 box B and 
d[CCAATAATCGCGATTATTGG]2 presented a well-ordered diffraction pattern at 2.68 Å 
resolution. Data collection were indexed in orthorhombic P22121 space group with cell 
parameters a = 29.94 Å, b = 89.65 Å, c = 109.1 Å, α = β = γ = 90°. Well-defined spots 
of two orientations of diffraction ~90° to each other were shown in the diffraction 
patterns. Consequently, it is expected that the oligonucleotides have packed in a 




provoked a ~90° kink on the DNA, as previously reported (Ngo et al., 2014; Ngo et al., 
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4 .1  Interaction of Minor Groove Binding Drugs with 
AT-Rich DNA 
The high affinity and selectively recognition of the HMG proteins to AT-rich binding 
sites offers an excellent opportunity for rational design of AT minor grove binding 
drugs (MGBD) to contest important human diseases. For that reason, in this work the 
binding and interactions of eleven bis(2-aminoimidazoline) compounds (listed in Table 
2-9) with AT-rich DNA have been analyzed. 
4 .2  DNA-MGBD Binding Analysis by SPR 
Surface Plasmon Resonance (SPR) experiments were carried out to study the direct 
binding affinity of the bis(2-aminoimidazoline) compounds to dsDNA hairpins 
containing GGAATAATCGCGATTATTCC [AATAAT_ATTATT], CGAATTCG [AATT], CATATATAT 
[(AT)4], and CGCGCGCG [(CG)4] sequences (Table 2-13).  
As an initial analysis, a binding screening of the eleven compounds to the DNA hairpin 
[AATAAT_ATTATT] (see Table 2-13) were evaluated. The compound CD27 (Figure 1-18) 
was also added in this assay. Samples with a fix concentration of 24 µM of each 
compound in HEPES 1 were prepared and injected over the immobilized DNA surfaces 
(~400 RU) followed by running buffer injection, which was also HEPES 1. The flow rate 
used for these experiments was 18 µL/min for an association period of 300 s followed 
by a dissociation period of 300 s. Subsequently, a solution containing 200 mM NaCl/10 
mM NaOH was used to regenerate the free DNA surface after each injection using a 
flow rate of 10 µL/min during 60 s.  
Figure 4-1 shows that the FR60 and derivatives (Ref 1-10 in Table 2-9) as well as the 
drug CD27 exhibited, in general, an affinity for the DNA hairpin [AATAAT_ATTATT] 
similar to that showed by the lead drug FR60. The compound JNI18 was the FR60 
derivative that showed the higher affinity for the DNA hairpin, presenting a slightly 




to the DNA, probably because of the fluorine atom position, which permits the 
formation of an H-bond with the central [–NH] group of the drug and thus the DNA-
drug binding could be obstructed. Interestingly, a unique pattern of interaction was 
observed between DNA-CDIV32. Compound CDIV32 (see Table 2-9) presented higher 
affinity compared to the rest of compounds, and a particularly slow rate of dissociation. 
 
Figure 4-1. Binding screening by SPR of bis(2-aminoimidazoline) compounds to 
biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT hairpin in HEPES 1  at 25°C.  
Based on those results, next experiments were performed with the there compounds 
that showed the most interesting binding features: FR60, JNI18 and CDIV32.  
Direct binding affinity assays of the compounds FR60, JNI18 and CDIV32 were 
performed as described section 2.8. Drug samples were prepared at a series of 
concentrations (from 0.25 nM to 57.6 µM) by dilution into HEPES 1 buffer. These 
experiments were performed using the same conditions as in the previous binding 
screening. Figure 4-2 shows the sensorgrams for FR60 binding to hairpin 
[AATAAT_ATTATT] and the binding curve adjusted to a two-site binding model. 
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Figure 4-2. (a)  SPR sensorgrams for binding of drug FR60 to dsDNA biotin-
GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT in HEPES 1  at 25°C, using 
increasing concentrations of the l igand in the range of 0.25-57.6 µM. (b)  Binding 
curve for interaction of FR60 with target DNA and f itt ing curve for a two-site 
aff inity model .  
SPR binding affinity for the drugs FR60 and CDIV32 binding to the DNA hairpin [AATT], 
[(AT)4] and [(CG)4] are given by Ríos Martínez et al. (2015a). Figure 4-3 and Figure 4-4 
show the binding affinity of drug CDIV32 to DNA hairpin [AATAAT_ATTATT] and drug 
JNI18 to the four DNA hairpin sequences studied, respectively. Binding curves for 
interactions of the drugs with DNA [(CG)4] were adjusted to one-site binding (K2 = 0). 
The summary of the binding constants of all compounds is listed in Table 4-1. 
 
Figure 4-3. (a)  SPR sensorgrams for binding of drug CDIV32 to dsDNA  biotin-
GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT in HEPES 1  at 25°C, using 
increasing concentrations of the l igand in the range of 0.25-57.6 µM. (b)  Binding 
curve for interaction of CDIV32 with target DNA and f itt ing curve for a two-site 






Figure 4-4. SPR sensorgrams and binding curves for interaction of drug JNI18 with 
hairpins (a)  biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT; (b)  biotin-  
CGAATTCGTCTCCGAATTCG; (c)  biotin-CATATATATCCCCATATATATG; and (d)  biotin-
CGCGCGCGTTTTCGCGCGCG in HEPES 1  at 25°C, using increasing concentrations of 
the l igand in the range of 0.25-57.6 µM. For the AT-r ich sequences,  the curve was 
adjusted to a two-site aff inity model and for the CG-r ich sequence to a one-site 
binding model .  
Compounds FR60 and JNI18 bound selectively to AT-containing DNA versus CG-
containing DNA (from >10-fold to >60-fold). Binding curves of both compounds were 
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adjusted to a two-sites affinity model where primary binding constants were in the 
submicromolar range with slight selectivity toward [AATT] versus [(AT)4] (1.8- to 2.5-
fold) or [AATAAT_ATTATT] oligonucleotides (1.6- to 3-fold). With the DNA hairpin 
[AATAAT_ATTATT], compounds FR60 and JNI18 displayed submicromolar primary 
binding constants (high affinity binding site) and a 133- and 48-times weaker 
secondary binding constant, respectively.  
Moreover, compound CDIV32 bound more selectively to AT-containing DNA versus CG-
containing DNA than the other two compounds (~120-fold). Primary binding constants 
were in the submicromolar range and for [(AT)4] in the micromolar range. CDIV32 
showed slight selectivity toward [AATT] versus [(AT)4] or [AATAAT_ATTATT] similar to 
the compounds FR60 and JNI18 (3.1-fold and 1.6-fold, repectively). Compound CDIV32 
displayed a high affinity binding site to the AT sequences and 22-, 185 and -46 times 
weaker secondary binding with [AATAAT_ATTATT], [AATT] and [(AT)4], respectively. 
In these experiments, secondary binding generally accounts for non-specific binding 
interaction with the DNA hairpin loop as previously reported (Ríos Martínez et al., 
2015c). 
Table 4-1. DNA binding constants determined by SPR for dsDNA containing 
AATAAT_ATTATT,  AATT,  (AT)4,  and (CG)4 sequences.
 
Compound KD (×10











K1 = 0.56 




K2 = 207 
K1 = 0.307
b 




K1 = 0.43 
K2 = 20.8 
K1 = 0.262 
K2 = 230 
K1 = 0.65 
K2 = 39 
K = 6.85c 
CDIV32 
K1 = 0.92 
K2 = 20.2 
K1 = 0.568
b 
K2 = 105 
K1 = 1.79
b 
K2 = 83.4  
K = 66.7b,c 
 
‡dsDNA hairpins used in the study: 5’-biotin-GGGAATAATCGCGATTATTCCCCAATAATCGCGATTATT 
[AATAAT_ATTATT], 5’-biotin-CGAATTCGTCTCCGAATTCG-3’ [AATT], 5’-biotin-
CATATATATCCCCATATATATG-3’ [(AT)4], and 5’-biotin-CGCGCGCGTTTTCGCGCGCG-3’ [(CG)4].
 aBinding 
constants for fitting to a two-site binding model. K1 corresponds to the primary binding constant for 
fitting to a two-site binding model. The secondary binding constant (K2) corresponds to nonspecific 
binding to the hairpin loop (Nguyen & Wilson, 2009). bReference (Ríos Martínez et al., 2015a). 




4 .3  DNA Binding Competition Assay: HMG Proteins 
vs Bis(2-aminoimidazoline) Derivatives 
Competition assays were performed to test the capacity of compound JNI18 to inhibit 
the formation of HMGA1a–DNA and HMGB1–DNA complexes (Figure 4-5). Solutions of 
fixed concentration of HMGA1a(Δ50–91) or HMGB1 box AB proteins (2 µM) in the 
presence of increasing concentrations of drug JNI18 were injected over the DNA 
immobilized surface. The sensorgrams showed a clear decrease in RU signal when 
increasing the concentration of JNI18 indicating a dose-dependent inhibition of 
HMGA1a and HMGB1 binding to DNA (Figure 4-5).  
 
Figure 4-5. (a)  SPR competit ion sensorgrams showing the inhibit ion of a f ixed 
concentration (2 µM) of HMGA1a1a(∆50-91) (Top left panel)  and HMGB1 box AB 
(top r ight panel)  binding to dsDNA containing [AATAAT_ATTATT] ol igonucleotide in 
the presence of increasing concentration of JNI18. Drug concentration range from 
0.05 to 200 µM (for HMGA1a[∆50-91]) and 0.05 to 400 µM (for HMGB1).  (b)  
Inhibit ion curves and IC50 values for inhibit ion of binding of HMGA1a(∆50-91) 
( lower left panel)  and HMGB1 box AB ( lower r ight panel)  to dsDNA by 
compound JNI18. 
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IC50 values, determined by fitting the inhibition data with a model according to a 
competition system with 1:1 binding stoichiometry for HMGA1a(∆50-91) and HMGB1 
box AB and two-site binding for competitor (Miao et al., 2008) were in the low 
micromolar range (6.0 and 3.4 µM for HMGA1a and HMGB1, respectively). Thus, it can 
be concluded that drug JNI18 competes with HMGA1a and HMGB1 binding to DNA 
and it is able to displace the proteins from its binding sites. 
4 .4  DNA-Bis(2-aminoimidazoline) Crystal lography 
Assays 
Crystallography assays were performed with AT-rich DNA and the bis(2-
aminoimidazoline) compounds studied following the protocol described in section 2.5 
in order to obtain X-ray quality crystals and solve the 3D structure of the complex. For 
this purpose, multiple crystallization conditions were screened.  
For the crystallization of drugs FR60, JNI18 and CDIV32, 6-12 base pair all-AT or AT-
rich oligonucleotides used are listed in Table 4-2. 
Table 4-2. Ol igonucleotide sequences used for crystal lographic assays with bis(2-
aminoimidazoline) compounds.  
DNA sequence Length [bp] MW [mol ·g -1]  
  2. ATTATTAATAAT 12 7285 
  4. AAATATATTT 10 6050.2 
  6. ATTAATTAAT 10 6050.2 
11. AATTTAAATT 10 6050.2 
12. ATTTATAAAT 10 6050.2 
15. AAATTT  6 3580.6 
16. AATAATTATT 10 6050.2 
17. CATATATATG 10 6050.2 
18. AATTATAATT 10 6050.2 
19. ATAATATTAT 10 6050.2 
Molecular weight is given in terms of DNA duplex. 
DNA-drug crystallography assays were performed in individual capsules by vapor 




the salts MgCl2, Mg(CH3COO)2, MnCl2 and NH4CH3COO in sodium cacodylate pH 6 
adding spermine to get a final concentration 2:1 DNA/spermine molar ratio. In all cases, 
MPD was used as precipitant (18-20% MPD initial concentration). Droplets of 3 to 4 
µL size were set up. The Hampton Natrix HR2-116 number 7 and 42 were also 
employed, both of them containing MgCl2 (see Appendix D). Detailed information on 
the crystallization conditions used for DNA-drugs complexes is found in Appendix E. 
4 .4.1  Structure of CDIV32 – d[AAATTT]2 
Extensive crystallization assays were performed with complexes of DNA-CDIV32, using 
several oligonucleotide sequences. However, special attention was given to the 6 bp 
DNA (15) d[AAATTT]2 during this research work due to its capacity to form crystals with 
the compounds studied. Crystallization screening was performed in individual capsules 
using different crystallization conditions as described in Appendix E. Several crystals 
appeared after 16 weeks in different droplets containing 1:2 and 1:4 DNA/drug molar 
ratios using the buffers D1 and D3 (see Appendix D) (Figure 4-6).  
 
Figure 4-6. Crystals of d[AAATTT]2 with drug CDIV32 with different morphologies .  
Numerous crystals were fished and diffracted. The best crystallization condition was 
obtained in the presence of Mn2+ (25 mM sodium cacodylate buffer pH 6, 0.2 mM 
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oligonucleotide, 0.8 mM drug CDIV32, 0.1 mM spermine) (buffer D1, Appendix D) 
against 55% MPD reservoir (Figure 4-7).  
Diffraction of the best crystal (DB.5-4-1) (see Figure 4-7) was indexed and integrated 
using the program iMOSFLM as orthorhombic crystalline system with a space group 
C2221. The parameters of the unit cell are a = 62.79, b = 451.08 and c = 80.93; α = β 
= γ = 90°. The resolution range was 69.27-3.10 Å.  
 
Figure 4-7. Image of crystal  DB.5-4-1 and diffraction pattern of ol igonucleotide (15) 
d[AAATTT]2 with drug CDIV32. Crystal l ization condit ions and an image of the crystal  
in the loop taken at the moment of the diffraction are also shown. Arrows indicate 
the crystal  diffracted.  
The diffraction patterns of this crystal show well-defined spots of two orientations of 
diffraction that are at ∼90° to each other. The best approximation of a solution was 
obtained by the construction of a theoretical straight column with 16 oligonucleotides; 
the model of B-form AAATTT dsDNA was generated with Turbo-Frodo (Roussel et al., 
1998) with base-pair staking of 3.25 Å, a uniform twist of 36° and Watson–Crick base-
pair pairing. The column of the stacked oligonucleotides forming a pseudo-continuous 
helix was created with Pymol (Schrödinger, LLC, 2015), considering that the virtual 
step T-A, in the end-to-end interaction of stacked oligonucleotides, had a negative 
rotational setting angle ωT (i.e. helical twist) of about -25° for WC conformation. The 
distance between oligonucleotides was adjusted to 3.446 Å by measuring the total 




was used for molecular replacement of the partial solution. The refinement of this 
partial solution (3.10 Å, Rwork/Rfree 0.3817/0.4584, using REFMAC5 (Murshudov et al., 
2011) shows the DNA molecules are organized in a crossed column configuration of 
sixteen stacked oligonucleotides at about 90° (Figure 4-8).  
The presence of the CDIV32 drug has modulated this structure of oligonucleotides. In 
spite of the low resolution, solving this structure could be of interest to determine if 
the drug may act as a cross-linking agent, forming links between neighbour DNA 
columns and consequently, causing the crossed column organization found, as reported 
for alternative DNA-drug complexes (Moreno et al., 2010; Acosta-Reyes et al., 2014). 
 
Figure 4-8. View of the packing of the model ,  where the crossed columns 
organization and the asymmetric unit are vis ible .  
The analysis of the Patterson function by Phenix.Xtriange (Zwart et al., 2005) reveals a 
significant off-origin peak (0.5, 0.217, 0) corresponding to 40.46% of the origin peak, 
indicating pseudo translational symmetry. This detectable translational NCS hinders 
the full resolution of the structure. 
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Figure 4-9. View of the electron density map at 1σ and difference map at 3σ of the 
stacked ol igonucleotides d[AAATTT]2 in crossed columns at 3 .10 Å resolution. The 
virtual step A-T between ol igonucleotides has an hel ical  twist of about -25°. 
4 .4.2  Structure of FR60 – d[AAATTT]2 
The lead compound FR60 was widely studied by crystallography assays with (15) 
d[AAATTT]2 oligonucleotide. The crystallization of this oligonucleotide was tested in the 
presence of various divalent ions (Appendix E). The best crystallization conditions were 
obtained with the divalent ion Mg2+ (D2 buffer: 25 mM sodium cacodylate buffer pH 6, 
0.2 mM oligonucleotide, 0.4 mM drug CDIV32, 0.1 mM spermine) (see Appendix D) 
against gradually increased concentration of MPD up to 50% in the reservoir. A single 
perfectly defined crystal (F6-1, see Figure 4-10 left panel) in a droplet with those 
conditions appeared after 14 months. 
 
Figure 4-10. Image of crystal  F6-1 and diffraction pattern of ol igonucleotide (15) 





Figure 4-11. View of the different crystal lographic units of the complex.  The black 
lozenge indicates the dyad axes.  Four independent s ingle ol igonucleotides chains 
are shown; two of them (blue-green) form the central  duplex and the other two 
single strands (orange and red) form two different DNA duplexes with their  
symmetrical chain.  Three crystal lographical ly independent drug molecules are 
indicated in different colours .  Drug F (pink) ,  Drugs E (green) and G (blue) .  (b)  
Hydrogen bonds formed by the drugs with the minor-groove atoms of the DNA 
duplexes show similar interactions.  The orientation of the aromatic r ings in the 
central  drug (F ,  pink) differs from to the other two drugs.  Drug E and G have two 
possible inverted posit ions in the groove; for clar ity only one of them is shown. 
Image prepared with PyMOL (http://www.pymol.org) .  
The single-crystal was diffracted and data was collected with a maximum resolution of 
1.2 Å. Diffraction data were integrated using iMOSFLM (Battye et al., 2011) and scaled 
with Aimless Pointless (Evans, 2006) from the CCP4 suite (Winn et al., 2011). The space 
group turned out to be the monoclinic space group I121 with unit cell parameters (a, b, 
c, α, β, γ) 22.33 40.25 72.42 90.0 93.67 90.0. A theoretical B-DNA model was 
constructed using Turbo-Frodo (Roussel et al., 1998), with a base-pair stacking of 
3.286 Å, a uniform twist of 36° and Watson–Crick base-pair pairing. This was a 
starting search model for molecular replacement with MOLREP (Vagin & Teplyakov, 
2010). Due to the lack of success after an extensive search in different monoclinic 
space groups, another theoretical model was generated, formed by half of the 
oligonucleotide and placed it in the correct position by molecular replacement using 
Phaser (McCoy et al., 2007). The missing base pairs of the oligonucleotide were added 
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with Coot (Emsley et al., 2010) following the well-defined electron density map. The 
replacement was next refined with REFMAC5 (Murshudov et al., 2011) and real-space 
refinement was performed with Coot.  
One duplex and two single strands of DNA in the asymmetric unit were placed. The 
coordinates and stereochemical restraint dictionary of the drug FR60 molecule were 
generated with Phenix (Adams et al., 2010), and one drug per duplex was placed in the 
minor groove of the DNA structure using Coot following the well-defined electron 
density map.  
 
Figure 4-12. (a)  View of the electron density map at 1σ of the stacked 
ol igonucleotides d[AAATTT]2 at 1 ,25 Å resolution.  (b)  OMIT 2Fo–Fc e lectron-density 
map (1  σ level)  of the three drugs in the complex.  Drug F is  at the top, fol lowed by 
E and G below. The bottom two frames show a superposit ion of the three drugs in 
two perpendicular views. Image prepared with the program CCP4mg  (McNicholas et 
al .  2011).  
The asymmetric unit in the final model contained three FR60 molecules (two of them 
show half-occupancy), plus one DNA duplex and two DNA single strands. Three 
complete duplexes and three drug molecules are shown in Figure 4-11 (electronic map 
is displayed in Figure 4-12a). Several cycles of maximum-likelihood isotropic restrained 
refinement were performed with REFMAC5 to 1.247 Å resolution. Finally, a last round 




Rwork/Rfree 0.1205/0.1668 in a resolution range of 36.137-1.247 Å, with a completeness 
of 92.54%. Four magnesium ions were detected. A summary of crystal data and 
refinement statistics is given in Table 4-3.  
Table 4-3. Data col lection and refinement statist ics of the crystal F6-1. 
Data col lection 
Beamline BL13-XALOC, ALBA 
Wavelength 0.998 
Resolution range (Å) 36.14  - 1.25 (1.279  - 1.247) 
Space group I 1 2 1 
Unit cell parameters (Å, °) 
a =22.33, b = 40.25, c =72.42, 
α= 90.00 β = 93.67 γ = 90.00 
Total reflections 245821 (22828) 
Unique reflections 16801 (1594) 
Multiplicity 14.7 (14.2) 
Completeness (%) 92.54 (90.67) 
Mean I/sigma(I) 14.1 (5.5) 
Wilson B-factor 9.90 
R-merge † 0.069 (0.227) 
Refinement statist ics 
Reflections used in refinement 15741 (1122) 
Reflections used for R-free 850 (89) 
R-work ‡ 0.1205 (0.141) 
R-free § 0.1668 (0.200) 
Number of non-hydrogen atoms 730 
DNA 480 





Average B-factor, all atoms (Å2) 13.0 
DNA 10.43 
FR60 (PDB name: 6XV) 10.33 
Water 22.38 
PDB-ID 5LIT 
Statistics for the highest-resolution shell are shown in parentheses. † Rmerge was calculated with 
Equation 2-6. ‡ Rwork and Rfree were calculated as R following the Equation 2-9. § Rfree is the R 
factor evaluated for the reflections (5%) used for cross-validation during refinement. 
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Solution coordinates have been deposited in the Protein Data Bank as PDB ID: 5LIT 
(drug FR60 corresponds to 6XV in PDB). The DNA structural parameters were calculated 
using the 3DNA software (Lu & Olson, 2003).  
The asymmetric unit contains one molecule of drug F, one half-occupancy drug E and 
one half-occupancy drug G. All of them interact in the middle of the DNA duplex, the 
central AATT sequence, as found in several other cases (Sheng et al., 2013). The 1σ 2Fo- 
Fc omit map of each drugs (F, E and G from top to bottom) are shown in Figure 4-12b, 
as well as two perpendicular superposition views of the three drugs.  
Drug E and G are practically identical (r.m.s. differences of 0.172 Å). Both drugs form 
three hydrogen bonds with two consecutive thymines from one DNA strand (T4 and T5) 
and another thymine (T5) from its symmetric strand, as shown in Figure 4-13. Values 
are given in Table 4-4. The nitrogen atoms that are not hydrogen bonded to 
oligonucleotides are associated with water molecules, as shown in Figure 4-13.  
 
Figure 4-13. Schematic representation of interactions between F and G or E drugs 
and d[AAATTT]2.  In the crystal ,  drugs G and E may be found in two alternative 
posit ions,  up and down, which are structural ly identical .  Symmetric chains are 
indicated with apostrophe. 
The central drug molecule F has maximum r.m.s. differences of 1.250 and 1.269 Å with 
drug E and G, respectively. Drug F forms also three hydrogen bonds with DNA (adenine 




Table 4-4. Hydrogen bonds formed by drug FR60 in the minor groove of d[AAATTT]2 
and interactions with neighbouring phosphates.  
Atoms involved Drug E Drug F Drug G 
O2(T4)-N3(FR60) 3.32 3.07 3.30 
O2(T5)-N22(FR60) -- 2.9 -- 
N3(A3)-N13(FR60) -- 3.05 -- 
O2(T5)-N25(FR60) 2.94 -- 2.87 
O2(T5’)-N13(FR60) 3.09 -- 3.05 
N10(FR60)-OP1(A3 oligo B’) -- 2.82 -- 
N20(FR60)-OP2(A2 oligo A’) -- 2.79 -- 
N25(FR60)-OP1(A2 oligo A’) -- 2.79 -- 
Values are given in Å. 
Moreover, the drug F molecules are well positioned and centered in their corresponding 
duplex, allowing that its central nitrogen atom (N3) interacts with the oxygen from 
thymine 4 [O2(T4)] either in the 3’-5’ direction (drug F with chain B) or in the 5’-3’ 
direction (drugs G and E) (Figure 4-13). A remarkable feature of this drug is its 
interactions with two phosphates from neighboring DNA molecules, as shown in Figure 
4-14 and Table 4-4.  
 
Figure 4-14. Packing of a layer of A-B duplexes.  An enlarged view of the 
interactions of drug F with the neighbouring phosphates of symmetrical  DNA chains 
is  shown at the left .  Images prepared with the program CCP4mg  (McNicholas et al .  
2011) .  
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The duplexes are stacked and organized as infinite continuous parallel columns, which 
are packed in a pseudo-tetragonal way (Figure 4-15) and stabilized in part by the 
interaction of the central molecule, drug F (pink) with the DNA phosphates of 
neighbouring molecules (Figure 4-14). Drug G (blue) and E (green) do not participate in 
the interactions with neighbour DNA duplexes.  
 
 
Figure 4-15. Views of the pseudo-tetragonal crystal  packing of d[AAATTT]2 and the 
drug FR60. Image prepared with PyMOL (http://www.pymol.org) .  
The three different DNA duplexes in the structure have similar and standard 
conformational parameters. The main difference is found in the twist angles in the 
pseudo base step T-A between the ends of neighbor duplexes in oligonucleotide 
columns, see Figure 4-16. As found in previous studies (Campos et al., 2006), the 
helical twist angle had a negative value (-21°) in the end-to-end interaction of 
stacked oligonucleotides at the virtual step T-A between oligos A-B and D-D’. 
Nevertheless, a peculiar feature of the present structure is the positive twist angle (29°) 
between oligos A-B and C-C’, allowing these two oligonucleotides form a pseudo-
continuous B-DNA helix Figure 4-16. These differences are probably due to packing 






Figure 4-16. End-to-end interaction hel ical  twist (ωT)  angles of a s ingle stacked 
ol igonucleotide column. The virtual step T-A between ol igos A-B and D-D’ form a ωT 
of -21°, while between ol igos A-B and C-C’ ωT.  value is  29°.  Image prepared with 
PyMOL (http://www.pymol.org) .  
4 .5  GENERAL DISCUSSION 
The binding analysis and structural studies of the interaction of the bis(2-
aminoimidazoline) compounds to AT-rich DNA were examined in this chapter. 
Direct DNA binding of all compounds to a 39 bases AT-rich DNA hairpin was confirmed 
by SPR. The bis(2-aminoimidazoline) derivatives CDIV32, JNI18 and FR60 were the 
strongest DNA binders. However, different binding behaviors and affinities were 
observed. Compound CDIV32 showed a distinctive association and dissociation 
patterns.  
The interaction of FR60, JNI18 and CDIV32 directly with four DNA hairpin sequences 
was measured by SPR. Strong affinity was found for the three AT-rich hairpin duplexes 
containing: [AATAAT_ATTATT], [AATT] and [(AT)4]. In contrast, none of the compounds 
bind significantly to the dsDNA containing [(CG)4] sequences as expected for this class 
of minor groove binders. This confirmed that FR60, JNI18 and CDIV32 are strong DNA 
minor groove binders and specifically target AT- over GC-rich sequences.  
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In addition, SPR experiments were performed in order to investigate whether the bis(2-
aminoimidazolinium) compounds could potentially compete with HMG-box proteins 
for binding to DNA. It was found that compound JNI18 was able to displace HMGB1 
box AB and the HMGA1a(∆50-91) proteins from their DNA binding sites. 
By X-ray crystallography, structural analyses of the DNA-drug complex at the 
molecular level were accomplished. The best crystals were found with the all-AT 
oligonucleotide d[AAATTT]2. A crystal containing this DNA sequence with the drug 
CDIV32 was studied thoroughly. The partial structure solution of the drug CDIV32 with 
d[AAATTT]2 at 3.10 Å resolution indicated that DNA columns were constituted by 
sixteen stacked oligonucleotides forming a pseudo-continuous helix with average 
helical twist of the T-A virtual step between stacked oligonucleotides (ωT) of about -
25°. The DNA molecules were conserved a related organization of crossed column. The 
drug CDIV32 could have coordinated this structure of oligonucleotides by the 
formation of cross-links between crossed columns. However, the analysis of the 
Patterson function revealed pseudo translational symmetry, which complicated the 
resolution of the structure. 
On the other hand, the crystal structure of drug FR60 in complex with the DNA 
d[AAATTT]2 at atomic resolution of 1.25 Å was solved (PDB: 5LIT; FR60 PDB name: 
6XV). The space group turned out to be the monoclinic I121. The asymmetric unit was 
containing three FR60 drugs, one per DNA duplex, interacting with DNA in several 
alternative positions (molecule F, G and E). The drugs were covered the minor groove of 
the DNA duplexes, filling the central part of the minor groove [AATT]. More remarkable, 
the drug was forming cross-link with neighboring DNA molecules stacked as infinite 
parallel columns in pseudo-tetragonal organization. Cross-linking interactions 
contribute to stabilize the crystal lattice. End to end oligonucleotides stacking were 
found forming a combination of negative helical twist (-21°) and WC configuration 
(positive ωT of about 29). 
It has been confirmed through genomic analysis that the number of occurances of the 
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5 .1  In vitro  Activity of Bis(2-aminoimidazoline) 
Compounds Against Trypanosomes 
Alamar blue assays were carried out according to the protocol described in section 
2.9.2, to obtain the half maximal effective concentration (EC50) values for the drugs 
FR60, JNI18 and CDIV32 against T. brucei Tb427WT, pentamidine-resistant strain 
TbAT1-B48 and isometamidium-resistant strain ISMR1. Compounds activity against T. 
congolense wild type IL3000 and diminazine-resistant cell lines 4C2 and 6C3 were also 
evaluated.  
5 .1.1  Drug sensitivity in Trypanosoma  brucei   
As the starting hypothesis was that kDNA might be a target for the bis(2-
aminoimidazoline) compounds, they were tested in parallel against the standard T. 
brucei wild type strain Tb427WT and against ISMR1 cell line (Table 5-1). ISMR1 is an 
isometamidium-adapted strain (Eze et al., 2016), which is dyskinetoplastic, meaning 
that the cell line has adapted to the loss of its kinetoplast. The compound CDIV32 was 
also tested against the pentamidine-resistant cell line TbAT1-B48 (Table 5-2).  
Table 5-1. Activity of bis(2-aminoimidazoline) compounds against T.  brucei 427WT 
and the isometamidium-resistant strain ISMR1.  
Compound EC50 [µM] ± SEM 
Resistance Factor 
ISMR1 vs .  Tb247WT 
 427WT a ISMR1 b  
FR60 0.83 ± 0.08 c 105.26 ± 3.22 127 *** 
JNI18 0.220 ± 0.06 c 28.97 ± 0.75 132 *** 
CDIV32 29.98 ± 2.17 118.87 ± 4.22 4 *** 
Compound EC50 [nM] ± SEM 
Resistance Factor 
ISMR1 vs .  Tb247WT 
Isometamidium 0.015  ± 0.0007 1464 ± 94.56 92522 *** 
EC50 values are given as mean of at least 3 independent determinations and SEM. The resistance 
factor (RF) is the ratio of the EC50 values of the adapted strain and the wild-type control. Statistical 
significance was determined using a two-tailed unpaired t-test. a Bloodstream form (BF) 
trypomastigotes of T. b. brucei Tb427WT. b BF trypomastigotes of T. b. brucei ISMR1. c Reference (Eze 
et al., 2016). Asterisks represent P-values for statistically significant resistance, as calculated using a 




In vitro drug sensitivity assay established that ISMR1 was highly resistant to 
isometamidium (ISM) when the EC50 values of the resistant clone were compared to 
those of the parent Tb427WT strain (Table 5-1) .  Significant cross-resistance was 
displayed by ISMR1 to the compounds FR60 and JNI18, with 127- and 132-fold 
increases in EC50 values, respectively, indicating that the independence from kDNA had 
made the cells resistant to the test compounds.  
Table 5-2. Activity of drug CDIV23 against T.  brucei  TbAT1-B48. 
Compound EC50 (µM)
 a ± SEM 
CDIV32 20.82 ± 2.25 
Pentamidine 0.35 ± 0.003  
 EC50 values are given as mean of at least 3 independent determinations and SEM. 
a TbAT1-B48, T. b. 
brucei strain that is resistant to diminazene, pentamidine, and melaminophenyl arsenicals. 
Minor loss of sensitivity was shown for the compound CDIV32 for ISMR1 (4-fold), 
which also presented less activity than drugs FR60 and JNI18 (36 and 136 times) to 
the T. brucei 427WT. No significant cross-resistance with FR60, JNI18 nor CDIV32 was 
observed to TbAT1-B48 cell line (see Table 1-5 and Table 5-2), presenting resistance 
factors (AT1-B48 vs 427WT) of 1.05, 1.6 and 0.7, respectively.  
5 .1.2  Drug sensitivity in Trypanosoma  congolense  
The bis(2-aminoimidazoline) compounds FR60, JNI18 and CDIV32 were tested against 
three strains of Trypanosoma congolense (Table 5-3). 
Table 5-3. Activity of bis(2-aminoimidazoline) compounds against T.  congolense.   
Compound EC50 (µM) ± SEM 
 IL3000 a 4C2 b 6C3  c 
FR60 3.95 ± 0.59 2.72 ± 0.01 3.73 ± 0.53 
JNI18 7.37 ± 1.37  7.27 ± 0.25 5.94 ± 0.17 
CDIV32 2.07 ± 0.26 1.94 ± 0.04 2.16 ± 0.49 
Compound EC50 (nM) ± SEM 
Diminazine 258.5 ± 15.8 2473 ± 150 2609 ± 120 
EC50 values are given as mean of at least 3 independent determinations and SEM.
 a Trypomastigotes 
of T. congolense wild type IL3000 and, b 4C2 and c 6C3 diminazine-resistant cell lines.  
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Compounds FR60 and JNI18 presented better activity against T. brucei 427WT than 
against T. congolense IL3000WT (4.75 and 33.5 times, respectively). However, drug 
CDIV32 displayed around 14 times better activity against T. congolense IL3000. No 
cross-resistance was observed by the diminazine-resistant cell lines to any of the 
compounds.  
Next experiments were performed by testing the compounds only in Trypanosoma 
brucei Tb427WT. 
5 .2  In vitro  Eff icacy and Effect of Bis(2-
aminoimidazoline) Compounds on Trypanosome 
Growth  
In order to determinate how fast these compounds act on cell proliferation and cell 
survival, T. b. brucei s427WT was exposed to each compound at four different 
concentrations according to their EC50: 0.5×, 1×, 2.5× and 5× EC50 values (see Table 
5-1). 
 
Figure 5-1. Effect of the bis(2-aminoimidazoline) compounds on the growth curve 
of bloodstream form T.  brucei  427WT. Microscopic cel l  counts were performed in 
duplicate using a haemocytometer .  The results shown are the average of the 
duplicate determinations.  Phenylarsine oxide (PAO) 1 µM and untreated cel ls  (Drug 




Figure 5-1 shows the growth curve for all the compounds at each EC50 concentration. 
Analyzing the effect of the compounds on the growth and survival of the 
trypanosomes it can be implied that this set of diamidine-like derivatives tested are, in 
general, effective in reducing the normal growth rate of the parasite. At concentrations 
equal to the EC50 value, CDIV32, FR60, JNI18, CRMV49 and JNI17 inhibit the growth by 
more than 50% compared to the untreated cells after 24 h of incubation with the 
compounds.  
 
Figure 5-2. Growth curves of untreated control  (Drug Free) T.  brucei  427WT and of 
paral lel  cultures treated with compounds FR60, JNI18 and CDIV32 at 0.5 ,  1 ,  2 .5 and 
5×  their  EC50 values.  Microscopic cel l  counts were performed in tr ipl icate,  using a 
haemocytometer .  Error bars show the standard error of the mean for three 
independent determinations.   
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Figure 5-2 depicts the growth curve for the four concentrations tested of the three 
compounds (FR60, JNI18 and CDIV32). The initial cell concentration was 2 × 104 
cell/mL as described in section  2.9.3, and growth curves were produced by assessing 
trypanosome counts at 4, 8, 24, 36 and 48 h after incubation with appropriate 
concentrations of drugs.  
Treated with 2.5 times the EC50 values, the growth rate was decreased for cells treated 
with every compound compared to the control. Nevertheless, cells are still increasing 
the population after the 48 h of incubation. Therefore, the compounds are affecting 
the growth rate of the trypanosomes but not killing them even at those concentrations. 
Drug concentrations of 0.5× and 1× EC50 (Figure 5-2a & b) do not appear to have a 
significant effect on the growth curve of T. b. brucei 427WT after 24 h of incubation. 
However, cell population was reduced to half when parasites are incubated with 0.5× 
and 1× EC50 for 32 h. After 48 h incubated with 0.5× CDIV32 EC50, and 1× EC50 
concentrations of FR60 and JNI18, two-thirds of the population of parasites was 
decreased. Moreover, for concentrations above EC50 (2.5× & 5×), FR60 and JNI18 
blocked almost completely the cell proliferation after the first 24 h of incubation, and 
allowed only a gradual, slow increase in the cell population at 32 and 48 h of 
incubation, while the compound CDIV32 blocked completely the cell proliferation after 
24 h. The observations show that the compounds have a growth-limiting, trypanostatic 
effect rather than an immediate trypanocidal effect. 
5 .3  Cell  Cycle Analysis of Bis(2-aminoimidazoline)-
Exposed Trypanosoma brucei   
In the T. brucei cell cycle, replication and division of kDNA necessarily precedes nuclear 
division (Gluenz et al., 2011), and bis(2-aminoimidazoline) compounds that directly 
impact on kDNA are thus expected to interfere with cell division. Indeed, compounds 
FR60, JNI18 and CDIV32 dose-dependently reduced T. brucei growth rates and, at 




To analyze whether compounds have an effect on the cell cycle, the DNA content was 
measured by flow cytometry, with emphasis on the ratio between cells with G1 phase 
of cell cycle and those cells synthesizing DNA (S phase of cell cycle), as well as on the 
appearance of cells in G2 phase. Moreover, in order to observe cell cycle progression in 
detail, i.e. to visualise DNA configuration from nuclei and kinetoplast, fluorescence 
microscopy was carried out. 
Trypanosomes were exposed to the compounds during 24 h and flow cytometry assay 
was performed as described in section 2.9.4.2. Cell density was adjusted to 2 × 106 
cells/mL, exposed with 1× and 5× EC50 concentrations of each compound and 
incubated for the duration of the experiment. Samples were taken at 0, 12 and 24 hour 
and a Becton Dickinson FACSCalibur was used to analyze them. Table 5-4 shows the 
histograms of treated and untreated cells for 0, 12 and 24 h of one of three 
independent assays performed. CellQuest™ and ©FlowJo software have been used to 
analyze the flow cytometry data by modelling the histogram peaks and defining the 
percentages of the population at each cell cycle phase. Thus, G1 is the non-dividing 
stage of the cell, i.e. cells that have one kinetoplast and one nucleus; S phase is where 
DNA replication occurs; and in G2 cells have two kinetoplasts and two nuclei. 
Table 5-4. Histograms of f low cytometric analysis of propidium iodide f luorescence 
associated with Tb427WT trypanosomes treated with the bis(2-aminoimidazoline) 
compounds.  
Compound 0 h 12 h 24 h 
Untreated 
(Control) 
   
FR60 
(EC50) 
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Compound 0 h 12 h 24 h 
FR60 
(5 × EC50) 
   
JNI18 
(EC50) 
   
JNI18 
(5 × EC50) 
   
CDIV32 
(EC50) 
   
CDIV32 
(5 × EC50) 
   
Cells in G1 phase (blue peak) contain a single set of chromosomes; S-phase (green), DNA synthesis 
and G2 phase (orange), cells with 2 sets of chromosomes. Results from one of three independent 
experiments that produced similar results are shown. Percentage of the population at each cell cycle 
phase is shown above its histogram peak. Untreated cells were included in each assay as control. 
The results show a clear effect of the tested compounds on the S phase of the cell 




5-4 and Figure 5-3). The proportion of cells in G2 phases initially showed a slight 
increase (at 12 h of treatment), and a small reduction later (after 24 h), while an 
increase of cells in G1 phase was observed. The percentage of treated cells in S phase 
decreased dose-dependently throughout the experiment, whereas there was no 
significant change in the S phase for the control which maintained a normal growth 
rate (Table 5-4). 
 
Figure 5-3. Percentage of T.  brucei  427WT in each stage of the cel l  cycle after 24 h 
incubated with the compounds FR60, JNI18 and CDIV32. Parasites were treated with 
1×  and 5×EC50 values of each compound. Error bars show the standard error of the 
mean for three independent determinations.  G1: al l  cel ls  have one kinetoplast and 
one nucleus; G2: al l  cel ls  have two kinetoplast and two nucleus; S phase: DNA 
synthesis .  Untreated cel ls  (Drug Free) as control was included in each assay.  
The most outstanding result to emerge from the data is the strong relationship 
between the S phase and the growth curve (see Figure 5-2). A significant S phase 
reduction coincides with an inhibition of the growth after 24 h treatment with the 
drugs. Apparently, the observed decrease of DNA synthesis led to a reduction of growth 
and finally to a complete arrest of cell proliferation. 
To evaluate whether nuclear and/or kinetoplast division was affected and to observe 
cell cycle progression in detail, the cellular DNA configuration was assessed by 
fluorescence microscopy using the dye DAPI for compound FR60 and CDIV32 and 
SYTOX® Green nuclei acid stain for compound JNI18 (as this compound fluoresces at a 
similar wavelength as DAPI). Following the protocol described in section 2.9.4.2, cells 
exposed to the compounds for 8 h and 24 h were scored into the following standard 
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groups (Figure 5-4): 1N1K (one nucleus and one kinetoplast), 1N2K (one nucleus and 
two kinetoplasts), 2N2K-E (two nuclei and two kinetoplasts, but no clear furrow 
towards cell division), 2N2K-L (two nuclei and two kinetoplasts when cells were almost 
completely divided into two daughter cells. Another group was added to the 
classification: 1N/2N (1 or 2 nuclei and no kinetoplast) due to the high incidence of 
cells with such a DNA configuration after 8h (Figure 5-5a) or 24 h of treatment (Figure 
5-5b).  
 
Figure 5-4. Classif ication of the DNA content analysis .  Images taken by the Zeiss 
Axioskop 2  f luorescent microscope of Tb427WT cel ls  stained with DAPI .  The outl ine 
of al l  cel ls  is  shown by DIC imaging. Images were processed using the program Fi j i  
( ImageJ) .  N, nucleus; K ,  k inetoplast;  E ,  early stage of divis ion; L ,  late stage of 
divis ion. 
In cells treated with either compound there was a dose-dependent reduction in cells 
with 1 nucleus and 2 kinetoplasts, indicative of a failure to initiate a new cell division 
cycle. Similarly, the number of cells in the early stages of cell division, with 2 
kinetoplasts and nuclei, was approximately halved after 24 h of exposure to the 
compounds. At the same time, cells without any kinetoplast (1N/2N) started to appear 




apparently concluded mitosis despite the non-division of the kinetoplasts. In addition, 
completely aberrant cells (‘others’) also appeared in the treated cultures, which 
typically contained DNA fragmentation, multiple nuclei and/or kinetoplasts, or none at 
all. The combined evidence shows that the three compounds tested affect the normal 
progression of the T. brucei cell cycle, most likely by preventing kinetoplast division. 
 
Figure 5-5. DNA content of cel ls  treated (a)  8 and (b)  24 h with compounds FR60, 
JNI18 and CDIV32 at 1×  and 5×  EC50 as determined by f luorescence microscopy.  For 
each sample,  about 500 cel ls  were counted and scored in terms of nuclei  and 
kinetoplasts .  N, nucleus; K ,  k inetoplast;  1N/2N, cel ls  with one or two nuclei  but no 
observable kinetoplastid .  E ,  early stage of divis ion; L ,  late stage of divis ion.  
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5 .4  Cellular Localization of the Compound JNI18  
To study the cellular distribution of the bis(2-aminoimidazolinium) compounds, cells 
were incubated with the fluorescent compound JNI18 (emission: 450 nm), using the 
green-fluorescent SYTOX® Green nucleic acid stain (excitation/emission: 504/523 nm) 
to visualize the nuclei and kinetoplasts. The T. brucei mitochondrion was further 
visualized with the red-fluorescent dye MitoTracker Red CMXRos (excitation/emission: 
579/599 nm), which produces a highly specific stain of T. brucei mitochondria (Vassella 
et al., 1997; Huang et al., 2013).  
After 3 h of exposure, compound JNI18 can just be detected inside of the cell but no 
particular distribution is discernible (Figure 5-6). After 6 h, compound JNI18 shows a 
homogeneous distribution throughout the cytoplasm, and is becoming concentrated in 
the mitochondria. At that moment, the kinetoplast is no longer visible in many of the 
cells, although the SYTOX® Green still strongly highlights the nuclei. After 24 h of 
treatment, drug JNI18 seems to be even more concentrated in the mitochondrion with 
intense spots of the fluorescence coinciding with the most intense MitoTracker 
staining; kinetoplast staining with SYTOX® Green was absent from almost all cells.  
In untreated cells grown in parallel, no changes in fluorescence were observed at the 
blue wavelength that visualized JNI18, and normal kinetoplast staining with SYTOX® 







Figure 5-6. Fluorescence local ization of the JNI18 in Trypanosoma brucei 427WT 
cel ls .  Images were taken at 0,  3 ,  6 and 24 h of incubation with 5 µM compound 
JNI18. Al l  f luorescent images are shown with compound 2 (λ=450, blue channel) ,  
SYTOX Green  (λ=523, green channel) ,  MitoTracker  (λ=599, red channel) ,  and merge,  
where arbitrary colours were used to visual ise the various dyes: blue for JNI18, 
purple for SYTOX ,  yel low for Mitotracker .  The outl ine of al l  cel ls  is  shown by 
differential  interference contrast (DIC) imaging. Images were acquired using a 
DeltaVision  imaging system and deconvolved using the ratio conservative method, 
on SoftWoRx  software.  
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5 .5  Effect of the Bis(2-aminoimidazoline) 
Derivatives on the Mitochondrial Membrane 
Potential of T.  brucei 
In order to investigate whether the compounds affect the mitochondrial function of 
the Trypanosome brucei, flow cytometry was carried out. Bloodstream forms of T. 
brucei were cultured for up to 12 h in the presence and absence of compounds FR60, 
JNI18 and CDIV32. Samples were taken at 0, 3, 6 and 12 h of incubation. The 
quantitative changes in the mitochondrial membrane potential were measured by 
using tetramethylrhodamine ethyl ester (TMRE) following the protocol described in 
section 2.9.5. A shift to higher fluorescence indicates an increase of Ψm 
(hyperpolarisation), whereas a shift to lower fluorescence indicates a decrease of Ψm 
(depolarization) (Denninger et al., 2007). Valinomycin was used as control for 
depolarization and troglitazone as control for hyperpolarization. Samples were 
analyzed via flow cytometry by using a FL2-height detector and data were processed 
with CellQuest and FlowJo software.  
The summary of the results of three independent determinations of TMRE fluorescence 
of treated and untreated cells with FR60, JNI18 and CDIV32 for 3, 6 and 12 h is shown 
as a line graph in Figure 5-7. Histograms from the three determinations performed are 
shown Appendix F. Values are given as the percentage of cells with fluorescence above 
100 arbitrary units (AU), which was set to approximately 50% for the controls. A shift 
to higher fluorescence signifies increased Ψm; lower fluorescence signifies 
depolarization of the mitochondrial membrane; for the untreated cell culture, Ψm 
remained stable for the duration of the experiment, at approximately 50%.  
As expected, Ψm for untreated cells was remained unaffected throughout the 12 h 
experiment. In contrast, valinomycin rapidly induced a deep depolarization of the 
mitochondrial membrane while troglitazone induced a clear hyperpolarisation.  
Compounds FR60 and JNI18 acted in a dose dependent form, progressively reducing 




dose-dependent depolarization of the Ψm evident at 12 h (Figure 5-7). Slightly more 
significant Ψm depolarization was caused by the compound CDIV32 at 3 h, and more 
significant by 6 h as compared to the other two compounds, causing a depolarization 
of about 30% an 60% when parasites are treated with 1× and 5× EC50 concentrations, 
respectively. At 12 h, CDIV32 induced a deep Ψm depolarization of T. brucei (Figure 
5-8).  
 
Figure 5-7. Effect of compounds FR60, JNI18 and CDIV32 on mitochondrial  
membrane potential  (Ψm) of T.  b .  brucei  427WT. The results shown are the mean of 
three independent determinations; error bars depict standard errors .  Untreated cel ls  
(drug free) ,  val inomycin (depolarization) and trogl itazone (hyperpolarization) are 
employed as controls .  
The data are consistent with mitochondrial targeting of the compounds as cations, but 
their effect on the membrane potential is slower than has been reported for some 
other compounds such as bisphosphonium salts, which appeared to impact directly on 
the FoF1-ATPase (Alkhaldi et al., 2016). 
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Figure 5-8. Superposed histograms of T.  b .  brucei  427WT mitochondrial  membrane 
potential  (Ψm) assay after 12 h incubation for (a)  the controls:  drug free,  
val inomycin and trogl itazone and  (b)  with the compounds FR60, JNI18 and CDIV32 
at 5×EC50 concentrations.  (c)  Graph bar with Ψm percentage of cel ls  treated 12 h 
with the compounds with f luorescence above the 100 AU (50% of untreated cel ls) .  
The results shown are the mean of three independent determinations; error bars 
depict standard errors .   
5 .6  PCR Amplif ication of Kinetoplast DNA Markers 
In order to determine whether the mitochondrial genome of T. brucei had been 
completely eliminated when parasites were treated with the compound JNI18, 
rendering it undetectable by DAPI staining, DNA was extracted and subjected to PCR 
analysis. Fragments of 4 genes known to be encoded only by the kinetoplast 
maxicircles, two representative minicircles genes and two nuclearly-encoded genes 





Entire genome from trypanosomes exposed with 5 µM JNI18 for 0, 3, 6, 9, 12, 24 and 
32 h were purified and forward and reverse PCR primers described in Table 2-15 were 
used following the protocol described in section 2.9.8. PCR products were run on 1% 
agarose gel to observe the PCR products (Figure 5-9).  
 
Figure 5-9. PCR amplif ication of the maxicircles genes ND5, ND7 and ND4; 
minicircles genes Type A and Type A –l ike; nuclearly encoded actin & TbAT-1 gene 
as a posit ive control for a nuclearly-encoded single copy gene from Trypanosoma 
brucei 427WT. T ime of exposure with the compound JNI18 is  indicated above of 
each band. (- )  Negative control (no DNA in the PCR sample) .  (+) Posit ive control of 
Tb427-WT DNA. 
Figure 5-9 shows that both kinetoplast and nuclear DNA standard markers were 
amplified by PCR even after 32 h exposure with compound JNI18. Nevertheless, no 
information was provided about the abundance or organisation of these genes in the 
cell, which was therefore further investigated using Transmission Electron Microscopy 
(TEM). 
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5 .7  Effect of Compounds FR60 and JNI18 on the 
Kinetoplast Network 
Transmission Electron Microscopy (TEM) was used to study the trypanosomes’ 
ultrastructure after exposure to 5 µM compounds FR60 and JNI18, in order to analyze 
the effects of these compounds on the cellular structure of the parasite. Based on the 
information obtained with the cellular localization of the compounds in the cell by 
fluorescence microscopy (see section 5.4), TEM samples were taken after 3 h and 24 h 
incubation, as ‘early’ and ‘late’ time points to determine the structural effects of the 
compounds.  
Figure 5-10 shows the TEM images for untreated cells (drug free control) after 3 and 
24 h of experiment. Kinetoplast appears normal in all the cases.  
 
Figure 5-10. TEM images showing normal ultrastructure of untreated cel ls  of 
Tb427WT after (a)  3 h of experiment and (b)  24 h.  F ,  f lagel lum, FP,  f lagel lum pocket ,  
k ,  k inetoplast .  Images were observed in a Tecnai T20 (FEI)  at 200 kV. 
Analyzing the images obtained with TEM of cells treated 3 h (Figure 5-11) and 24 h 
(Figure 5-12), it can be confirmed that compounds FR60 and JNI18 have the same 
mechanism of action in the cell. Both compounds cause ultrastructural abnormalities 
in the kinetoplast, which were clearly far more severe at 24 h than at 3 h of incubation, 
when many cells appeared still undamaged, i.e., the drug has not yet impacted on the 




population show dark dots or empty space inside the kinetoplast (bottom row; arrows 
indicate the abnormalities), which confirm an initial level of damage in the kDNA of 
some cells during the first 3 h exposure with the compounds. 
 
Figure 5-11. TEM images showing cel ls  of Tb427WT treated with (a)  FR60 and (b)  
JNI18 for 3 h.  F ,  f lagel lum, k ,  k inetoplast .  Images were observed in a Tecnai T20 (FEI)  
at 200 kV. Irregular structures in the kinetoplast are shown with arrows and 
arrowheads,  indicating kDNA damage. 
 
Figure 5-12. TEM images showing cel ls  of Tb427WT treated with (a)  FR60 and (b)  
JNI18 for 24 h.  F ,  f lagel lum, k ,  k inetoplast .  Images were observed in a Tecnai T20 
(FEI)  at 200 kV. Irregular structures in the kinetoplast are shown with arrows and 
arrowheads,  indicating kDNA severe damage. 
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After 24 h of treatment with compounds FR60 and JNI18, all cells displayed clear 
damage to kinetoplasts, which has completely lost the characteristic disk-like structure 
of uniform electron-density, a structure of intercalating minicircles and maxicircles 
that is essential for both the functioning and replication of the kinetoplast (Povelones, 
2014). This is completely consistent with the lack of kDNA staining observed with 
SYTOX Green (see Figure 5-6). Since no other structures were found to be affected at 
24 h but only the mitochondrial DNA is largely absent and completely disorganised, it 
can be concluded that they directly affect the kinetoplast.  
5 .8  In vivo  Activity in a Mouse Model of First Stage 
HAT 
In vivo efficacy studies were conducted at the Swiss Tropical and Public Health 
Institute (Basel) according to the rules and regulations for the protection of animal 
rights of the Swiss ‘Bundesant für Veterinärwesen’. They were approved by the 
veterinary office of Canton Basel-stadt, Switzerland. 
The in vivo activity of FR60, assessed before this research work, showed that this 
compound is 100% curative in the STIB900 mouse model of acute T. b. rhodesiense 
infection by intraperitoneal (4×5 mg/kg/day) and oral (4×50 mg/kg/day) dosage (Ríos 
Martínez el at., 2015c; Rodríguez et al., 2008).  
During this work, the in vivo activity of JNI18 against T. b. rhodesiense was assessed in 
the same mouse model. For that reason, JNI18 was administered to a group of four 
female NMRI mice by intraperitoneal route using a 4-day treatment regimen of 20 
mg/kg/day using a previously reported protocol described in Ríos Martínez et al., 2014. 
Parasitemia was monitored over a 60-day observation period. Mice were considered 
cured when no relapse was detected in the tail blood over the observation period.  
The intraperitoneal administration of JNI18 at 4×4 mg/kg/day increased the mean day 
of relapse of parasitemia (17.5 days) in mice although no cures were obtained. 
However, a 5-fold higher dosage (4×20 mg/kg/day i.p.) provided a 100% cure rate in 




5 .9  GENERAL DISCUSSION 
Trypanocidal dications such as diamidines and bisimidazolinium compounds have long 
been speculated to act on mitochondrial targets (Lanteri et al., 2008; Roy Chowdhury 
et al., 2010) and some clearly bind to DNA (see section 1.6.1.1). However, although 
their abilities to act as minor groove binding drugs (MGBD) are well established, it is 
much less clear whether this is necessarily the principal trypanocidal mode of action, 
and whether binding to kDNA and/or nuclear DNA contributes most to cell death. In 
this chapter is presented the most comprehensive analysis to date that one class of 
aromatic dications, the bis(2-aminoimidazolines), directly act on the kinetoplast. 
Significant resistance (>100-fold) by the dyskinetoplastic cell line ISMR1, relative to 
the wild type cell line, indicated the kinetoplast as a probable target of compounds 
FR60 and JNI18. Moreover, a study of the T. brucei cell cycle by flow cytometry showed 
that incubation with the FR60, JNI18 and CDIV32 compounds caused a progressive cell 
cycle arrest in G1 phase, reflected in the major decrease in S-phase cells after 24 h. 
The failure to initiate DNA synthesis was almost certainly the result of damage to the 
kinetoplast, as kDNA division necessarily precedes nuclear division (McKean, 2003), and 
both fluorescence microscopy and TEM showed major damage to the kinetoplast but 
not to the nucleus. Starting at just 8 h, as fluorescent compound JNI18 had 
accumulated in the mitochondrion, significant numbers of cells were found without an 
observable kinetoplast or with one kinetoplast and two, or even three nuclei, which 
clearly evidence a defect in kinetoplast replication. By 24 hours this was leading to the 
gross destruction and/or disorganisation of the kinetoplast as observed by TEM and 
concomitant growth arrest. Importantly, the electron microscopy did not reveal any 
damage to the nuclei or other cellular structures.  
Despite the absence of ultrastructural damage to the mitochondrion, Ψm began to 
decrease from 6 h of incubation. In bloodstream trypanosomes, which lack the 
common oxidative phosphorylation complexes, Ψm is generated by the FoF1 ATPase 
pumping protons from the mitochondrial matrix, using ATP (Dean, et al., 2013; 
Schnaufer et al., 2005; Bhat et al., 1990) clearly this process would progressively be 
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impeded as the lack of functional kDNA precludes the production of the A6 subunit of 
Fo, leading to the slow membrane depolarization observed. Accumulation of cationic 
compounds in the mitochondria, driven by the negative electrostatic potential 
(negative inside), is a well-described phenomenon for cationic and dicationic 
compounds (Ibrahim et al., 2011; Alkhaldi et al., 2016; Fueyo Gonzalez et al., 2017) but 
the relatively slow effect of compounds FR60 and JNI18 on the Ψm compared with 
CDIV32, and with that of compounds that act directly on the F1F0-ATPase complex 
(Alkhaldi et al., 2016) is consistent with the hypothesis that the antiparasitic effect 
derives from preventing the accurate replication of kDNA and consequently the 
assembly of F0.  
Altogether, these results show that the N-phenylbenzamide bis(2-aminoimidazolinium) 
compounds FR60 and JNI18 act specifically on the kinetoplast DNA of the T. brucei by 
altering its structure and replication.  
Finally, the in vivo screening for trypanocidal activity against Trypanosoma brucei 
rhodesiense of compounds FR60 and JNI18 showed, for both compounds, 100% 





























                                                                                                                            
CONCLUSIONS 
  
 225 25 
CONCLUSIONS 
 
Part I .  DNA–ligand interactions  
1. HMGA1a (∆50-91) as well as HMGB1 box B and HMGB1 box AB fragments were 
expressed in E. coli strain Rosetta (DE3) pLysS and purified. 
2. A clear supercoiling effect on circular DNA was induced by HMGA1a (∆50-91), 
demonstrating its functionality and unwinding activity.  
3. Surface plasmon resonance (SPR) successfully demonstrated a strong binding 
affinity of the HMGA1a and HMGB proteins towards an immobilized AT-rich DNA 
oligonucleotide containing [AATAAT_ATTATT]. The KD was found similar and in the 
low micromolar range for both proteins (KD =0.35 × 10-6 M and KD =0.33 × 10-6 M, 
respectively).  
4. After more than 100 crystallization assays with 6 different AT-rich 
oligonucleotides and the protein HMGA1a (∆50-91), the appropriate 
crystallization condition was not found.  
5. Numerous crystallization trials with the HMGB box B and 10 different AT-rich 
oligonucleotides were performed, from which 20 crystals suitable for X-ray 
crystallography were diffracted.  
6. A crystal of HMGB1 box B in complex with the 20 bp oligonucleotide 
d[CCAATAATCGCGATTATTGG]2 diffracted to 2.68 Å resolution, presented well-
defined spots revealing two diffraction orientations. The space group was P22121 
with a = 29.94 Å, b = 89.65 Å, c = 109.1 Å, α = β = γ = 90°.  
7. The capacity of bis(2-aminoimidazoline) compounds to selectively bind AT-rich 
sequences over CG-containing DNA was confirmed by SPR. All KD were found in 
the submicromolar range. 




8. Compound JNI18 was able to displace the HMG proteins from their DNA binding 
sites, showing IC50 values for inhibition of binding of 6.0 µM and 3.4 µM for 
HMGA1a and HMGB1, respectively. 
9. Several crystallization trials with the bis(2-aminoimidazolines) FR60, JNI18 and 
CDIV32 and 10 different AT-rich oligonucleotides permitted the diffraction of 
about 50 crystals suitable for X-ray crystallography.  
10. The compound CDIV32 in complex with the all-AT oligonucleotide d[AAATTT]2 was 
crystallized in a pseudo-continuous helix, packed in a crossed column 
configuration. Sixteen stacked oligonucleotides with average helical twist of 
about -25° conformed the asymmetrical unit. The cell parameters were a = 62.79 
Å, b = 451.08 Å and c = 80.93 Å; α = β = γ = 90° in C2221 space group. The drug 
modulates the crossed helical arrangement. Pseudo translational symmetry 
detected in the crystal impeded complete resolution of the structure. 
11. Crystal structure of the FR60-d[AAATTT]2 complex at atomic resolution of 1.25 Å 
revealed important features: FR60 interacts in the middle of the DNA duplex, the 
central [AATT] sequence; it fills the minor groove of the all-AT oligonucleotide 
and displaces water from the hydration spine. The drug also protrudes from DNA, 
forming hydrogen bond interactions with phosphates from neighboring DNA 
molecules acting as a cross-linking agent. This originates the packing in a 
pseudo-tetragonal configuration. 
 
Part I I .  Functional analysis  of the effect of bis(2-aminoimidazol ine) 
compounds on Trypanosoma brucei   
1. In vitro drug sensitivity assays established that T. brucei isometamidium-adapted 
dyskinetoplastic cell line ISMRI was highly resistant to compounds FR60 and 
JNI18 when EC50 values were compared to those of the Trypanosoma brucei 
Tb427 wild type strain, pointing to kDNA as a target for these compounds.  
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2. A series of FR60 derivatives and CDIV32 dose-dependently reduced the T. brucei 
growth rates and, at concentrations above EC50 appeared to induce growth arrest 
after 24 h.  
3. Bis(2-aminoimidazolines) FR60, JNI18 and CDIV32 caused a progressive cell cycle 
arrest in G1 phase, as reflected by a major decrease in S-phase cells after 24 h.  
4. Failure to initiate a new cell division cycle in treated T. brucei was confirmed by 
the reduction of cell population replicating the kinetoplast (kDNA). 
5. FR60 and JNI18 drugs caused a slow decline in mitochondrial membrane 
potential (Ψm) of T. brucei, showing its partial depolarization after a 12 h 
exposure. Compound CDIV32 reduced the Ψm more strongly at 6 h exposure, and 
completely after 12 h of treatment. 
6. Fluorescent compound JNI18 (a chloro derivative of the lead FR60) tended to 
accumulate in the mitochondrion of T. brucei. Cells showed a homogeneous 
distribution throughout the cytoplasm after 6 h of treatment with the drug, but a 
visible accumulation in the mitochondrion after 24 h exposure. 
7. TEM images of trypanosomes treated with FR60 and JNI18 showed dark dots or 
empty space inside the kinetoplast, confirming initial kDNA damage. After 24 h, 
kinetoplast was largely absent and completely disorganized. No damage to the 
nuclei or other cellular structures was displayed. 
8. Compounds JNI18 and FR60 share the same mechanism of action and cellular 
target against Trypanosoma brucei, acting specifically on the integrity of the 
kinetoplast by altering the structure and replication of kDNA. Direct effect on 
kinetoplast DNA causing the destruction of the network was confirmed. 
9. As both compounds showed 100% curative activity in a mouse model of T. brucei 
rhodesiense infection, they have a potential as effective chemotherapeutic agents 
for the treatment of sleeping sickness. 
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ABSTRACT 
Trypanosoma brucei, the causative agent of sleeping sickness (Human African 
Trypanosomiasis, HAT), contains a kinetoplast with the mitochondrial DNA (kDNA), 
comprising of >70% AT base pairs. This has prompted studies of drugs interacting with 
AT-rich DNA, such as the N-phenylbenzamide bis(2-aminoimidazoline) derivatives 1 
[4-((4,5-dihydro-1Himidazol-2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-2-yl)amino) 
phenyl)benzamide dihydrochloride] and 2 [N-(3-chloro-4-((4,5-dihydro-1H-imidazol-
2-yl)amino)phenyl)-4-((4,5-dihydro-1H-imidazol-2-yl)amino)benzamide] as potential 
drugs for HAT. Both compounds show in vitro effects against T. brucei and in vivo 
curative activity in a mouse model of HAT. The main objective was to identify their 
cellular target inside the parasite. We were able to demonstrate that the compounds 
have a clear effect on the S-phase of T. brucei cell cycle by inflicting specific damage 
on the kinetoplast. Surface plasmon resonance (SPR)–biosensor experiments show that 
the drug can displace HMG box-containing proteins essential for kDNA function from 
their kDNA binding sites. The crystal structure of the complex of the oligonucleotide 
d[AAATTT]2 with compound 1 solved at 1.25 °A (PDB-ID: 5LIT) shows that the drug 
covers the minor groove of DNA, displaces bound water and interacts with 
neighbouring DNA molecules as a cross-linking agent. We conclude that 1 and 2 are 
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Appendix A 
IPTG INDUCTION OF PROTEIN EXPRESSION 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) is a molecular mimic of allolactose, a 
lactose metabolite that triggers transcription of the lac operon, and it is therefore used 
to induce recombinant protein expression where the gene is under the control of the 
lac operator. 
Usually, the gene of interest is inserted into a commercial vector pET that contains: (1) 
a gene coding for antibiotic resistance (e.g. ampR); (2) the lacI gene (lac Iq) from the lac 
operon that codes for the lac repressor (LacI); and (3) the gene of interest inserted just 
after the T7 promoter DNA sequence, the lac operator DNA sequence, and the ribosome 
binding site (at the start of the future mRNA transcript).  
The lac repressor protein (LacI) evolved to sense the presence of lactose. In the absence 
of lactose, the lac repressor binds to the operator sequence on DNA and bends the DNA 
by 40° (as seen in the crystal structure PDB ID: 1EFA). This blocks access of T7 RNA 
polymerase to the promoter site and thus prevents leaky transcription of the gene 
before induction. 
When lactose binds to LacI it induces a conformational change in the protein structure 
that renders it incapable of binding to the operator DNA sequence. IPTG, like 
allolactose, also binds to the lac repressor and induces a similar conformational change 
(PDB ID: 2P9H) that greatly reduces its affinity for DNA. Unlike lactose, IPTG is not part 
of any metabolic pathways and so will not be broken down or used by the cell. This 
ensures that the concentration of IPTG added remains constant, making it a more 
useful inducer of the lac operon than lactose itself. 





Figure A1. Mechanism of action of the IPTG induction.  Image taken from 
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Appendix B 
CULTURE MEDIA 
§ HMI-9 medium (10% FCS)  
A pack of HMI-9 powder (Gibco®) was emptied into a 5-litre capacity beaker, followed 
by 4.5 L of ddH2O and 15 g of NaHCO3. After stirring on a magnetic stirrer for about 1 
h at room temperature, 500 mL of FBS (Fetal Bovine Serum; Gibco®) and 71.5 µl of β-
mercaptoethanol were added. The solution was left stirring overnight at 4°C. The pH 
was adjusted to 7.4 the next day. Finally, the media was filtered into 10 sterile 500 ml 
reagent bottles and stored at 4°C. 
§ TcBCF-3 medium 
Table B-1. Trypanosoma congolense  culture media TcBCF-3 composit ion. 





Base powder Hep Gluc Pyr Ade Hypo Thy Bac Gln 2 Me RBC FGS SP 
MEM 25 5.5 1 0.04 0.1 0.02 0.02 2 0.2 0.5 20 5 
MEM, Eagle's Minimum Essential Medium powder medium (M0643, Sigma-Aldrich), supplemented 
with 2.2 g of sodium bicarbonate (Sigma-Aldrich). Basal medium components were resuspended in 1 
L Versol water (Revol, Villeurbanne) and after adjustment of the pH to 7.3 with 5 N NaOH, the 
medium was filter sterilized (Millipore 0.22 um), stored at 4°C and used within 10 days. Before use, 
basal medium was supplemented with the components listed (Sigma-Aldrich) and serum. Hep, HEPES 
Acid; Gluc, D-Glucose; Pyr, Sodium Pyruvate; Ade, Adenosine; Hypo, Hypoxanthine; Thy, Thymidine; 
Bac, Bathocuproin; Gln, Glutamine; 2 Me, 2-mercaptoethanol. RBC, Red Blood Cell lysate was 
obtained after centrifugation (1 min 2000 rpm) of 100 µl of mouse blood, and resuspending of the 















Inorganic Salts    
Calcium Chloride (CaCl2) (anhyd.) 111.0 140.0 1.2612612 
Magnesium Chloride (MgCl
2
-6H2O) 203.0 100.0 0.49261084 
Magnesium Sulfate (MgSO4-7H2O) 246.0 100.0 0.40650406 
Potassium Chloride (KCl) 75.0 400.0 5.3333335 
Potassium Phosphate monobasic (KH2PO4) 136.0 60.0 0.44117647 
Sodium Bicarbonate (NaHCO3) 84.0 350.0 4.1666665 
Sodium Chloride (NaCl) 58.0 8000.0 137.93103 
Sodium Phosphate dibasic (Na2HPO4) 
anhydrous 
142.0 48.0 0.33802816 
Other Components  
  
D-Glucose (Dextrose) 180.0 1000.0 5.5555553 
HBSS, calcium, magnesium, no phenol red. Hanks & Wallace, 1949. 
Table B-3. Electrophoresis buffers .  
Buffer Working Solution  Stock Solution  
[per 1 L] 
TAE 
1×  
40 mM Tris-acetate 
1 mM EDTA 
50x 
242 g Tris base 
57.1 mL of glacial acetic acid 
100 mL of 0.5 M EDTA (pH 8.0) 
TPE 
1×  
90 mM Tris-phosphate 
2 mM EDTA 
10x 
108 g Tris base 
15.5 mL of phosphoric acid (85%, 1.679 g/mL) 
40 mL of 0.5 M EDTA (pH 8.0) 
TBE 
1×  
90 mM Tris-phosphate 
2 mM EDTA 
5×  
54 g Tris base 
27.5 g of boric acid 
20 mL of 0.5 M EDTA (pH 8.0) 
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Appendix C 
RELEVANT SPECIFICATIONS OF THE USED SYNCHROTRON LINE 
Beamline Xaloc bl13 
§ Source type bending magnet 
§ Energy Range: 5-22 keV 
§ Wavelength Range: 2.4-0.58 Å 
§ 12-foil attenuators ESRF type 
§ Fast shutter: FPS400 CEDRAT 
§ Slits: JJ-Xray ESRF type 
§ Automatic Sample Changer: CATS - IRELEC 
§ Detector: PILATUS 6M - Dectris 
§ Cryostream: 700 series - Oxford Cryosystems 
§ Monochromator: Si(111) channel-cut, cryocooled 
§ KB Mirrors, Elliptically bent mirror (Si, Rh, Ir) (2)  






Table D-1. Crystal l ization Kit  Natrix HR2-116 Hampton. 
No. Composit ion  
1 0.01 M Mg Chloride, 0.05 M MES pH 5.6, 2.0 M Lithium Sulfate 
2 0.01 M Mg Acetate, 0.05 M MES pH 5.6, 2.5 M Ammonium Sulfate 
3 0.1 M Mg Acetate, 0.05 M MES pH 5.6, 20% MPD 
4 0.2 M K Chloride, 0.01 M Mg Sulfate, 0.05 M MES pH 5.6, 10% PEG 400 
5 0.2 M K Chloride, 0.01 M Mg Chloride, 0.05 M MES pH 5.6, 5% PEG 8000 
6 0.1 M Ammonium Sulfate, 0.01 M Mg Chloride, 0.05 M MES pH 5.6, 20% PEG 8000 
7 0.02 M Mg Chloride, 0.05 M MES pH 6.0, 15% iso-Propanol 
8 0.005 M Mg Sulfate, 0.1 M Ammonium Acetate, 0.05 M MES pH 6.0, 0.6 M NaCl 
9 0.1 M K Chloride, 0.01 M Mg Chloride, 0.05 M MES pH 6.0, 10% PEG 400 
10 0.005 M Mg Sulfate, 0.05 M MES pH 6.0, 5% PEG 4000 
11 0.01 M Mg Chloride, 0.05 M Na Cacodylate pH 6.0, 1.0 M Lithium Sulfate 
12 0.01 M Mg Sulfate, 0.05 M Na Cacodylate pH 6.0, 1.8 M Lithium Sulfate 
13 0.015 M Mg Acetate, 0.05 M Na Cacodylate pH 6.0, 1.7 M Ammonium Sulfate 
14 0.1 M K Chloride, 0.025 M Mg Chloride, 0.05 M Na Cacodylate pH 6.0, 15% iso-Propanol 
15 0.04 M Mg Chloride, 0.05 M Na Cacodylate pH 6.0, 5% MPD 
16 0.04 M Mg Acetate, 0.05 M Na Cacodylate pH 6.0, 30% MPD 
17 0.2 M K Chloride, 0.01 M Ca Chloride, 0.05 M Na Cacodylate pH 6.0, 10% PEG 4000 
18 0.01 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 1.3 M Lithium Sulfate 
19 0.01 M Mg Sulfate, 0.05 M Na Cacodylate pH 6.5, 2.0 M Ammonium Sulfate 
20 
0.1 M Ammonium Acetate, 0.015 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 10% iso-
Propanol 
21 0.2 M K Chloride, 0.005 M Mg Chloride, 0.05 M Na Cacodylate pH 6.5, 10% 1,6 Hexanediol 
22 0.08 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 15% PEG 400 
23 0.2 M K Chloride, 0.01 M Mg Chloride, 0.05 M Na Cacodylate pH 6.5, 10% PEG 4000 
24 0.2 M Ammonium Acetate, 0.01 M Ca Chloride, 0.05 M Na Cacodylate pH 6.5, 10% PEG 4000 
25 0.08 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 30% PEG 4000 
26 0.2 M K Chloride, 0.1 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 10% PEG 8000 
27 
0.2 M Ammonium Acetate, 0.01 M Mg Acetate, 0.05 M Na Cacodylate pH 6.5, 30% PEG 
8000 
28 0.05 M Mg Sulfate, 0.05 M HEPES - Na pH 7.0, 1.6 M Lithium Sulfate 
29 0.01 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 4.0 M Lithium Chloride 
30 0.01 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 1.6 M Ammonium Sulfate 
31 0.005 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 25% PEG Monomethyl Ether 550 
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32 0.2 M KCl, 0.01 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 20% 1,6 Hexanediol 
33 
0.2 M Ammonium Chloride, 0.01 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 30% 1,6 
Hexanediol 
34 0.1 M K Chloride, 0.005 M Mg Sulfate, 0.05 M HEPES - Na pH 7.0, 15% MPD 
35 0.1 M K Chloride, 0.01 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 5% PEG 400 
36 0.1 M K Chloride, 0.01 M Ca Chloride, 0.05 M HEPES - Na pH 7.0, 10% PEG 400 
37 0.2 M K Chloride, 0.025 M Mg Sulfate, 0.05 M HEPES - Na pH 7.0, 20% PEG 200 
38 0.2 M Ammonium Acetate, 0.15 M Mg Acetate, 0.05 M HEPES - Na pH 7.0, 5% PEG 4000 
39 0.1 M Ammonium Acetate, 0.02 M Mg Chloride, 0.05 M HEPES - Na pH 7.0, 5% PEG 8000 
40 0.01 M Mg Chloride, 0.05 M Tris HCl pH 7.5, 1.6 M Ammonium Sulfate 
41 0.1 M KCl, 0.015 M Mg Chloride, 0.05 M Tris HCl pH 7.5, 10% PEG Monomethyl Ether 550 
42 0.01 M Mg Chloride, 0.05 M Tris HCl pH 7.5, 5% iso-Propanol 
43 0.01 M Mg Chloride, 0.05 M Ammonium Acetate, 0.05 M Tris HCl pH 7.5, 10% MPD 
44 0.2 M K Chloride, 0.05 M Mg Chloride, 0.05 M Tris HCl pH 7.5, 10% PEG 4000 
45 0.025 M Mg Sulfate, 0.05 M Tris HCl pH 8.5, 1.8 M Ammonium Sulfate 
46 0.005 M Mg Sulfate, 0.05 M Tris HCl pH 8.5, 35% 1,6 Hexanediol 
47 0.1 M K Chloride, 0.01 M Mg Chloride, 0.05 M Tris HCl pH 8.5, 30% PEG 400 
48 0.01 M Ca Chloride, 0.2 M Ammonium Chloride, 0.05 M Tris HCl pH 8.5, 30% PEG 4000 
 
  




Table D-2. Crystal l ization condit ions for DNA-HMG protein complex.  
Name Ion  Buffer pH Precipitants Addit ive  
C1 10 mM NH4(OAc)  25 mM NaCac 6 3% PEG 3350 1 mM DTT 
C2 10 mM NH4(OAc)  25 mM NaCac 6 5% MPD 1 mM DTT 
C3 10 mM Mg(OAc)2  25 mM NaCac 6 3% PEG 3350 1 mM DTT 
C4 10 mM Mg(OAc)2 25 mM NaCac 6 5% MPD 1 mM DTT 
C5 10 mM MgCl2 25 mM NaCac 6 3% PEG 3350 1 mM DTT 
C6 10 mM MgCl2 25 mM NaCac 6 5% MPD 1 mM DTT 
C7 10 mM CaCl2 25 mM NaCac 6 3% PEG 3350 1 mM DTT 
C8 10 mM CaCl2 25 mM NaCac 6 5% MPD 1 mM DTT 
C9 12.5 mM MgCl2 25 mM NaCac 6 5% MPD 1 mM DTT 
C10 7.5 mM MgCl2 25 mM NaCac 6 5% MPD 1 mM DTT 
T1 10 mM NH4(OAc)  25 mM Tris-HCl 7.5 3% PEG 3350 1 mM DTT 
T2 10 mM NH4(OAc)  25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T3 10 mM Mg(OAc)2  25 mM Tris-HCl 7.5 3% PEG 3350 1 mM DTT 
T4 10 mM Mg(OAc)2 25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T5 10 mM MgCl2 25 mM Tris-HCl 7.5 3% PEG 3350 1 mM DTT 
T6 10 mM MgCl2 25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T7 10 mM CaCl2 25 mM Tris-HCl 7.5 3% PEG 3350 1 mM DTT 
T8 10 mM CaCl2 25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T9 12.5 mM MgCl2 25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T10 7.5 mM MgCl2 25 mM Tris-HCl 7.5 5% MPD 1 mM DTT 
T11 7 mM MgCl2 25 mM Tris-HCl 7.5 5% MPD 
1 mM DTT 
40 mM NaCl 
T12 7 mM MgCl2 25 mM Tris-HCl 7.5 5% MPD 
1 mM DTT 
40 mM NaCl 
CA1 10 mM Mg(OAc)2 25 mM NaCac 6 - - 
CA2 10 mM MgCl2 25 mM NaCac 6 - - 
CA3 25 mM Mg(OAc)2 25 mM NaCac 6 - - 
CA4 25 mM MgCl2 25 mM NaCac 6 - - 
TA1 10 mM Mg(OAc)2 25 mM Tris-HCl 7.5 - - 
TA2 10 mM MgCl2 25 mM Tris-HCl 7.5 - - 
TA3 25 mM Mg(OAc)2 25 mM Tris-HCl 7.5 - - 
TA4 25 mM MgCl2 25 mM Tris-HCl 7.5 - - 
OAc; acetate.  
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Table D-3. Crystal l ization condit ions for the DNA and N-phenylbenzamide bis(2-
aminoimidazolinium) compounds complexes.  
Name Ion  Buffer pH Precipitants Addit ives 
D1 8 mM MnCl2 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
D2 10 mM Mg(OAc)2 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
D3 8 mM MgCl2 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
D4 10 mM NH4(OAc) 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
D2.2 8 mM Mg(OAc)2 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
D4.2 8 mM NH4(OAc) 25 mM NaCac 6 5% MPD 0.1 mM Spermine 
OAc; acetate.  
  






Table E-1. Crystal l ization assays with DNA-HMGA1a protein complexes.  





















7, 15, 16, 25, 31, 
42, 43, 46. 
 
T6, T9, T11, T12 
CA1, CA2, CA3, 
CA4, TA1, TA2, 
TA3, TA4. 
0.25 mM NiCl2 












15, 16, 25, 43, 
48. 








7, 15, 16, 43. 










7, 15, 16, 43. 










T6, T9, T11, T12 
CA1, CA2, CA3, 
CA4, TA1, TA2, 
TA3, TA4. 
0.25 mM NiCl2 
Up to 50% -Amorphous 
precipitate 
-Crystalline points 
ATTAATTAAT 0.2 1:4 
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Table E-2. Crystal l ization assays with DNA-HMGB1 proteins complexes.  



















T1-T10 (T6, T9) 
C1-C10 (C9) 
MPD:  

















T6, T9, T10 
C6, C9, C10 
Up to 70%  -Phase separation 
-Liquid crystals 















- Amorphous crystals 
- Small rectangular 
crystals 





















































T6, T9, T10 
C6, C9, C10 
MPD:  
















Up to 50% 
-Phase separation 
-Crystalline points 






























T6, T9, T10 
C6, C9, C10 
MPD:  




Best crystallization conditions found are underlined. 
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Table E-3. Crystal l ization assays with DNA-bis(2-aminoimidazolines) complexes.  




















D1, D2, D3, D4, 
D2.2, D4.2. 
C2, C4, C6 












- Amorphous crystals 
ATTAATTAAT 











0.2  1:2 
1:4 
D1, D2, D3, D4 Up to 30% -Amorphous crystals 
-Small needles 
AAATTT  
0 .2 1:2 
1:4 






















0.2 1:2 D1, D2, D3, D4 Up to 30% -Small needles 
-Liquid crystals 
-Crystalline precipitate 
Best crystallization conditions found are underlined. 






Figure F1.  F luorescence images of untreated cel l  samples of Trypanosoma brucei 
427WT cel ls  taken at 0,  3 ,  6 and 24 h of experiment.  Al l  f luorescent images are 
shown with Blue channel (λ=450),  SYTOX Green  (λ=523, green channel) ,  MitoTracker  
(λ=599, red channel) ,  and merge,  where arbitrary colours were used to visual ise the 
various dyes: blue for Blue channel ,  purple for SYTOX ,  yel low for Mitotracker .  No 
changes in f luorescence were observed at blue wavelength as untreated cel ls  (no 
f luorescent compound JNI18 added) were visual ized.  Normal cel ls  were observed 
containing 1N1K (one nuclei  and one kinetoplast) .  The outl ine of al l  cel ls  was 
shown by differential  interference contrast (DIC) imaging. Images were acquired 
using a DeltaVision  imaging system and deconvolved using the ratio conservative 
method, on SoftWoRx  software.  
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Table F 1.  Mitochondrial  membrane potential  assay.  
Untreated cel ls  (drug free) 
Time Repeat 1 Repeat 2 Repeat 3 
0 h 
   
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 0, 3, 6 and 12 h by a 
BD FACSCalibur™ using a FL2-height detector. Data were processed with CellQuest™ and ©FlowJo 
software. 
  




Treated cel ls  with 1×  EC50 FR60 (0 .83 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 





Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 
FACSCalibur™ using a FL2-height detector. Data were processed with CellQuest™ and ©FlowJo 
software. 
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Treated cel ls  with 5×  EC50 FR60 (4 .15 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 













Treated cel ls  with 1×  EC50 JNI18 (0 .22 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 
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Treated cel ls  with 5×  EC50 JNI18 (1 .1 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 













Treated cel ls  with 1×  EC50 CDIV32 (29.98 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 









                                                                                                                            
APPENDIXES 
  
 253 253 
Treated cel ls  with 5×  EC50 CDIV32 (149.9 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 













Val inomycin (100 nM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 
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Trogl itazone (10 µM) 
Time Repeat 1 Repeat 2 Repeat 3 
3 h 
   
6 h 
   
12 h 
   
Values are given as the percentage of cells with fluorescence above 1 × 102 arbitrary units (AU), 
equivalent to approximately 50% for the untreated cells. Samples are taken at 3, 6 and 12 h by a BD 
FACSCalibur™ using a FL2-height detector. Data were processed with CellQuest™ and ©FlowJo 
software. 
  





Trypanosoma brucei brucei strain Lister 427 (Tb427WT) minicircle, complete sequence; 
kinetoplast (Dean, et al., 2013) 



















The AT content represents the 73.6% of the minicircle genome of Tb427WT (A = 394 and T = 
342); and CG-content the 26.5% (G = 206 and C = 59). The sequence AAA appears 28 times 
and the sequence TTT 26 times; both are shown in red, bold font. The sequence AATT exists 14 
times and is highlighted in yellow. Tracts with more than 10 A/T are found 15 times (red and 
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